Enovis (ENOV) 10-K 18 Feb 21 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Feb. 12, 2021	Jul. 03, 2020
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-34045
Entity Registrant Name	COLFAX CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	54-1887631
Entity Address, Address Line One	420 National Business Parkway,
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	Annapolis Junction,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20701
City Area Code	301
Local Phone Number	323-9000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 2,823
Entity Common Stock Shares Outstanding	118,496,687	118,545,523
Entity Central Index Key	0001420800
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	CFX
Security Exchange Name	NYSE
Tangible Equity Unit
Document Information [Line Items]
Title of 12(b) Security	5.75% Tangible Equity Units
Trading Symbol	CFXA
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net sales	$ 3,070,769	$ 3,327,458	$ 2,193,083
Cost of sales	1,782,664	1,926,402	1,463,707
Gross profit	1,288,105	1,401,056	729,376
Selling, general and administrative expense	1,087,401	1,132,149	548,763
Restructuring and other related charges	38,413	65,295
Restructuring and other related charges	45,027	73,747	29,077
Operating income	162,291	203,612	151,536
Pension settlement loss (gain)	0	33,616	(39)
Interest expense, net	104,262	119,503	49,083
Loss on short-term investments	0	0	10,128
Income from continuing operations before income taxes	58,029	50,493	92,364
Income tax expense (benefit)	(6,053)	31,630	(29,508)
Net income from continuing operations	64,082	18,863	121,872
Income (loss) from discontinued operations, net of taxes	(18,311)	(536,009)	32,601
Net income (loss)	45,771	(517,146)	154,473
Less: income attributable to noncontrolling interest, net of taxes	3,146	10,500	14,277
Net income (loss) attributable to Colfax Corporation	$ 42,625	$ (527,646)	$ 140,196
Net income (loss) per share - basic
Continuing operations	$ 0.45	$ 0.10	$ 1.01
Discontinued operations	(0.13)	(3.99)	0.16
Consolidated operations	0.31	(3.89)	1.17
Net income (loss) per share - diluted
Continuing operations	0.44	0.10	1
Discontinued operations	(0.13)	(3.99)	0.16
Consolidated operations	$ 0.31	$ (3.89)	$ 1.16

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 45,771	$ (517,146)	$ 154,473
Other comprehensive income (loss):
Foreign currency translation, net of tax expense of $(25), $2,248 and $3,018	59,880	(47,734)	(249,907)
Unrealized gain (loss) on hedging activities, net of tax expense of $(9,120), $1,574 and $5,273	(26,268)	5,832	14,745
Changes in unrecognized pension and other post-retirement benefit (cost), net of tax expense (benefit) of $(1,502), $(3,980) and $366	(8,169)	(27,931)	10,116
Amounts reclassified from Accumulated other comprehensive loss:
Amortization of pension and other post-retirement net actuarial gain, net of tax expense (benefit) of $883, $779 and $805	3,735	2,597	3,623
Amortization of pension and other post-retirement prior service cost, net of tax of $0, $0 and $(411)	0	32	(1,998)
Divestiture-related recognition of foreign currency translation, pension, and other post-retirement cost	0	291,263	0
Other comprehensive income (loss)	29,178	224,059	(223,421)
Comprehensive income (loss)	74,949	(293,087)	(68,948)
Less: comprehensive income (loss) attributable to noncontrolling interest	585	(97,101)	(8,491)
Comprehensive income (loss) attributable to Colfax Corporation	$ 74,364	$ (195,986)	$ (60,457)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Parenthetical] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (25)	$ 2,248	$ 3,018
Unrealized gain on hedging activities, tax	(9,120)	1,574	5,273
Changes in unrecognized pension and other post-retirement benefit cost, tax expense (benefit)	(1,502)	(3,980)	366
Amortization of pension and other post-retirement net actuarial gain (loss), tax expense (benefit)	883	779	805
Amortization of pension and other post-retirement prior service cost, tax	$ 0	$ 0	$ (411)

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 97,068	$ 109,632
Trade receivables, less allowance for credit losses of $37,666 and $32,634	517,006	561,865
Inventories, net	564,822	571,558
Prepaid expenses	69,515	70,429
Other current assets	113,418	90,761
Total current assets	1,361,829	1,404,245
Property, plant and equipment, net	486,960	491,241
Goodwill	3,314,541	3,202,517
Intangible assets, net	1,663,446	1,719,019
Lease asset - right of use	173,942	173,320
Other assets	350,831	396,490
Total assets	7,351,549	7,386,832
CURRENT LIABILITIES:
Current portion of long-term debt	27,074	27,642
Accounts payable	330,251	359,782
Accrued liabilities	454,333	469,890
Total current liabilities	811,658	857,314
Long-term debt, less current portion	2,204,169	2,284,184
Non-current lease liability	139,230	136,399
Other liabilities	608,618	619,307
Total liabilities	3,763,675	3,897,204
Equity:
Common stock, $0.001 par value; 400,000,000 shares authorized; 118,496,687 and 118,059,082 issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	118	118
Additional paid-in capital	3,478,008	3,445,597
Retained earnings	517,367	479,560
Accumulated other comprehensive loss	(452,106)	(483,845)
Total Colfax Corporation equity	3,543,387	3,441,430
Noncontrolling interest	44,487	48,198
Total equity	3,587,874	3,489,628
Total liabilities and equity	$ 7,351,549	$ 7,386,832

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]
Trade receivables, allowance for doubtful accounts	$ 37,666	$ 32,634
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	118,496,687	118,059,082
Common Stock, Shares, Outstanding		118,059,082

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interest
Cumulative effect of accounting change	$ 0			$ 5,152	$ (5,152)
Beginning balance (in shares) at Dec. 31, 2017		123,245,827
Beginning balance at Dec. 31, 2017	3,727,264	$ 123	$ 3,228,174	846,490	(574,372)	$ 226,849
Net income (loss)	154,473			140,196		14,277
Distributions to noncontrolling owners	(11,172)					(11,172)
Other comprehensive (loss) income	(223,421)				(200,653)	(22,768)
Common stock repurchases (in shares)		(6,449,425)
Common stock repurchases	(200,000)	$ (6)	(199,994)	0	0	0
Common stock-based award activity (in shares)		478,815
Common stock-based award activity	29,802		29,802
Ending balance (in shares) at Dec. 31, 2018		117,275,217
Ending balance at Dec. 31, 2018	3,476,946	$ 117	3,057,982	991,838	(780,177)	207,186
Cumulative effect of accounting change	0			15,368	(15,368)
Net income (loss)	(517,146)			(527,646)		10,500
Distributions to noncontrolling owners	(12,379)					(12,379)
Noncontrolling interest share repurchase	(93,505)		(24,037)		(19,960)	(49,508)
Other comprehensive (loss) income	224,059				331,660	(107,601)
Issuance of Tangible Equity Units	377,814		377,814
Common stock-based award activity (in shares)		783,865
Common stock-based award activity	33,839	$ 1	33,838
Ending balance (in shares) at Dec. 31, 2019		118,059,082
Ending balance at Dec. 31, 2019	3,489,628	$ 118	3,445,597	479,560	(483,845)	48,198
Cumulative effect of accounting change	(4,818)			(4,818)	0
Net income (loss)	45,771			42,625		3,146
Distributions to noncontrolling owners	(4,296)					(4,296)
Other comprehensive (loss) income	29,178				31,739	(2,561)
Common stock-based award activity (in shares)		437,605
Common stock-based award activity	32,411		32,411
Ending balance (in shares) at Dec. 31, 2020		118,496,687
Ending balance at Dec. 31, 2020	$ 3,587,874	$ 118	$ 3,478,008	$ 517,367	$ (452,106)	$ 44,487

CONSOLIDATED STATEMENTS OF EQ_2

CONSOLIDATED STATEMENTS OF EQUITY [Parenthetical] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cumulative Effect of Change in New Accounting Principle, tax impact				$ 2,808
Other comprehensive income, tax	$ 9,764	$ 621	$ 9,051

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ 45,771	$ (517,146)	$ 154,473
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Divestiture impairment loss	0	449,000	0
Impairment of property, plant and equipment	0	0	7,086
Depreciation, amortization and other impairment charges	246,229	236,026	141,877
Stock-based compensation expense	28,911	21,960	25,103
Non-cash interest expense	5,739	9,937	4,415
Loss on short-term investments	0	0	10,128
Deferred income tax benefit	(29,218)	(590)	(66,573)
(Gain) loss on sale of property, plant and equipment	(491)	61	(21,108)
(Gain) loss on sale of business	0	(14,233)	4,337
Pension settlement loss (gain)	0	77,390	(39)
Changes in operating assets and liabilities:
Trade receivables, net	42,688	49,924	(72,405)
Inventories, net	23,787	(44,887)	(47,156)
Accounts payable	(30,747)	(119,325)	70,085
Other operating assets and liabilities	(30,734)	(17,169)	16,144
Net cash provided by operating activities	301,935	130,948	226,367
Cash flows from investing activities:
Purchases of property, plant and equipment	(114,785)	(125,402)	(69,646)
Proceeds from sale of property, plant and equipment	9,552	7,781	34,829
Acquisitions, net of cash received	(69,846)	(3,151,056)	(290,918)
Proceeds from sale of business, net	0	1,635,920	18,404
Sale of short-term investments, net	0	0	139,480
Net cash used in investing activities	(175,079)	(1,632,757)	(167,851)
Cash flows from financing activities:
Proceeds from borrowings on term credit facility	0	1,725,000	0
Payments under term credit facility	(40,000)	(1,387,500)	(131,250)
Proceeds from borrowings on revolving credit facilities and other	860,681	2,045,083	1,271,051
Repayments of borrowings on revolving credit facilities and other	(938,997)	(2,273,802)	(981,563)
Proceeds from borrowings on senior unsecured notes	0	1,000,000	0
Payment of debt issuance costs	(4,560)	(23,380)	0
Proceeds from prepaid stock purchase contracts	0	377,814	0
Proceeds from issuance of common stock, net	3,500	11,879	4,699
Payment for noncontrolling interest share repurchase	0	(93,505)	0
Payments for common stock repurchases	0	0	(200,000)
Deferred consideration payments and other	(12,275)	(12,095)	(10,090)
Net cash provided by (used in) financing activities	(131,651)	1,369,494	(47,153)
Effect of foreign exchange rates on Cash and cash equivalents and Restricted cash	(3,768)	(3,072)	(28,363)
Decrease in Cash and cash equivalents and Restricted cash	(8,563)	(135,387)	(17,000)
Cash and cash equivalents and Restricted Cash, beginning of period	109,632	245,019	262,019
Cash and cash equivalents and Restricted cash, end of period	101,069	109,632	245,019
Supplemental Disclosure of Cash Flow Information:
Interest payments	104,620	139,268	50,389
Income tax payments, net	$ 59,377	$ 134,915	$ 97,452

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations Colfax Corporation (the “Company” or “Colfax”) is a leading diversified technology company that provides fabrication technology and medical device products and services to customers around the world under the ESAB and DJO brands. The Company conducts its operations through two operating segments, “Fabrication Technology”, which incorporates the operations of ESAB and its related brands, and “Medical Technology”, which incorporates the operations of DJO and its related brands. The Company completed the purchase of DJO Global, Inc. (“DJO”) on February 22, 2019 becoming a new growth platform for Colfax. See Note 5, “Acquisitions”, for further information. Later that year, Colfax completed the sale of its Air and Gas Handling business on September 30, 2019. See Note 4, “Discontinued Operations”, for further information. These transactions were the culmination of a multi-year strategic plan to remodel the Company into a faster growth, higher-margin, and less cyclical business with opportunities for significant bolt-on and adjacent acquisitions over time. The Company applies the Colfax Business System (“CBS”) to continuously improve and pursue growth in revenues and increase profits and cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries and the noncontrolling parties’ ownership share is presented as a noncontrolling interest. All significant intercompany accounts and transactions have been eliminated. Equity Method Investments Investments in joint ventures, where the Company has a significant influence but not a controlling interest, are accounted for using the equity method of accounting. Investments accounted for under the equity method are initially recorded at the amount of the Company’s initial investment and adjusted each period for the Company’s share of the investee’s income or loss and dividends paid. All equity investments are reviewed periodically for indications of other-than-temporary impairment, including, but not limited to, significant and sustained decreases in quoted market prices or a series of historic and projected operating losses by investees. If the decline in fair value is considered to be other-than-temporary, an impairment loss is recorded and the investment is written down to a new carrying value. Investments in joint ventures acquired in a business combination are recognized in the opening balance sheet at fair value. Revenue Recognition The Company recognizes revenue when control of promised goods or services is transferred to the customer. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the goods or services. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance and represent the Company’s best judgment at the time. Any estimates are evaluated on a quarterly basis until the uncertainty is resolved. Additionally, related to sales of its medical device products and services, the Company maintains provisions for estimated contractual allowances for reimbursement amounts from certain third-party payers based on negotiated contracts, historical experience for non-contracted payers, and the impact of new contract terms or modifications of existing arrangements with these customers. We report these allowances as a reduction to net sales. The Company provides a variety of products and services to its customers. Most of the Company’s contracts consist of a single, distinct performance obligation or promise to transfer goods or services to a customer. A majority of revenue recognized by the Company relates to contracts with customers for standard or off-the-shelf products. As control typically transfers to the customer upon shipment of the product in these circumstances, revenue is generally recognized at that point in time. Revenue recognition and billing typically occur simultaneously for contracts recognized at a point in time. Therefore, we do not have material revenues in excess of customer billings or billings to customers in excess of recognized revenues. For service contracts, the Company recognizes revenue ratably over the period of performance as the customer simultaneously receives and consumes the benefits of the services provided. The Company applies the available practical expedient involving the existence of a significant financing component. As the Company generally does not receive payments greater than one year in advance or arrears of revenue recognition, the Company does not consider any arrangements to include financing components. The period of benefit for the Company’s incremental costs of obtaining a contract generally have less than a one-year duration; therefore, the Company applies the practical expedient available and expenses costs to obtain a contract when incurred. Taxes Collected from Customers and Remitted to Governmental Authorities The Company collects various taxes and fees as an agent in connection with the sale of products and remits these amounts to the respective taxing authorities. These taxes and fees have been presented on a net basis in the Consolidated Statements of Operations and are recorded as a component of Accrued liabilities in the Consolidated Balance Sheets until remitted to the respective taxing authority. Research and Development Expense Research and development costs of $68.6 million, $61.8 million and $34.2 million for the years ended December 31, 2020, 2019 and 2018, respectively, are expensed as incurred and are included in Selling, general and administrative expense in the Consolidated Statements of Operations. These amounts do not include development and application engineering costs incurred in conjunction with fulfilling customer orders and executing customer projects. Interest Expense, Net Interest expense, net includes interest income of $3.2 million, $3.2 million and $2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively, primarily associated with interest bearing deposits of certain foreign subsidiaries. Cash and Cash Equivalents Cash and cash equivalents include all financial instruments purchased with an initial maturity of three months or less. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. Restricted cash is recorded as a component of Other current assets on the Consolidated Balance Sheets. The following table summarizes the Company’s Cash and cash equivalents and Restricted cash: December 31, 2020 2019 (In thousands) Cash and cash equivalents $ 97,068 $ 109,632 Restricted cash 4,001 — Total cash and cash equivalents and restricted cash $ 101,069 $ 109,632 Trade Receivables Trade receivables are presented net of an allowance for credit losses. The Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments as of January 1, 2020. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Estimated credit losses are reviewed periodically by management. Inventories Inventories, net include the cost of material, labor and overhead and are stated at the lower of cost (determined under various methods including average cost, last-in, first-out and first-in, first-out, but predominantly first-in, first-out) or net realizable value. The value of inventory stated using the last-in, first-out method as of December 31, 2020 and 2019 was $105.1 million and $121.8 million, respectively. The Company periodically reviews its quantities of inventories on hand and compares these amounts to the expected usage of each particular product. The Company records a charge to Cost of sales for any amounts required to reduce the carrying value of inventories to its net realizable value. Property, Plant and Equipment Property, plant and equipment, net is stated at historical cost, which includes the fair values of such assets acquired through acquisitions. Repair and maintenance expenditures are expensed as incurred unless the repair extends the useful life of the asset. The Company capitalizes surgical implant instruments that are provided free of charge to surgeons for use while implanting our surgical products and the related depreciation expense is recorded as a component of Selling, general and administrative expense. Impairment of Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the costs in excess of the fair value of net assets acquired through acquisitions by the Company. Indefinite-lived intangible assets consist of certain trade names. The Company evaluates the recoverability of Goodwill and indefinite-lived intangible assets annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. The annual impairment test date elected by the Company is the first day of our fourth quarter. Goodwill and indefinite-lived intangible assets are considered to be impaired when the carrying value of a reporting unit or asset exceeds its fair value. The Company currently has two reporting units: Medical Technology and Fabrication Technology. In the evaluation of goodwill for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If the Company determines that it is more likely than not for a reporting unit’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not for a reporting unit’s fair value to be less than its carrying value, a calculation of the reporting entity’s fair value is performed and compared to the carrying value of that entity. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that reporting unit is impaired and an impairment loss is recorded equal to the excess of the reporting unit’s carrying value over its fair value. When a quantitative impairment test is needed, the Company measures fair value of reporting units based on a present value of future discounted cash flows and a market valuation approach. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted average cost of capital, revenue growth rates, long-term rate of growth, profitability of our business, tax rates, and working capital effects. The market valuation approach indicates the fair value of the business based on a comparison against certain market information. Significant estimates in the market approach model include identifying appropriate peer companies, market multiples and assessing earnings before interest, income taxes, depreciation and amortization. A quantitative annual impairment test of Goodwill for the Fabrication Technology reporting unit was performed for the year ended December 31, 2020, while qualitative assessments were performed for the years ended December 31, 2019 and 2018, both of which indicated no impairment existed. A quantitative annual impairment test of Goodwill for the Medical Technology reporting unit was performed for the year ended December 31, 2020, and a qualitative assessment was performed for the year ended December 31, 2019, both of which indicated no impairment existed. In the evaluation of indefinite-lived intangible assets for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying value. If the Company determines that it is more likely than not for the indefinite-lived intangible asset’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not that the indefinite-lived intangible asset’s fair value is less than its carrying value, a calculation is performed and compared to the carrying value of the asset. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying amount of the indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company measures the fair value of its indefinite-lived intangible assets using the “relief from royalty” method. Significant estimates in this approach include projected revenues and royalty and discount rates for each trade name evaluated. A quantitative impairment test was performed for all the indefinite-lived trade name brands in the Fabrication Technology segment for the year ended December 31, 2020, while a combination of quantitative impairment tests and qualitative assessments were performed for the years ended December 31, 2019 and 2018, all of which indicated no impairment existed. Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets Intangible assets primarily represent acquired trade names, customer relationships, acquired technology and software license agreements. A portion of the Company’s acquired customer relationships is being amortized on an accelerated basis over periods ranging from seven two The Company assesses its long-lived assets and finite-lived intangible assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected cash flows are less than the carrying amounts, an impairment loss equal to the difference between the carrying amount of the asset and its fair value would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. Assets held for sale are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques. The Company recorded asset impairment losses related to facility closures totaling $3.5 million, $4.2 million and $5.5 million during the years ended December 31, 2020, 2019 and 2018, respectively, as a component of Restructuring and other related charges in the Consolidated Statements of Operations. The aggregate carrying value of these assets subsequent to impairment was $62.5 million, $44.6 million and $39.8 million as of December 31, 2020, 2019 and 2018, respectively. Derivatives The Company is subject to foreign currency risk associated with the translation of the net assets of foreign subsidiaries to United States (“U.S.”) dollars on a periodic basis. On April 19, 2017. the Company issued senior unsecured notes with an aggregate principal amount of €350 million (as defined and further discussed in Note 13, “Debt”), which has been designated as a net investment hedge in order to mitigate a portion of its foreign currency risk. Derivative instruments are generally recognized on a gross basis in the Consolidated Balance Sheets in either Other current assets, Other assets, Accrued liabilities or Other liabilities depending upon their respective fair values and maturity dates. For all instruments designated as hedges, including net investment hedges and cash flow hedges, the Company formally documents the relationship between the hedging instrument and the hedged item, as well as the risk management objective and the strategy for using the hedging instrument. The Company assesses whether the relationship between the hedging instrument and the hedged item is highly effective at offsetting changes in the fair value both at inception of the hedging relationship and on an ongoing basis. For cash flow hedges and net investment hedges, unrealized gains and losses are recognized as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets to the extent that it is effective at offsetting the change in the fair value of the hedged item and realized gains and losses are recognized in the Consolidated Statements of Operations consistent with the underlying hedged instrument. The Company does not enter into derivative contracts for speculative purposes. See Note 17, “Financial Instruments and Fair Value Measurements” for additional information regarding the Company’s derivative instruments. Warranty Costs Estimated expenses related to product warranties are accrued as the revenue is recognized on products sold to customers and included in Cost of sales in the Consolidated Statements of Operations. Estimates are established using historical information as to the nature, frequency, and average costs of warranty claims. The activity in the Company’s warranty liability, which is included in Accrued liabilities and Other liabilities in the Company’s Consolidated Balance Sheets, consisted of the following: Year Ended December 31, 2020 2019 (In thousands) Warranty liability, beginning of period $ 15,528 $ 12,312 Accrued warranty expense 7,253 6,038 Changes in estimates related to pre-existing warranties 1,849 1,668 Cost of warranty service work performed (9,708) (9,502) Acquisition-related liability 300 5,520 Foreign exchange translation effect 321 (508) Warranty liability, end of period $ 15,543 $ 15,528 Income Taxes Income taxes for the Company are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the Consolidated Financial Statements and their respective tax basis. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets and liabilities are reported in Other assets and Other liabilities in the Company’s Consolidated Balance Sheets, respectively. The effect on deferred income tax assets and liabilities of a change in tax rates is generally recognized in Income tax expense (benefit) in the period that includes the enactment date. Global Intangible Low-Taxed Income (“GILTI”) is accounted for as a current tax expense in the year the tax is incurred. Valuation allowances are recorded if it is more likely than not that some portion of the deferred income tax assets will not be realized. In evaluating the need for a valuation allowance, the Company considers various factors, including the expected level of future taxable income and available tax planning strategies. Any changes in judgment about the valuation allowance are recorded through Income tax expense (benefit) and are based on changes in facts and circumstances regarding realizability of deferred tax assets. The Company must presume that an income tax position taken in a tax return will be examined by the relevant tax authority and determine whether it is more likely than not that the tax position will be sustained upon examination based upon the technical merits of the position. An income tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The Company establishes a liability for unrecognized income tax benefits for income tax positions for which it is more likely than not that a tax position will not be sustained upon examination by the respective taxing authority to the extent such tax positions reduce the Company’s income tax liability. The Company recognizes interest and penalties related to unrecognized income tax benefits in Income tax expense (benefit) in the Consolidated Statements of Operations. Foreign Currency Exchange Gains and Losses The Company’s financial statements are presented in U.S. dollars. The functional currencies of the Company’s operating subsidiaries are generally the local currencies of the countries in which each subsidiary is located. Assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the balance sheet date. The amounts recorded in each year in Foreign currency translation are net of income taxes to the extent the underlying equity balances in the entities are not deemed to be permanently reinvested. Revenues and expenses are translated at average rates of exchange in effect during the year. Transactions in foreign currencies are translated at the exchange rate in effect at the date of each transaction. Differences in exchange rates during the period between the date a transaction denominated in a foreign currency is consummated and the date on which it is either settled or translated for inclusion in the Consolidated Balance Sheets are recognized in Selling, general and administrative expense or Interest expense, net in the Consolidated Statements of Operations for that period. During the year ended December 31, 2020, the Company recognized net foreign currency transaction gains of $2.8 million in Interest expense, net and net foreign currency transaction loss of $2.4 million in Selling, general and administrative expense in the Consolidated Statements of Operations. During the year ended December 31, 2019, the Company recognized net foreign currency transaction gain of $0.5 million in Interest expense, net and net foreign currency transaction loss of $0.7 million in Selling, general and administrative expense in the Consolidated Statements of Operations. During the year ended December 31, 2018, the Company recognized net foreign currency transaction loss of $1.4 million and $7.8 million in Interest expense, net and Selling, general and administrative expense, respectively, in the Consolidated Statements of Operations. Debt Issuance Costs and Debt Discount Costs directly related to the placement of debt are capitalized and amortized to Interest expense primarily using the effective interest method over the term of the related obligation. Further, the carrying value of debt is reduced by an original issue discount, which is accreted to Interest expense, net using the effective interest method over the term of the related obligation. As of December 31, 2020, $7.0 million and $15.6 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. As of December 31, 2019, $6.1 million and $17.7 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. See Note 13, “Debt” for additional discussion regarding the Company’s borrowing arrangements. Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates. Reclassifications Certain prior period amounts have been reclassified to conform to current year presentations, including Prepaid expenses on the Company’s Consolidated Balance Sheets and certain items within Note 8, “Income Taxes”. Accounting Guidance Implemented in 2020 Standards Adopted Description Effective Date ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments The ASU eliminates the probable initial recognition threshold under current GAAP and broadens the information an entity must consider when developing its expected credit loss estimates to include forward-looking information. The standard applies to most financial assets held at amortized costs, as well as certain other instruments. Under the current expected credit loss (“CECL”) model, entities must estimate losses over the entire contractual term of the asset from the date of initial recognition. In determining expected losses, consideration must be given to historical loss experience, current conditions, and reasonable and supportable forecasts incorporating forward looking information. The Company adopted Topic 326 on January 1, 2020 using a modified retrospective transition method, which requires a cumulative-effect adjustment to the opening balance sheet of retained earnings to be recognized on the date of adoption without restating prior periods. The cumulative-effect adjustment, net of tax, on January 1, 2020 was $4.8 million. January 1, 2020 ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement The ASU modifies the disclosure requirements for fair value measurements. The adoption of this standard did not result in any changes to the current disclosures, as the requirements modified by the ASU are not applicable or are immaterial for disclosure. January 1, 2020 New Accounting Guidance to be Implemented Standards Pending Adoption Description Anticipated Impact Effective/Adoption Date ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans The ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This accounting standard update impacts disclosures only. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures. January 1, 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of accounting for income taxes. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. January 1, 2021

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Recently Issued Accounting Pronouncements	Summary of Significant Accounting Policies Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries and the noncontrolling parties’ ownership share is presented as a noncontrolling interest. All significant intercompany accounts and transactions have been eliminated. Equity Method Investments Investments in joint ventures, where the Company has a significant influence but not a controlling interest, are accounted for using the equity method of accounting. Investments accounted for under the equity method are initially recorded at the amount of the Company’s initial investment and adjusted each period for the Company’s share of the investee’s income or loss and dividends paid. All equity investments are reviewed periodically for indications of other-than-temporary impairment, including, but not limited to, significant and sustained decreases in quoted market prices or a series of historic and projected operating losses by investees. If the decline in fair value is considered to be other-than-temporary, an impairment loss is recorded and the investment is written down to a new carrying value. Investments in joint ventures acquired in a business combination are recognized in the opening balance sheet at fair value. Revenue Recognition The Company recognizes revenue when control of promised goods or services is transferred to the customer. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the goods or services. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance and represent the Company’s best judgment at the time. Any estimates are evaluated on a quarterly basis until the uncertainty is resolved. Additionally, related to sales of its medical device products and services, the Company maintains provisions for estimated contractual allowances for reimbursement amounts from certain third-party payers based on negotiated contracts, historical experience for non-contracted payers, and the impact of new contract terms or modifications of existing arrangements with these customers. We report these allowances as a reduction to net sales. The Company provides a variety of products and services to its customers. Most of the Company’s contracts consist of a single, distinct performance obligation or promise to transfer goods or services to a customer. A majority of revenue recognized by the Company relates to contracts with customers for standard or off-the-shelf products. As control typically transfers to the customer upon shipment of the product in these circumstances, revenue is generally recognized at that point in time. Revenue recognition and billing typically occur simultaneously for contracts recognized at a point in time. Therefore, we do not have material revenues in excess of customer billings or billings to customers in excess of recognized revenues. For service contracts, the Company recognizes revenue ratably over the period of performance as the customer simultaneously receives and consumes the benefits of the services provided. The Company applies the available practical expedient involving the existence of a significant financing component. As the Company generally does not receive payments greater than one year in advance or arrears of revenue recognition, the Company does not consider any arrangements to include financing components. The period of benefit for the Company’s incremental costs of obtaining a contract generally have less than a one-year duration; therefore, the Company applies the practical expedient available and expenses costs to obtain a contract when incurred. Taxes Collected from Customers and Remitted to Governmental Authorities The Company collects various taxes and fees as an agent in connection with the sale of products and remits these amounts to the respective taxing authorities. These taxes and fees have been presented on a net basis in the Consolidated Statements of Operations and are recorded as a component of Accrued liabilities in the Consolidated Balance Sheets until remitted to the respective taxing authority. Research and Development Expense Research and development costs of $68.6 million, $61.8 million and $34.2 million for the years ended December 31, 2020, 2019 and 2018, respectively, are expensed as incurred and are included in Selling, general and administrative expense in the Consolidated Statements of Operations. These amounts do not include development and application engineering costs incurred in conjunction with fulfilling customer orders and executing customer projects. Interest Expense, Net Interest expense, net includes interest income of $3.2 million, $3.2 million and $2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively, primarily associated with interest bearing deposits of certain foreign subsidiaries. Cash and Cash Equivalents Cash and cash equivalents include all financial instruments purchased with an initial maturity of three months or less. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. Restricted cash is recorded as a component of Other current assets on the Consolidated Balance Sheets. The following table summarizes the Company’s Cash and cash equivalents and Restricted cash: December 31, 2020 2019 (In thousands) Cash and cash equivalents $ 97,068 $ 109,632 Restricted cash 4,001 — Total cash and cash equivalents and restricted cash $ 101,069 $ 109,632 Trade Receivables Trade receivables are presented net of an allowance for credit losses. The Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments as of January 1, 2020. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Estimated credit losses are reviewed periodically by management. Inventories Inventories, net include the cost of material, labor and overhead and are stated at the lower of cost (determined under various methods including average cost, last-in, first-out and first-in, first-out, but predominantly first-in, first-out) or net realizable value. The value of inventory stated using the last-in, first-out method as of December 31, 2020 and 2019 was $105.1 million and $121.8 million, respectively. The Company periodically reviews its quantities of inventories on hand and compares these amounts to the expected usage of each particular product. The Company records a charge to Cost of sales for any amounts required to reduce the carrying value of inventories to its net realizable value. Property, Plant and Equipment Property, plant and equipment, net is stated at historical cost, which includes the fair values of such assets acquired through acquisitions. Repair and maintenance expenditures are expensed as incurred unless the repair extends the useful life of the asset. The Company capitalizes surgical implant instruments that are provided free of charge to surgeons for use while implanting our surgical products and the related depreciation expense is recorded as a component of Selling, general and administrative expense. Impairment of Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the costs in excess of the fair value of net assets acquired through acquisitions by the Company. Indefinite-lived intangible assets consist of certain trade names. The Company evaluates the recoverability of Goodwill and indefinite-lived intangible assets annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. The annual impairment test date elected by the Company is the first day of our fourth quarter. Goodwill and indefinite-lived intangible assets are considered to be impaired when the carrying value of a reporting unit or asset exceeds its fair value. The Company currently has two reporting units: Medical Technology and Fabrication Technology. In the evaluation of goodwill for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If the Company determines that it is more likely than not for a reporting unit’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not for a reporting unit’s fair value to be less than its carrying value, a calculation of the reporting entity’s fair value is performed and compared to the carrying value of that entity. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that reporting unit is impaired and an impairment loss is recorded equal to the excess of the reporting unit’s carrying value over its fair value. When a quantitative impairment test is needed, the Company measures fair value of reporting units based on a present value of future discounted cash flows and a market valuation approach. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted average cost of capital, revenue growth rates, long-term rate of growth, profitability of our business, tax rates, and working capital effects. The market valuation approach indicates the fair value of the business based on a comparison against certain market information. Significant estimates in the market approach model include identifying appropriate peer companies, market multiples and assessing earnings before interest, income taxes, depreciation and amortization. A quantitative annual impairment test of Goodwill for the Fabrication Technology reporting unit was performed for the year ended December 31, 2020, while qualitative assessments were performed for the years ended December 31, 2019 and 2018, both of which indicated no impairment existed. A quantitative annual impairment test of Goodwill for the Medical Technology reporting unit was performed for the year ended December 31, 2020, and a qualitative assessment was performed for the year ended December 31, 2019, both of which indicated no impairment existed. In the evaluation of indefinite-lived intangible assets for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying value. If the Company determines that it is more likely than not for the indefinite-lived intangible asset’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not that the indefinite-lived intangible asset’s fair value is less than its carrying value, a calculation is performed and compared to the carrying value of the asset. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying amount of the indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company measures the fair value of its indefinite-lived intangible assets using the “relief from royalty” method. Significant estimates in this approach include projected revenues and royalty and discount rates for each trade name evaluated. A quantitative impairment test was performed for all the indefinite-lived trade name brands in the Fabrication Technology segment for the year ended December 31, 2020, while a combination of quantitative impairment tests and qualitative assessments were performed for the years ended December 31, 2019 and 2018, all of which indicated no impairment existed. Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets Intangible assets primarily represent acquired trade names, customer relationships, acquired technology and software license agreements. A portion of the Company’s acquired customer relationships is being amortized on an accelerated basis over periods ranging from seven two The Company assesses its long-lived assets and finite-lived intangible assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected cash flows are less than the carrying amounts, an impairment loss equal to the difference between the carrying amount of the asset and its fair value would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. Assets held for sale are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques. The Company recorded asset impairment losses related to facility closures totaling $3.5 million, $4.2 million and $5.5 million during the years ended December 31, 2020, 2019 and 2018, respectively, as a component of Restructuring and other related charges in the Consolidated Statements of Operations. The aggregate carrying value of these assets subsequent to impairment was $62.5 million, $44.6 million and $39.8 million as of December 31, 2020, 2019 and 2018, respectively. Derivatives The Company is subject to foreign currency risk associated with the translation of the net assets of foreign subsidiaries to United States (“U.S.”) dollars on a periodic basis. On April 19, 2017. the Company issued senior unsecured notes with an aggregate principal amount of €350 million (as defined and further discussed in Note 13, “Debt”), which has been designated as a net investment hedge in order to mitigate a portion of its foreign currency risk. Derivative instruments are generally recognized on a gross basis in the Consolidated Balance Sheets in either Other current assets, Other assets, Accrued liabilities or Other liabilities depending upon their respective fair values and maturity dates. For all instruments designated as hedges, including net investment hedges and cash flow hedges, the Company formally documents the relationship between the hedging instrument and the hedged item, as well as the risk management objective and the strategy for using the hedging instrument. The Company assesses whether the relationship between the hedging instrument and the hedged item is highly effective at offsetting changes in the fair value both at inception of the hedging relationship and on an ongoing basis. For cash flow hedges and net investment hedges, unrealized gains and losses are recognized as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets to the extent that it is effective at offsetting the change in the fair value of the hedged item and realized gains and losses are recognized in the Consolidated Statements of Operations consistent with the underlying hedged instrument. The Company does not enter into derivative contracts for speculative purposes. See Note 17, “Financial Instruments and Fair Value Measurements” for additional information regarding the Company’s derivative instruments. Warranty Costs Estimated expenses related to product warranties are accrued as the revenue is recognized on products sold to customers and included in Cost of sales in the Consolidated Statements of Operations. Estimates are established using historical information as to the nature, frequency, and average costs of warranty claims. The activity in the Company’s warranty liability, which is included in Accrued liabilities and Other liabilities in the Company’s Consolidated Balance Sheets, consisted of the following: Year Ended December 31, 2020 2019 (In thousands) Warranty liability, beginning of period $ 15,528 $ 12,312 Accrued warranty expense 7,253 6,038 Changes in estimates related to pre-existing warranties 1,849 1,668 Cost of warranty service work performed (9,708) (9,502) Acquisition-related liability 300 5,520 Foreign exchange translation effect 321 (508) Warranty liability, end of period $ 15,543 $ 15,528 Income Taxes Income taxes for the Company are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the Consolidated Financial Statements and their respective tax basis. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets and liabilities are reported in Other assets and Other liabilities in the Company’s Consolidated Balance Sheets, respectively. The effect on deferred income tax assets and liabilities of a change in tax rates is generally recognized in Income tax expense (benefit) in the period that includes the enactment date. Global Intangible Low-Taxed Income (“GILTI”) is accounted for as a current tax expense in the year the tax is incurred. Valuation allowances are recorded if it is more likely than not that some portion of the deferred income tax assets will not be realized. In evaluating the need for a valuation allowance, the Company considers various factors, including the expected level of future taxable income and available tax planning strategies. Any changes in judgment about the valuation allowance are recorded through Income tax expense (benefit) and are based on changes in facts and circumstances regarding realizability of deferred tax assets. The Company must presume that an income tax position taken in a tax return will be examined by the relevant tax authority and determine whether it is more likely than not that the tax position will be sustained upon examination based upon the technical merits of the position. An income tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The Company establishes a liability for unrecognized income tax benefits for income tax positions for which it is more likely than not that a tax position will not be sustained upon examination by the respective taxing authority to the extent such tax positions reduce the Company’s income tax liability. The Company recognizes interest and penalties related to unrecognized income tax benefits in Income tax expense (benefit) in the Consolidated Statements of Operations. Foreign Currency Exchange Gains and Losses The Company’s financial statements are presented in U.S. dollars. The functional currencies of the Company’s operating subsidiaries are generally the local currencies of the countries in which each subsidiary is located. Assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the balance sheet date. The amounts recorded in each year in Foreign currency translation are net of income taxes to the extent the underlying equity balances in the entities are not deemed to be permanently reinvested. Revenues and expenses are translated at average rates of exchange in effect during the year. Transactions in foreign currencies are translated at the exchange rate in effect at the date of each transaction. Differences in exchange rates during the period between the date a transaction denominated in a foreign currency is consummated and the date on which it is either settled or translated for inclusion in the Consolidated Balance Sheets are recognized in Selling, general and administrative expense or Interest expense, net in the Consolidated Statements of Operations for that period. During the year ended December 31, 2020, the Company recognized net foreign currency transaction gains of $2.8 million in Interest expense, net and net foreign currency transaction loss of $2.4 million in Selling, general and administrative expense in the Consolidated Statements of Operations. During the year ended December 31, 2019, the Company recognized net foreign currency transaction gain of $0.5 million in Interest expense, net and net foreign currency transaction loss of $0.7 million in Selling, general and administrative expense in the Consolidated Statements of Operations. During the year ended December 31, 2018, the Company recognized net foreign currency transaction loss of $1.4 million and $7.8 million in Interest expense, net and Selling, general and administrative expense, respectively, in the Consolidated Statements of Operations. Debt Issuance Costs and Debt Discount Costs directly related to the placement of debt are capitalized and amortized to Interest expense primarily using the effective interest method over the term of the related obligation. Further, the carrying value of debt is reduced by an original issue discount, which is accreted to Interest expense, net using the effective interest method over the term of the related obligation. As of December 31, 2020, $7.0 million and $15.6 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. As of December 31, 2019, $6.1 million and $17.7 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. See Note 13, “Debt” for additional discussion regarding the Company’s borrowing arrangements. Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates. Reclassifications Certain prior period amounts have been reclassified to conform to current year presentations, including Prepaid expenses on the Company’s Consolidated Balance Sheets and certain items within Note 8, “Income Taxes”. Accounting Guidance Implemented in 2020 Standards Adopted Description Effective Date ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments The ASU eliminates the probable initial recognition threshold under current GAAP and broadens the information an entity must consider when developing its expected credit loss estimates to include forward-looking information. The standard applies to most financial assets held at amortized costs, as well as certain other instruments. Under the current expected credit loss (“CECL”) model, entities must estimate losses over the entire contractual term of the asset from the date of initial recognition. In determining expected losses, consideration must be given to historical loss experience, current conditions, and reasonable and supportable forecasts incorporating forward looking information. The Company adopted Topic 326 on January 1, 2020 using a modified retrospective transition method, which requires a cumulative-effect adjustment to the opening balance sheet of retained earnings to be recognized on the date of adoption without restating prior periods. The cumulative-effect adjustment, net of tax, on January 1, 2020 was $4.8 million. January 1, 2020 ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement The ASU modifies the disclosure requirements for fair value measurements. The adoption of this standard did not result in any changes to the current disclosures, as the requirements modified by the ASU are not applicable or are immaterial for disclosure. January 1, 2020 New Accounting Guidance to be Implemented Standards Pending Adoption Description Anticipated Impact Effective/Adoption Date ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans The ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This accounting standard update impacts disclosures only. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures. January 1, 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of accounting for income taxes. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. January 1, 2021

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2020
Discontinued Operations [Abstract]
Discontinued Operations	Discontinued Operations Sale of Air and Gas Handling Business As discussed previously in Note 1, “Organization and Nature of Operations,” the Company sold its Air and Gas Handling business on September 30, 2019. Accordingly, the accompanying Consolidated Financial Statements for all periods presented reflect the Air and Gas Handling business as a discontinued operation. The total consideration for the sale was $1.8 billion, including $1.67 billion in cash paid at closing, subject to certain adjustments pursuant to the purchase agreement, and the assumption of certain liabilities and minority interests by the purchaser. Based on the purchase price and the carrying value of the net assets being sold, the Company recorded an impairment loss of $481 million in the second quarter of 2019, which is included in Income (loss) from discontinued operations, net of taxes in the Consolidated Statements of Operations. The impairment loss included a $449 million goodwill impairment charge and a $32 million valuation allowance charge on assets held for sale relating to the initial estimated cost to sell the business. An accumulated other comprehensive loss of approximately $350 million associated with the Air and Gas Handling business was included in the determination of the goodwill impairment charge, which is mostly attributable to the recognition of cumulative foreign currency translation effects from the long-term strengthening of the U.S. Dollar. The Company recorded a pre-tax gain on disposal of $14.2 million which is included in Income (loss) from discontinued operations, net of taxes in the Consolidated Statements of Operations. The total divestiture-related expenses incurred for the Air and Gas Handling sale were $48.6 million in the year ended December 31, 2019. In connection with the purchase agreement, the Company entered into various agreements to provide a framework for its relationships after the disposition, including a transition services agreement. The transition services under the above agreements have been completed and were not material to the Company’s results of operations. The key components of Income (loss) from discontinued operations, net of taxes related to the Air and Gas Handling business for the years ended December 31, 2020, 2019 and 2018 were as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net sales $ — $ 998,793 $ 1,473,729 Cost of sales — 689,004 1,070,266 Selling, general and administrative expense — 194,589 269,447 Restructuring and other related charges — 13,354 48,609 Goodwill impairment charge — 449,000 — Divestiture-related expense (1) 9,040 48,640 — Operating income (loss) (9,040) (395,794) 85,407 Interest expense (2) — 47,553 (5,031) Pension settlement loss — 43,774 — Gain on disposal — 14,233 — Loss from discontinued operations before income taxes (9,040) (472,888) 90,438 Income tax expense (benefit) (3) (238) 44,062 29,487 Income (loss) from discontinued operations, net of taxes (4) $ (8,802) $ (516,950) $ 60,951 (1) Primarily related to professional, consulting, and legal fees associated with the divestiture including seller due diligence and preparation of regulatory filings, as well as other disposition-related activities. (2) The Company reclassified the portion of its interest expense associated with the mandatory pay down of the Term Loan Facilities using net proceeds from the sale of the business. (3) Income tax expense for the year ended December 31, 2019 is largely due to nondeductible items that do not provide a tax benefit on the loss. (4) Income (loss) from discontinued operations, net of taxes on the Statements of Operations includes the results from retained asbestos-related contingencies attributable to the divested fluid handling business as discussed in the Asbestos Contingencies section below. Total income attributable to noncontrolling interest related to the Air and Gas Handling business, net of taxes was $5.9 million and $13.6 million for the years ended December 31, 2019 and 2018, respectively. These amounts are presented within Income attributable to noncontrolling interest, net of taxes on the Consolidated Statements of Operations. Cash used in operating activities related to the discontinued operations of the divested Air and Gas Handling business for the years ended December 31, 2020 and 2019 was $9.4 million and $18.1 million, respectively. Cash provided by operating activities related to the discontinued operations of the divested Air and Gas Handling business for the year ended December 31, 2018 was $127.8 million. Cash used in investing activities related to the discontinued operations of the divested Air and Gas Handling business was $27.5 million and $43.6 million for the years ended December 31, 2019 and 2018, respectively. Asbestos Contingencies As a result of previous divestitures, the Company retained certain asbestos-related contingencies and insurance coverages. Income (loss) from discontinued operations, net of taxes on the Statements of Operations for the years ended December 31, 2020, 2019 and 2018 includes a loss from retained asbestos-related contingencies and the 2017 divestiture of the fluid handling business of $9.5 million, $19.0 million, and $28.4 million, respectively. Net cash outflows related to asbestos claims of divested businesses were $2.2 million, $3.2 million and $5.6 million for the years ended December 31, 2020, 2019 and 2018, respectively. See Note 18, “Commitments and Contingencies” for further information.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Acquisitions	Acquisitions General The Company completed five acquisitions during the year ended December 31, 2020, which are accounted for under the acquisition method of accounting, and accordingly, the Consolidated Financial Statements include the financial position and results of operations from the respective acquisition date. The assets acquired and liabilities assumed reported on the Consolidated Balance Sheets represent the Company’s best estimate. Four of these acquisitions closed in the fourth quarter of 2020 and the Consolidated Balance Sheet at December 31, 2020 reflects our preliminary estimates of fair value and are subject to adjustment. The estimated proforma annual revenues of the acquisitions in the year ended December 31, 2020 are approximately 2% of Colfax consolidated revenues. The Company also made three other immaterial investments in medical technology businesses during the year ended December 31, 2020. For the years ended December 31, 2020, 2019, and 2018, Net sales associated with acquisitions consummated during the period were $7.1 million, $1,080.4 million, and $78.9 million, respectively. Net Income attributable to Colfax Corporation common shareholders associated with acquisitions consummated during the years ended December 31, 2020 and 2018 was not material for each respective period. Net Income attributable to Colfax Corporation common shareholders associated with acquisitions consummated during the year ended December 31, 2019 was $57.3 million. Medical Technology All five acquisitions completed in 2020 were in our Medical Technology segment for total consideration, net of cash received, of $67.5 million, subject to certain purchase price adjustments. Total Goodwill acquired through the acquisitions was $21.4 million, of which $15.9 million is expected to be deductible for income tax purposes. Acquisitions in our Medical Technology segment included LiteCure LLC (“LiteCure”), a U.S. leader in high-powered laser rehabilitation products for human and veterinary medical applications. The acquisition was completed in the fourth quarter of 2020 for net cash consideration of $39.6 million. Net working capital and intangible assets acquired represent 10% and 69% of the total consideration paid, respectively, with the residual amount primarily attributable to Goodwill. The Medical Technology segment platform at Colfax was established on February 22, 2019 when Colfax completed the acquisition of DJO. The Company paid an aggregate net purchase price of $3.15 billion. The Company incurred $2.8 million and $60.8 million of advisory, legal, audit, valuation and other professional service fees in connection with the DJO acquisition in the years ended December 31, 2020 and 2019, respectively, which are included in Selling, general and administrative expense in the Consolidated Statements of Operations. During the first quarter of 2020, as part of the fair value adjustments to the assets and liabilities acquired, the Company increased the valuation allowance on U.S. deferred taxes, presented net within Other liabilities, by $51.4 million as of the acquisition date, with a corresponding increase to Goodwill. As of the end of the first quarter of 2020, the accounting related to the DJO acquisition was finalized, and the assets and liabilities acquired are no longer subject to adjustment. The following unaudited proforma financial information presents Colfax’s consolidated financial information assuming the acquisition had taken place on January 1, 2018. These amounts are presented in accordance with U.S. GAAP, consistent with the Company’s accounting policies. Year Ended December 31, 2020 2019 2018 (In thousands) Net sales $ 3,070,769 $ 3,496,624 $ 3,395,018 Net income from continuing operations attributable to Colfax Corporation 68,039 105,491 97,410 Fabrication Technology During year ended December 31, 2018, the Company completed two acquisitions in our Fabrication Technology segment for total consideration, net of cash received, of $245.1 million, subject to certain purchase price adjustments. These acquisitions expanded the segment’s presence in specialty gas applications and broadened its global presence.

Revenue Revenue

Revenue Revenue	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company’s Fabrication Technology segment formulates, develops, manufactures and supplies consumable products and equipment. Substantially all revenue from the Fabrication Technology business is recognized at a point in time. The Company further disaggregates its Fabrication Technology revenue into the following product groups: Year Ended December 31, 2020 2019 2018 (In thousands) Equipment $ 607,504 $ 703,024 $ 623,987 Consumables 1,342,565 1,544,002 1,569,096 Total $ 1,950,069 $ 2,247,026 $ 2,193,083 Contracts with customers in the consumables product grouping generally have a shorter fulfillment period than equipment contracts. The Company’s Medical Technology segment provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s Medical Technology sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all its revenue is recognized at a point in time. The Company disaggregates its Medical Technology revenue into the following product groups: Year Ended December 31, 2020 2019 (1) (In thousands) Prevention & Rehabilitation $ 781,007 $ 766,429 Reconstructive 339,693 314,003 Total $ 1,120,700 $ 1,080,432 (1) For the year ended December 31, 2019, the Medical Technology segment includes results from the acquisition date of February 22, 2019. Given the nature of the Fabrication Technology and Medical Technology businesses, the total amount of unsatisfied performance obligations with an original contract duration of greater than one year as of December 31, 2020 is immaterial. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. In some circumstances, customers are billed in advance of revenue recognition, resulting in contract liabilities. As of December 31, 2020, 2019 and 2018, total contract liabilities were $36.6 million, $14.8 million and $13.0 million, respectively. During the years ended December 31, 2020 and 2019, all of the revenue that was included in the contract liability balance at the beginning of the respective year was recognized. Allowance for Credit Losses The Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments as of January 1, 2020. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Management elected to disaggregate trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. Pooling was further disaggregated based on either geography or product type. The Company leveraged historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model further considers current conditions and reasonable and supportable forecasts using an adjustment for current and projected macroeconomic factors. Management identified appropriate macroeconomic indicators based on tangible correlation to historical losses considering the location and risks associated with the Company. A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated Balance Sheets is as follows: Year Ended December 31, 2020 Balance at Charged to Expense, net Write-Offs and Deductions Foreign Balance at (In thousands) Allowance for credit losses $ 36,009 $ 7,574 $ (5,165) $ (752) $ 37,666

Net Income Per Share

Net Income Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Income Per Share from Continuing Operations	Net Income Per Share from Continuing Operations Net income per share from continuing operations was computed as follows: Year Ended December 31, 2020 2019 2018 (In thousands, except share and per share data) Computation of Net income per share from continuing operations - basic: Net income from continuing operations attributable to Colfax Corporation (1) $ 60,936 $ 14,245 $ 121,211 Weighted-average shares of Common stock outstanding – basic 136,766,124 135,716,944 120,288,297 Net income per share from continuing operations – basic $ 0.45 $ 0.10 $ 1.01 Computation of Net income per share from continuing operations - diluted: Net income from continuing operations attributable to Colfax Corporation (1) $ 60,936 $ 14,245 $ 121,211 Weighted-average shares of Common stock outstanding – basic 136,766,124 135,716,944 120,288,297 Net effect of potentially dilutive securities - stock options, restricted stock units and tangible equity units 2,144,304 949,942 506,759 Weighted-average shares of Common stock outstanding – diluted 138,910,428 136,666,886 120,795,056 Net income per share from continuing operations – diluted $ 0.44 $ 0.10 $ 1.00 (1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the income attributable to noncontrolling interest, net of taxes, of $3.1 million, $4.6 million, and $0.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income from continuing operations before income taxes and Income tax expense (benefit) consisted of the following: Year Ended December 31, 2020 2019 2018 (In thousands) Income from continuing operations before income taxes: Domestic operations $ (156,675) $ (129,182) $ (60,352) Foreign operations 214,704 179,675 152,716 $ 58,029 $ 50,493 $ 92,364 Income tax expense (benefit): Current: Federal $ (39,376) $ 811 $ (15,132) State 1,454 6,712 816 Foreign 56,076 56,477 41,831 $ 18,154 $ 64,000 $ 27,515 Deferred: Domestic operations $ 3,641 $ (24,151) $ (21,908) Foreign operations (27,848) (8,219) (35,115) (24,207) (32,370) (57,023) $ (6,053) $ 31,630 $ (29,508) See Note 4, “Discontinued Operations” for the income (loss) from discontinued operations before income taxes and related income taxes. On December 22, 2017, the Tax Act was signed into law making significant changes to the Internal Revenue Code which included how the U.S. imposes income tax on multinational corporations. Coinciding with the enactment of the Tax Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of enactment of the Tax Act or December 22, 2018. The Company filed its 2017 U.S. income tax return in the fourth quarter of 2018 which changed its tax basis in temporary differences and transition tax estimated as of December 31, 2017, resulting in an adjustment to the tax provision to the re-measurement amount recorded in the financial statements. As a result of this tax filing, the Company reduced its provisional amount by $10.8 million and $0.7 million for transition tax and the remeasurement of U.S. deferred taxes, respectively, for the year ended December 31, 2018. In addition, in 2020 the Company timely filed changes to U.S. federal tax returns to credit rather than to deduct foreign taxes and reduced its transition tax further by $6.8 million. The Company’s Income tax expense (benefit) from continuing operations differs from the amount that would be computed by applying the U.S. federal statutory rate as follows: Year Ended December 31, 2020 2019 (1) 2018 (1) (In thousands) Taxes calculated at the U.S. federal statutory rate $ 12,186 $ 10,677 $ 19,392 State taxes (2,196) (5,358) (3,543) Effect of tax rates on international operations (18,577) (14,115) (9,323) Change in enacted international tax rates (1,023) (2,843) (2,403) Changes in valuation allowance (24,149) 11,196 (11,577) Changes in tax reserves 1,394 1,119 (1,704) Tax Act - re-measurement of U.S. deferred taxes — — (667) Tax Act - mandatory repatriation taxes (6,766) — (10,804) Research and development tax credits (1,649) (4,029) (7,123) Foreign tax credits (12,197) (15,299) (21,927) Net items not deductible in an international jurisdiction 5,365 10,060 12,077 SubPart F and GILTI 27,797 29,407 12,872 U.S. Deal Costs and other non-deductibles 38 5,556 — Withholding taxes 8,570 4,545 3,446 Non-deductible employee compensation 6,619 714 1,068 Other (1,465) — (9,292) Income tax expense (benefit) $ (6,053) $ 31,630 $ (29,508) (1) Certain prior period amounts have been reclassified to conform with current year presentation. The valuation allowance benefit reflected above is predominately the utilization of net operating losses in the current period. Certain movements of valuation allowance, particularly related to repatriation taxes, foreign tax credits, SubPart F and GILTI, and withholding taxes haven been aggregated with that particular line item within the rate reconciliation. Deferred income taxes, net reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. The significant components of deferred tax assets and liabilities included in continuing operations, in addition to the reconciliation of the beginning and ending amount of gross unrecognized tax benefits, are as follows: December 31, 2020 2019 (In thousands) Deferred tax assets: Post-retirement benefit obligation $ 11,617 $ 11,295 Expenses currently not deductible 147,636 131,921 Net operating loss carryforward 308,965 342,442 Tax credit carryforward 33,674 16,727 Depreciation and amortization 6,433 6,487 Other 42,881 42,407 Valuation allowance (203,341) (149,037) Deferred tax assets, net $ 347,865 $ 402,242 Deferred tax liabilities: Depreciation and amortization $ (403,704) $ (415,888) Inventory (1,559) (3,694) Outside basis differences and other (78,012) (84,706) Total deferred tax liabilities $ (483,275) $ (504,288) Total deferred tax liabilities, net $ (135,410) $ (102,046) The Company evaluates the recoverability of its deferred tax assets on a jurisdictional basis by considering whether deferred tax assets will be realized on a more likely than not basis. To the extent a portion or all of the applicable deferred tax assets do not meet the more likely than not threshold, a valuation allowance is recorded. During the year ended December 31, 2020, the valuation allowance increased from $149.0 million to $203.3 million with a net increase of $6.2 million recognized in Income tax expense (benefit), $48.5 million increase attributed to finalizing our DJO purchase accounting for income taxes in the first quarter of 2020, and a $0.4 million decrease related to changes in foreign currency rates. Consideration was given to tax planning strategies and, when applicable, future taxable income as to how much of the relevant deferred tax asset could be realized on a more likely than not basis. The Company has U.S. net operating loss carryforwards of $611.3 million expiring in years 2021 through 2037 and $72.6 million that may be carried forward indefinitely. The Company’s ability to use these various carryforwards to offset any taxable income generated in future taxable periods may be limited under Section 382 and other federal tax provisions. At December 31, 2020, the Company also has $581.3 million foreign net operating loss carryforwards primarily in Brazil, Germany, the Netherlands, Sweden, and the United Kingdom that may be subject to local tax restrictive limitations including changes in ownership. The foreign net operating losses can be carried forward indefinitely, except in applicable jurisdictions that make up less than five percent of the available net operating losses. The Company has U.S. foreign tax and R&D tax credits that may be used to offset U.S. tax in previous or future tax periods subject to Section 382 and other federal provisions. The Company’s $22.7 million foreign tax credit can be carried back one year and can be carried forward to tax years through 2025-2030. The Company’s $14.0 million R&D credit can be carried back one year and can be carried forward to tax years through 2021-2040. For the year ended December 31, 2020, all undistributed earnings of the Company’s foreign subsidiaries, which are indefinitely reinvested outside the U.S., were provisionally estimated to be $184.0 million. The Company has assessed a total deferred tax liability of $1.9 million as of December 31, 2020 on such earnings that have not been indefinitely reinvested. This is a decrease of $2 million as compared to the deferred tax liability as of December 31, 2019. The Company records a liability for unrecognized income tax benefits for the amount of benefit included in its previously filed income tax returns and in its financial results expected to be included in income tax returns to be filed for periods through the date of its Consolidated Financial Statements for income tax positions for which it is more likely than not that a tax position will not be sustained upon examination by the respective taxing authority. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (inclusive of associated interest and penalties): (In thousands) Balance, December 31, 2017 $ 41,018 Addition for tax positions taken in prior periods 2,525 Addition for tax positions taken in the current period 240 Reductions related to settlements with taxing authorities (461) Reductions resulting from a lapse of applicable statute of limitations (4,477) Other, including the impact of foreign currency translation and U.S. tax rate changes (1,224) Balance, December 31, 2018 $ 37,621 Acquisitions and divestitures 18,248 Addition for tax positions taken in prior periods 1,441 Addition for tax positions taken in the current period 2,054 Reductions related to settlements with taxing authorities (118) Reductions resulting from a lapse of applicable statute of limitations (3,643) Other, including the impact of foreign currency translation and U.S. tax rate changes (123) Balance, December 31, 2019 $ 55,480 Addition for tax positions taken in prior periods $ 5,911 Addition for tax positions taken in the current period $ 1,980 Reductions related to settlements with taxing authorities $ — Reductions resulting from a lapse of applicable statute of limitations $ (5,689) Other, including the impact of foreign currency translation and U.S. tax rate changes $ 332 Balance, December 31, 2020 $ 58,014 The Company is routinely examined by tax authorities around the world. Tax examinations remain in process in multiple countries, including but not limited to the United States, Germany, Indonesia, the Netherlands, Mexico, Brazil, Russia, Italy and various U.S. states. The Company files numerous group and separate tax returns in U.S. federal and state jurisdictions, as well as international jurisdictions. In the U.S., tax years dating back to 2006 remain subject to examination, due to tax attributes available to be carried forward to open or future tax years. With some exceptions, other major tax jurisdictions generally are not subject to tax examinations for years beginning before 2014. The Company’s total unrecognized tax benefits were $58.0 million and $55.5 million as of December 31, 2020 and 2019, respectively, inclusive of $6.9 million and $5.7 million, respectively, of interest and penalties. The Company records interest and penalties on uncertain tax positions as a component of Income tax expense (benefit), which was $0.7 million, $1.0 million and $1.1 million for the years ended December 31, 2020, 2019 and 2018, respectively. Due to the difficulty in predicting with reasonable certainty when tax audits will be fully resolved and closed, the range of reasonably possible significant increases or decreases in the liability for unrecognized tax benefits that may occur within the next 12 months is difficult to ascertain. Currently, the Company estimates that it is reasonably possible that the expiration of various statutes of limitations, resolution of tax audits and court decisions may reduce its tax expense in the next 12 months up to $4.8 million.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	Goodwill and Intangible Assets The following table summarizes the activity in Goodwill, by segment during the years ended December 31, 2020 and 2019: Medical Technology Fabrication Total (In thousands) Balance, January 1, 2019 $ — $ 1,497,832 $ 1,497,832 Goodwill attributable to acquisitions (1) 1,674,328 8,406 1,682,734 Impact of foreign currency translation (1,407) 23,358 21,951 Balance, December 31, 2019 1,672,921 1,529,596 3,202,517 Goodwill attributable to acquisitions (1) 72,815 — 72,815 Impact of foreign currency translation 15,574 23,635 39,209 Balance, December 31, 2020 $ 1,761,310 $ 1,553,231 $ 3,314,541 (1) Includes purchase accounting adjustments associated with acquisitions discussed in Note 5, “Acquisitions”. See Note 4, “Discontinued Operations” for discussion of the Air And Gas segment impairment recorded in 2019 as part of the divestiture, which is presented within Income (loss) from discontinued operations, net of taxes on the Consolidated Statements of Operations. The following table summarizes the Company’s Intangible assets, excluding Goodwill: December 31, 2020 2019 Gross Accumulated Gross Accumulated (In thousands) Indefinite-Lived Intangible Assets Trade names $ 212,048 $ — $ 193,465 $ — Definite-Lived Intangible Assets Acquired customer relationships 952,007 (266,347) 919,574 (182,813) Acquired technology 455,738 (99,748) 440,719 (60,971) Acquired trade names 404,076 (41,960) 389,112 (21,069) Software 129,852 (90,196) 103,274 (71,644) Other intangible assets 24,511 (16,535) 22,809 (13,437) $ 2,178,232 $ (514,786) $ 2,068,953 $ (349,934) Amortization expense related to intangible assets was included in the Consolidated Statements of Operations as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Selling, general and administrative expense $ 158,427 $ 135,769 $ 43,703 See Note 2, “Summary of Significant Accounting Policies” for discussion regarding impairment of Intangible assets. Expected Amortization Expense The Company’s expected annual amortization expense for intangible assets for the next five years: December 31, 2020 (In thousands) 2021 $ 153,923 2022 148,995 2023 143,325 2024 137,707 2025 136,620

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net December 31, Depreciable Life 2020 2019 (In years) (In thousands) Land n/a $ 23,821 $ 25,138 Buildings and improvements 5-40 205,397 196,810 Machinery and equipment 3-15 570,411 528,848 799,629 750,796 Accumulated depreciation (312,669) (259,555) Property, plant and equipment, net $ 486,960 $ 491,241 Depreciation expense for the years ended December 31, 2020, 2019 and 2018, was $85.5 million, $76.1 million and $34.2 million, respectively. Impairment of fixed assets recorded for the years ended December 31, 2020, 2019 and 2018 was $2.1 million, $0.5 million and $3.1 million, respectively.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net Inventories, net consisted of the following: December 31, 2020 2019 (In thousands) Raw materials $ 110,848 $ 115,587 Work in process 40,517 37,019 Finished goods 476,297 475,933 627,662 628,539 Less: allowance for excess, slow-moving and obsolete inventory (62,840) (56,981) Inventories, net $ 564,822 $ 571,558

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Leases The Company leases certain office spaces, warehouses, facilities, vehicles, and equipment. Leases with an initial term of twelve months or less are not recorded on the balance sheet. Most leases include renewal options, which can extend the lease term into the future. The Company determines the lease term by assuming options that are reasonably certain of being renewed will be exercised. Certain of the Company’s leases include rental payments adjusted for inflation. The right-of-use lease asset and lease liability are recorded on the Consolidated Balance Sheet, with the current lease liability being included in Accrued liabilities. Operating lease expense was $45.0 million for the year ended December 31, 2020, and approximated cash paid for leases during the year. December 31, 2020 (In thousands) Future lease payments by year: 2021 $ 42,516 2022 33,809 2023 26,836 2024 18,987 2025 14,073 Thereafter 71,838 Total 208,059 Less: present value discount (30,578) Present value of lease liabilities $ 177,481 Weighted-average remaining lease term (in years): Operating leases 8.6 Weighted-average discount rate: Operating leases 3.7 %

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt Long-term debt consisted of the following: December 31, 2020 2019 (In thousands) Term loan $ 781,557 $ 822,945 Euro senior notes 425,045 388,925 TEU amortizing notes 31,251 54,044 2024 and 2026 notes 991,319 989,236 Revolving credit facilities and other 2,071 56,676 Total debt 2,231,243 2,311,826 Less: current portion (27,074) (27,642) Long-term debt $ 2,204,169 $ 2,284,184 Term Loan Facilities and Revolving Credit Facility The Company’s credit agreement (the “Credit Facility”) by and among the Company, as the borrower, certain U.S. subsidiaries of the Company, as guarantors, each of the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Citizens Bank, N.A., as syndication agent, and the co-documentation agents named therein consists of a $975 million revolving credit facility (the “Revolver”) and a Term A-1 loan with an initial aggregate principal amount of $825 million (the “Term Loan”), each with a maturity date of December 6, 2024. The Revolver contains a $50 million swing line loan sub-facility. Certain U.S. subsidiaries of the Company guarantee the obligations under the Credit Facility. The Credit Facility contains customary covenants limiting the ability of Colfax and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments or pay dividends. In addition, the Credit Facility contains financial covenants requiring Colfax to maintain (subject to certain exceptions) (i) a maximum total leverage ratio, calculated as the ratio of Consolidated Net Debt (as defined in the Credit Facility) to EBITDA (as defined in the Credit Facility) and (ii) a minimum interest coverage ratio. During the third quarter of 2020, the Company made a voluntary $40 million principal payment on the Term Loan. On May 1, 2020, the Company entered into an amendment to its Credit Facility (the “Amendment”). The Amendment, among other changes, modified the total leverage ratio by permitting the Company to deduct (subject to certain exceptions) up to $125 million of unrestricted cash and cash equivalents from the debt component of the ratio and by increasing the maximum total leverage ratio to 5.75:1.00 as of June 30, 2020, 6.50:1.00 as of each fiscal quarter thereafter until March 31, 2021, 5.25:1.00 for the quarter ending June 30, 2021, 4.50:1.00 for the quarter ending September 30, 2021, 4.25:1.00 for the quarters ending December 31, 2021 and March 31, 2022, 4.00:1.00 for the quarters ending June 30, 2022 and September 30, 2022, and 3.50:1.00 as of December 31, 2022 and for each fiscal quarter ending thereafter. Under the terms of the Amendment the interest coverage ratio remained at 3.00:1.00 for the quarter ending June 30, 2020, decreased to 2.75:1.00 for each of the fiscal quarters ending September 30, 2020 until June 30, 2021, and then will increase back to 3.00:1.00 for the quarters ending September 30, 2021 and thereafter. The Amendment added a “springing” collateral provision (based upon the Gross Leverage Ratio as defined in the Amendment to the Credit Facility) which requires the obligations under the Amendment to the Credit Facility to be secured by substantially all personal property of Colfax and its U.S. subsidiaries and the equity of its first tier foreign subsidiaries, subject to customary exceptions, in the event Colfax’s Gross Leverage Ratio under the Credit Facility is greater than 5.00:1.00 as of the last day of any fiscal quarter. Lastly, the Amendment added a fifth pricing tier in the event the total leverage ratio is greater than 4.50:1.00 (regardless of the corporate family rating), with pricing at 2.50%, in the case of the Eurocurrency margin, 1.50%, in the case of the base rate margin, and 0.50% when undrawn. The total commitment and maturity of the Credit Facility remained unchanged. The Credit Facility contains various events of default (including failure to comply with the covenants under the Credit Facility and related agreements) and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Term Loan Facilities and the Revolver. As of December 31, 2020, the Company was in compliance with the covenants under the Credit Facility. As of December 31, 2020, the weighted-average interest rate of borrowings under the Credit Facility was 1.90%, excluding accretion of original issue discount and deferred financing fees, and there was $975 million available on the Revolver. The Company has $10.4 million in deferred financing fees recorded in conjunction with the Credit Facility as of December 31, 2020, which is being accreted to Interest expense, net primarily using the effective interest method over the life of the facility. Euro Senior Notes On April 19, 2017, the Company issued senior unsecured notes with an aggregate principal amount of €350 million (the “Euro Notes”). The Euro Notes are due in April 2025, have an interest rate of 3.25% and are guaranteed by certain of our domestic subsidiaries (the “Guarantees”). The proceeds from the Euro Notes offering were used to repay borrowings under our previous credit facilities totaling €283.5 million, as well as for general corporate purposes. In conjunction with the issuance of the Euro notes, the Company recorded $6 million of deferred financing fees. The Euro Notes and the Guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction. TEU Amortizing Notes On January 11, 2019, the Company issued $460 million in tangible equity units. The Company offered 4 million of its 5.75% tangible equity units at the stated amount of $100 per unit and an option to purchase up to an additional 600,000 tangible equity units at the stated amount of $100 per unit, which was exercised in full at settlement. Total cash of $447.7 million was received upon closing, comprised of $377.8 million TEU prepaid stock purchase contracts and $69.9 million of TEU amortizing notes due January 2022. The proceeds were used to finance a portion of the purchase price for the DJO acquisition and for general corporate purposes. For more information, refer to Note 14, “Equity.” 2024 Notes and 2026 Notes On February 5, 2019, two tranches of senior notes with aggregate principal amounts of $600 million (the “2024 Notes”) and $400 million (the “2026 Notes”) were issued to finance a portion of the purchase price for the DJO acquisition. The 2024 Notes are due on February 15, 2024 and have an interest rate of 6.0%. The 2026 Notes are due on February 15, 2026 and have an interest rate of 6.375%. Each tranche of notes is guaranteed by certain domestic subsidiaries of the Company. Other Indebtedness In addition to the debt agreements discussed above, the Company is party to various bilateral credit facilities with a borrowing capacity of $195.0 million. As of December 31, 2020, there were no outstanding borrowings under these facilities. The Company is party to letter of credit facilities with an aggregate capacity of $340.5 million. Total letters of credit of $76.4 million were outstanding as of December 31, 2020. In total, the Company had deferred financing fees of $22.6 million included in its Condensed Consolidated Balance Sheet as of December 31, 2020, which will be charged to Interest expense, net, primarily using the effective interest method, over the life of the applicable debt agreements. Total Debt The contractual maturities of the Company’s debt as of December 31, 2020 are as follows: (In thousands) 2021 $ 27,074 2022 6,507 2023 — 2024 1,385,000 2025 428,242 Thereafter 400,000 Total contractual maturities 2,246,823 Debt discount (15,580) Total debt $ 2,231,243

Equity

Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Equity	Equity Share Repurchase Program On February 12, 2018, the Company’s Board of Directors authorized the repurchase of up to $100 million of the Company’s Common stock from time-to-time on the open market or in privately negotiated transactions. The Board of Directors increased the repurchase authorization by an additional $100 million on June 6, 2018. On July 19, 2018, the Board of Directors increased the repurchase authorization by another $100 million. The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. During the year ended December 31, 2018, the Company repurchased 6,449,425 shares of our Common stock in open market transactions for $200 million. There were no repurchases made during the years ended December 31, 2020 and 2019. As of December 31, 2020, the remaining stock repurchase authorization by the Company’s Board of Directors was $100 million. There is no term associated with the remaining repurchase authorization. Accumulated Other Comprehensive Loss The following table presents the changes in the balances of each component of Accumulated other comprehensive loss including reclassifications out of Accumulated other comprehensive loss for the years ended December 31, 2020, 2019 and 2018. All amounts are net of tax and noncontrolling interest, if any. Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post-Retirement Benefit Cost Foreign Currency Translation Adjustment Unrealized Gain (Loss) On Hedging Activities Changes in Fair Value of Available-for-Sale Securities Total (In thousands) Balance at January 1, 2018 $ (84,338) $ (525,324) $ 30,138 $ 5,152 $ (574,372) Other comprehensive income (loss) before reclassifications: Net actuarial gain 5,609 — — — 5,609 Foreign currency translation adjustment 1,145 (222,158) (424) — (221,437) Loss on long-term intra-entity foreign currency transactions — (5,507) — — (5,507) Gain on net investment hedges — — 16,745 — 16,745 Unrealized loss on cash flow hedges — — (2,153) — (2,153) Other comprehensive income (loss) before reclassifications: 6,754 (227,665) 14,168 — (206,743) Amounts reclassified from Accumulated other comprehensive loss (1) 6,090 — — — 6,090 Net current period Other comprehensive income (loss) 12,844 (227,665) 14,168 — (200,653) Cumulative effect of accounting change — — — (5,152) (5,152) Balance at December 31, 2018 $ (71,494) $ (752,989) $ 44,306 $ — $ (780,177) Other comprehensive income (loss) before reclassifications: Net actuarial loss (27,931) — — — (27,931) Foreign currency translation adjustment (404) (78,468) (65) — (78,937) Divestiture-related AOCI write-off — 400,143 — — 400,143 Gain on long-term intra-entity foreign currency transactions — 29,385 — — 29,385 Gain on net investment hedges — — 6,215 — 6,215 Unrealized loss on cash flow hedges — — 156 — 156 Other comprehensive income (loss) before reclassifications: (28,335) 351,060 6,306 — 329,031 Amounts reclassified from Accumulated other comprehensive loss (1) 2,629 — — — 2,629 Noncontrolling interest share repurchase — (19,960) — (19,960) Net current period Other comprehensive income (loss) (25,706) 331,100 6,306 — 311,700 Cumulative effect of accounting change (9,300) — (6,068) — (15,368) Balance at December 31, 2019 $ (106,500) $ (421,889) $ 44,544 $ — $ (483,845) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (1,849) 57,623 3,378 — 59,152 Gain on long-term intra-entity foreign currency transactions — 3,289 — — 3,289 Loss on net investment hedges — — (26,268) — (26,268) Other comprehensive income (loss) before reclassifications: (1,849) 60,912 (22,890) — 36,173 Amounts reclassified from Accumulated other comprehensive loss (1) (4,434) — — — (4,434) Net current period Other comprehensive income (loss) (6,283) 60,912 (22,890) — 31,739 Balance at December 31, 2020 $ (112,783) $ (360,977) $ 21,654 $ — $ (452,106) (1) Included in the computation of net periodic benefit cost. See Note 16, “Defined Benefit Plans” for additional details. During the year ended December 31, 2020, Noncontrolling interest decreased by $2.6 million as a result of Other comprehensive income, primarily due to foreign currency translation adjustments. During the years ended December 31, 2019 and 2018, Noncontrolling interest decreased by $107.6 million and $22.8 million, respectively, as a result of Other comprehensive income, primarily due to the Howden sale and foreign currency translation adjustment. Share-Based Payments On May 21, 2020, the shareholders of the Company approved the Colfax Corporation 2020 Omnibus Incentive Plan (the “2020 Plan”) which replaced the Colfax Corporation 2016 Omnibus Incentive Plan dated May 13, 2016 (the “2016 Plan”). Upon the approval of the 2020 Plan, no additional ordinary shares were to be granted under the previously approved plans. All awards previously granted and outstanding under the prior plans remain subject to the terms of those prior plans. The 2020 Plan provides the Compensation Committee of the Company’s Board of Directors discretion in creating employee equity incentives. Awards under the 2020 Plan may be made in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, performance-based stock, performance-based stock units, dividend equivalents, and other stock-based awards. The Company measures and recognizes compensation expense related to share-based payments based on the fair value of the instruments issued. Stock-based compensation expense is generally recognized as a component of Selling, general and administrative expense in the Consolidated Statements of Operations, as payroll costs of the employees receiving the awards are recorded in the same line item. The Company’s Consolidated Statements of Operations reflect the following amounts related to stock-based compensation: Year Ended December 31, 2020 2019 2018 (In thousands) Stock-based compensation expense $ 28,911 $ 21,960 $ 25,103 Deferred tax benefit 1,804 1,280 3,418 As of December 31, 2020, the Company had $32.4 million of unrecognized compensation expense related to stock-based awards that will be recognized over a weighted-average period of 0.9 years. The intrinsic value of awards exercised or issued upon vesting was $11.5 million, $11.2 million and $10.2 million during the years ended December 31, 2020, 2019 and 2018, respectively. Stock Options Under the 2020 Plan, the Company may grant options to purchase Common stock, with a maximum term of 10 years at a purchase price equal to the market value of the Company’s Common stock on the date of grant. Stock-based compensation expense for stock option awards is based upon the grant-date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense for stock option awards on a straight-line basis over the requisite service period of the entire award. The following table shows the weighted-average assumptions used to calculate the fair value of stock option awards using the Black-Scholes option pricing model, as well as the weighted-average fair value of options granted: Year Ended December 31, 2020 2019 2018 Expected period that options will be outstanding (in years) 4.62 4.56 4.54 Interest rate (based on U.S. Treasury yields at the time of grant) 1.09 % 2.46 % 2.65 % Volatility 37.76 % 34.51 % 31.89 % Dividend yield — — — Weighted-average fair value of options granted $ 11.81 $ 8.80 $ 10.37 During the years ended December 31, 2020, 2019 and 2018, expected volatility was estimated based on the historical volatility of the Company’s stock price. The Company considers historical data to estimate employee termination within the valuation model. Separate groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved “simplified method” noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. Stock option activity is as follows: Number Weighted- Weighted- Aggregate (1) (In thousands) Outstanding at January 1, 2020 4,675,281 $ 34.93 Granted 618,403 35.89 Exercised (126,576) 27.64 Forfeited and expired (568,041) 45.75 Outstanding at December 31, 2020 4,599,067 33.92 3.53 $ 29,875 Vested or expected to vest at December 31, 2020 4,543,740 33.94 3.53 $ 29,549 Exercisable at December 31, 2020 2,943,374 35.76 2.74 $ 17,315 (1) The aggregate intrinsic value is based upon the difference between the Company’s closing stock price at the date of the Consolidated Balance Sheet and the exercise price of the stock option for in-the-money stock options. The intrinsic value of outstanding stock options fluctuates based upon the trading value of the Company’s Common stock. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was $1.1 million, $2.0 million and $1.4 million, respectively. The fair value of options vested during the years ended December 31, 2020, 2019 and 2018 was $11.9 million, $10.9 million and $8.5 million, respectively. Restricted Stock Units Under the 2020 Plan, the Compensation Committee of the Board of Directors may award performance-based restricted stock units (“PRSUs”), the vesting of which is contingent upon meeting service conditions and various performance goals. During the years ended December 31, 2020 and 2019, the Company granted certain employees PRSUs, the vesting of which is fully based on the Company’s total shareholder return (“TSR”) ranking among a peer group over a three-year performance period. The awards also have a service requirement that equals the respective performance periods. During the year ended December 31, 2018, PRSUs were awarded under the 2016 Plan based upon two discrete measures: a profit performance metric and relative total shareholder return (TSR). The profit performance metric, which accounts for 50% of the PRSU award upon issuance, is measured upon the completion of a three-year performance period ending December 31, 2020. The vesting of the stock units is determined based on whether the Company achieves the applicable performance criteria established by the Compensation Committee of the Board of Directors. The remaining 50% of the PRSU award is tied exclusively to relative TSR performance, which will be measured against the three-year TSR of a custom index of companies. TSR relative to peers is considered a market condition under applicable authoritative guidance, while the profit performance metric is considered a performance condition. If the market condition or performance goals are achieved, the units may be subject to an additional holding period requirement as determined at the time of grant. PRSUs with TSR conditions are valued at grant date using a binomial-lattice model (i.e., Monte Carlo simulation model), while PRSUs with a profit performance metric are valued at the market value of a share of Common stock on the date of grant taking into consideration the probability of achieving the specified performance goal. The Company estimates the ultimate payout of PRSUs with a profit performance metric and adjusts the cumulative expense based on its estimate and the percent of the requisite service period that has elapsed. PRSUs with TSR conditions are recognized on a straight-line basis over the performance periods regardless of the performance condition achievement because the probability is factored into the valuation of the award. The related compensation expense for each of the awards is recognized, on a straight-line basis, over the vesting period. Based on the results of the profit performance metric, 2018 PRSUs are expected to vest above target. The performance period for the 2018 PRSUs with TSR conditions does not end until March 7, 2021 and they are expected to vest below target Under the 2020 Plan, the Compensation Committee of the Board of Directors may also award non-performance-based restricted stock units (“RSUs”) to select executives, employees and outside directors, which typically vest three years after the date of grant. With limited exceptions, the employee must remain in service until the vesting date. The Compensation Committee determines the terms and conditions of each award, including the restriction period and other criteria applicable to the awards. Directors may also elect to defer their annual board fees into RSUs with immediate vesting. Delivery of the shares underlying these director restricted stock units is deferred until termination of the director’s service on the Company’s Board of Directors. The activity in the Company’s PRSUs and RSUs is as follows: PRSUs RSUs Number Weighted- Number Weighted- Nonvested at January 1, 2020 741,375 $ 30.87 595,376 $ 29.25 Granted 142,987 50.91 554,192 34.80 Vested (103,629) 29.90 (226,912) 30.30 Forfeited and expired (49,332) 27.93 (88,693) 29.52 Nonvested at December 31, 2020 731,401 35.12 833,963 32.52 The weighted-average grant-date fair value of PRSUs granted during the years ended December 31, 2019 and 2018 was $24.77 and $33.92, respectively. The weighted-average grant-date fair value of RSUs granted during the years ended December 31, 2019 and 2018 was $27.58 and $32.92, respectively. The fair value of shares vested during the years ended December 31, 2020, 2019 and 2018 was $9.7 million, $10.9 million and $10.0 million, respectively. Tangible equity unit (“TEU”) offering On January 11, 2019, the Company issued $460 million in tangible equity units. The Company offered 4 million of its 5.75% tangible equity units at the stated amount of $100 per unit and an option to purchase up to an additional 600,000 tangible equity units at the stated amount of $100 per unit, which was exercised in full at settlement. Total cash of $447.7 million was received upon closing. The proceeds from the issuance of the TEUs were allocated initially to equity and debt based on the relative fair value of the respective components of each TEU as follows: TEU prepaid stock purchase contracts TEU amortizing notes Total (In millions, except per unit amounts) Fair value per unit $ 84.39 $ 15.61 $ 100.00 Gross proceeds $ 388.2 $ 71.8 $ 460.0 Less: Issuance costs 10.4 1.9 12.3 Net Proceeds $ 377.8 $ 69.9 $ 447.7 The $377.8 million fair value of the prepaid stock purchase contracts was recorded in Additional paid-in capital in the Consolidated Balance Sheets. The fair value of the $69.9 million of TEU amortizing notes due January 2022 has both a short-term and a long-term component. Upon the issuance of the TEUs, $47.3 million was initially recorded in Long-term debt, less current portion, and $22.6 million was initially recorded in Current portion of long-term debt in the Consolidated Balance Sheets. The Company deferred certain debt issuance costs associated with the debt component of the TEUs. These amounts offset the debt liability balance in the Consolidated Balance Sheets and are being amortized over its term. As of December 31, 2020, the TEU amortizing notes were recorded with $6.5 million in long-term debt and $25.0 million in Current portion of long-term debt in the Consolidated Balance Sheets. TEU prepaid stock purchase contracts Unless previously settled at the holder’s option, for each purchase contract the Company will deliver to holders on January 15, 2022 (subject to postponement in certain limited circumstances, the “mandatory settlement date”) a number of shares of common stock. The number of shares of common stock issuable upon settlement of each purchase contract (the “settlement rate”) will be determined using the arithmetic average of the volume average weighted price for the 20 consecutive trading days beginning on, and including, the 21st scheduled trading day immediately preceding January 15, 2022 (“the Applicable Market Value”) with reference to the following settlement rates: • if the Applicable Market Value of the common stock is greater than the threshold appreciation price of $25.00, then the holder will receive 4.0000 shares of common stock for each purchase contract (the “minimum settlement rate”); • if the Applicable Market Value of the common stock is greater than or equal to the reference price of $20.81, but less than or equal to the threshold appreciation price of $25.00, then the holder will receive a number of shares of common stock for each purchase contract having a value, based on the Applicable Market Value, equal to $100; and • if the Applicable Market Value of the common stock is less than the reference price of $20.81, the holder will receive 4.8054 shares of common stock for each purchase contract (the “maximum settlement rate”). TEU amortizing notes Each TEU amortizing note has an initial principal amount of $15.6099, bears interest at a rate of 6.50% per annum and has a final installment payment date of January 15, 2022. On each January 15, April 15, July 15 and October 15, the Company pays equal quarterly cash installments of $1.4375 per TEU amortizing note, which will constitute a payment of interest and a partial repayment of principal, and which cash payment in the aggregate per year will be equivalent to 5.75% per year with respect to the $100 stated amount per unit. The Company has paid $26.5 million representing a partial payment of principal and interest on the TEU amortizing notes in 2020. The TEU amortizing notes are the direct, unsecured and unsubordinated obligations of the Company and rank equally with all of the existing and future other unsecured and unsubordinated indebtedness of the Company. Earnings per share Unless the 4.6 million stock purchase contracts are redeemed by the Company or settled earlier at the unit holder’s option, they are mandatorily convertible into shares of Colfax common stock at not less than 4.0 shares per purchase contract or more than 4.8054 shares per purchase contract on January 15, 2022. This corresponds to not less than 18.4 million shares and not more than 22.1 million shares at the maximum. The 18.4 million minimum shares are included in the calculation of weighted-average shares of Common stock outstanding - basic. The difference between the minimum and maximum shares represents potentially dilutive securities. The Company includes them in its calculation of weighted-average shares of Common stock outstanding - diluted on a pro rata basis to the extent the average Applicable Market Value is higher than the reference price but is less than the conversion price. Repurchase of noncontrolling interest shares During 2019, the Company repurchased all of the noncontrolling interest shares of its South Africa consolidated subsidiary from existing shareholders under a general offer. As a part of the Air and Gas Handling business, this subsidiary was subsequently sold on September 30, 2019, and its results of operations are included in discontinued operations for all periods presented.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities in the Consolidated Balance Sheets consisted of the following: December 31, 2020 2019 (In thousands) Accrued compensation and related benefits $ 98,455 $ 100,290 Accrued taxes 57,286 55,258 Accrued asbestos-related liability 41,626 64,394 Warranty liability - current portion 15,543 15,513 Accrued restructuring liability - current portion 7,889 6,961 Accrued third-party commissions 25,480 30,768 Customer advances and billings in excess of costs incurred 36,737 16,009 Lease liability - current portion 39,695 40,021 Accrued interest 27,153 27,333 Other 104,469 113,343 Accrued liabilities $ 454,333 $ 469,890 Accrued Restructuring Liability The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated Balance Sheets is as follows: Year Ended December 31, 2020 Balance at Beginning of Period Provisions Payments Foreign Currency Translation Balance at End of Period (3) (In thousands) Restructuring and other related charges: Fabrication Technology: Termination benefits (1) $ 1,638 $ 11,381 $ (7,698) $ 15 $ 5,336 Facility closure costs (2) 1,284 8,358 (9,060) 9 591 Subtotal 2,922 19,739 (16,758) 24 5,927 Non-cash charges (2) 1,894 Fabrication Technology total provisions 21,633 Medical Technology: Termination benefits (1) 3,919 3,284 (5,405) 86 1,884 Facility closure costs (2) 257 17,125 (17,085) — 297 Subtotal 4,176 20,409 (22,490) 86 2,181 Non-cash charges (2) 2,985 Medical Technology total provisions 23,394 Total $ 7,098 40,148 $ (39,248) $ 110 $ 8,108 Non-cash charges (2) 4,879 Total Colfax provisions $ 45,027 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment and lease termination expense in connection with the closure of facilities. During the year ended December 31, 2020, the Company recorded a total of $1.9 million and $3.0 million non-cash impairment charges for facilities in the Fabrication Technology and Medical Technology segments, respectively, as part of Corporate approved restructuring activities. Restructuring charges in the Medical Technology segment during the year ended December 31, 2020 include costs related to product and distribution channel transformations, facilities optimization, and integration charges, as well as $6.6 million classified as Cost of sales on the Company’s Consolidated Statements of Operations for the year ended December 31, 2020. (3) As of December 31, 2020, $7.9 million and $0.2 million of the Company’s restructuring liability was included in Accrued liabilities and Other liabilities, respectively. Year Ended December 31, 2019 Balance at Beginning of Period Acquisitions Provisions Payments Foreign Currency Translation Balance at End of Period (3) (In thousands) Restructuring and other related charges: Fabrication Technology: Termination benefits (1) $ 5,494 $ 7,131 $ (10,588) $ (399) $ 1,638 Facility closure costs (2) 662 11,711 (11,136) 47 1,284 6,156 18,842 (21,724) (352) 2,922 Non-cash charges 4,198 23,040 Medical Technology: Termination benefits (1) — 6,096 5,449 (7,626) — 3,919 Facility closure costs (2) — 298 45,258 (45,299) — 257 — 6,394 50,707 (52,925) — 4,176 Total $ 6,156 $ 6,394 69,549 $ (74,649) $ (352) $ 7,098 Non-cash charges (2) 4,198 $ 73,747 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment and lease termination expense in connection with the closure of facilities. During the year ended December 31, 2019, the Company recorded a $4.2 million non-cash impairment charge for facilities in our Fabrication Technology segment as part of Corporate approved restructuring activities. Restructuring charges in the Medical Technology segment also include $8.5 million classified as Cost of sales on the Company’s Consolidated Statements of Operations for the year ended December 31, 2019. (3) As of December 31, 2019, $7.0 million and $0.1 million of the Company’s restructuring liability was included in Accrued liabilities and Other liabilities, respectively.

Defined Benefit Plans Defined B

Defined Benefit Plans Defined Benefit Plans	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Defined Benefit Plans	Defined Benefit Plans The Company sponsors various defined benefit plans, defined contribution plans and other post-retirement benefits plans, including health and life insurance, for certain eligible employees or former employees. The Company uses December 31 st as the measurement date for all of its employee benefit plans. In connection with the sale of the Air and Gas Handling business, the purchaser assumed the Air and Gas Handling liability for all defined benefit plans specific to the Air and Gas Handling business. Net benefit cost for the years ended December 31, 2019 and 2018 for the Air and Gas Handling business is included in Net income (loss) from discontinued operations, net of taxes, within the Consolidated Statements of Operations. See Note 4, “Discontinued Operations” for further information. During the year ended December 31, 2019, the Company settled two non-U.S. pension plans, one in our Fabrication Technology segment and one in our Air and Gas Handling segment through third-party buyout arrangements. As a result of these settlements, the Company has no further funding obligations under these two plans and recognized a loss of $77.4 million in 2019, which is partly reflected in Pension settlement loss in the Consolidated Statements of Operations. As the Company divested its Air and Gas Handling segment during the year ended December 31, 2019, the related settlement loss of $43.8 million is included in Net income (loss) from discontinued operations, net of taxes, within the Consolidated Statements of Operations. See Note 4, “Discontinued Operations” for further information. The following table summarizes the total changes in the Company’s pension and accrued post-retirement benefits and plan assets and includes a statement of the plans’ funded status: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2020 2019 (In thousands) Change in benefit obligation: Projected benefit obligation, beginning of year $ 361,146 $ 867,345 $ 13,057 $ 13,844 Acquisitions — 2,264 — — Service cost 1,933 2,462 8 5 Interest cost 7,454 16,556 313 445 Plan amendment 95 464 — 15 Actuarial loss (gain) (1) 21,642 183,084 1,139 (382) Foreign exchange effect 9,757 (912) (3) (4) Benefits paid (24,105) (40,131) (1,170) (866) Divestitures — (50,468) — — Settlements (418) (619,756) — — Other 1,791 238 — — Projected benefit obligation, end of year $ 379,295 $ 361,146 $ 13,344 $ 13,057 Accumulated benefit obligation, end of year $ 375,267 $ 356,741 $ 13,344 $ 13,057 Change in plan assets: Fair value of plan assets, beginning of year $ 251,291 $ 850,024 $ — $ — Actual return on plan assets 26,123 88,869 — — Employer contribution 9,830 10,793 1,170 866 Foreign exchange effect 2,806 1,236 — — Benefits paid (24,105) (40,131) (1,170) (866) Divestitures — (39,897) — — Settlements (418) (619,756) — — Other 1,727 153 — — Fair value of plan assets, end of year $ 267,254 $ 251,291 $ — $ — Funded status, end of year $ (112,041) $ (109,855) $ (13,344) $ (13,057) Amounts recognized on the Consolidated Balance Sheet at December 31: Non-current assets $ — $ — $ — $ — Current liabilities (3,800) (3,596) (1,028) (1,177) Non-current liabilities (108,241) (106,259) (12,316) (11,880) Total $ (112,041) $ (109,855) $ (13,344) $ (13,057) (1) The reported actuarial loss in 2020 is primarily due to the decrease in discount rates in most markets. The reported actuarial loss in 2019 is primarily due to the settlements of two pension plans and decrease in discount rates in most markets. For pension plans with accumulated benefit obligations in excess of plan assets, the accumulated benefit obligation and fair value of plan assets were $367.4 million and $259.1 million, respectively, as of December 31, 2020 and $345.1 million and $238.9 million, respectively, as of December 31, 2019. For pensions plans with projected benefit obligations in excess of plan assets, the projected benefit obligation and fair value of plan assets were $376.0 million and $263.9 million, respectively, as of December 31, 2020 and $359.5 million and $249.6 million, respectively, as of December 31, 2019. The following table summarizes the changes in the Company’s foreign pension benefit obligation, which is determined based upon an employee’s expected date of separation, and plan assets, included in the table above, and includes a statement of the plans’ funded status: Foreign Pension Benefits Year Ended December 31, 2020 2019 (In thousands) Change in benefit obligation: Projected benefit obligation, beginning of year $ 144,739 $ 661,084 Acquisitions — 2,264 Service cost 1,933 2,340 Interest cost 2,315 9,376 Plan amendments 95 464 Actuarial loss (1) 5,778 164,888 Foreign exchange effect 9,757 (912) Benefits paid (8,795) (24,779) Divestitures — (50,468) Settlements (418) (619,756) Other 1,791 238 Projected benefit obligation, end of year $ 157,195 $ 144,739 Accumulated benefit obligation, end of year $ 153,167 $ 140,335 Change in plan assets: Fair value of plan assets, beginning of year $ 67,535 $ 691,758 Acquisitions — — Actual return on plan assets 4,037 51,318 Employer contribution 6,222 7,502 Foreign exchange effect 2,806 1,236 Benefits paid (8,795) (24,779) Divestitures — (39,897) Settlements (418) (619,756) Other 1,727 153 Fair value of plan assets, end of year $ 73,114 $ 67,535 Funded status, end of year $ (84,081) $ (77,204) (1) The reported actuarial loss in 2020 is primarily due to the decrease in discount rates in most markets. The reported actuarial loss in 2019 is primarily due to the settlements of two pension plans and decrease in discount rates in most markets. Expected contributions to the Company’s pension and other post-employment benefit plans for the year ending December 31, 2021, related to plans as of December 31, 2020, are $6.9 million. The following benefit payments are expected to be paid during each respective fiscal year: Pension Benefits Other Post-Retirement Benefits All Plans Foreign Plans (In thousands) 2021 $ 25,147 $ 9,276 $ 1,028 2022 24,495 8,925 954 2023 23,858 8,641 884 2024 22,989 8,182 839 2025 22,689 8,315 830 2026 - 2030 105,337 40,832 3,731 The Company’s primary investment objective for its pension plan assets is to provide a source of retirement income for the plans’ participants and beneficiaries. The assets are invested with the goal of preserving principal while providing a reasonable real rate of return over the long term. Diversification of assets is achieved through strategic allocations to various asset classes. Actual allocations to each asset class vary due to periodic investment strategy changes, market value fluctuations, the length of time it takes to fully implement investment allocation positions, and the timing of benefit payments and contributions. The asset allocation is monitored and rebalanced as required, as frequently as on a quarterly basis in some instances. The following are the actual and target allocation percentages for the Company’s pension plan assets: Actual Asset Allocation 2020 2019 Allocation U.S. Plans: Equity securities: U.S. 44 % 44 % 30%-45% International 16 % 15 % 10% -20% Fixed income 39 % 39 % 30% -50% Other — % — % 0%-20% Cash and cash equivalents 1 % 2 % 0%-5% Foreign Plans: Equity securities 27 % 27 % 0%-40% Fixed income securities 10 % 11 % 0%-15% Cash and cash equivalents — % — % 0%-25% Other 63 % 62 % 55%-90% A summary of the Company’s pension plan assets for each fair value hierarchy level for the periods presented follows (see Note 17, “Financial Instruments and Fair Value Measurements” for further description of the levels within the fair value hierarchy): December 31, 2020 Measured at Net Asset Value (1) Level Level Level (In thousands) U.S. Plans: Cash and cash equivalents $ — $ 1,752 $ — $ — 1,752 Equity securities: U.S. large cap 51,728 — — — 51,728 U.S. small/mid cap 21,175 12,895 — — 34,070 International 30,552 — — — 30,552 Fixed income mutual funds: U.S. government and corporate 74,978 — — — 74,978 Other (2) — 1,060 — — 1,060 Foreign Plans: Cash and cash equivalents — 239 — — 239 Equity securities — 19,513 — — 19,513 Non-U.S. government and corporate bonds — 5,331 1,922 — 7,253 Other (2) — — 46,109 — 46,109 $ 178,433 $ 40,790 $ 48,031 $ — $ 267,254 (1) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term. (2) Represents diversified portfolio funds, reinsurance contracts and money market funds. December 31, 2019 Measured at Net Asset Value (1) Level Level Level (In thousands) U.S. Plans: Cash and cash equivalents $ — $ 2,855 $ — $ — $ 2,855 Equity securities: U.S. large cap 48,582 — — 48,582 U.S. small/mid cap 20,093 12,268 — — 32,361 International 28,573 — — — 28,573 Fixed income mutual funds: U.S. government and corporate 70,334 — — — 70,334 Other (2) — 1,051 — — 1,051 Foreign Plans: Cash and cash equivalents — 215 — — 215 Equity securities — 18,462 — — 18,462 Non-U.S. government and corporate bonds — 5,299 1,911 — 7,210 Other (2) — — 41,648 — 41,648 $ 167,582 $ 40,150 $ 43,559 $ — $ 251,291 (1) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting primarily of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term. (2) Represents diversified portfolio funds, reinsurance contracts and money market funds. The following table sets forth the components of net periodic benefit cost (income) and Other comprehensive income of the Company’s defined benefit pension plans and other post-retirement employee benefit plans: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 (In thousands) Components of Net Periodic Benefit Cost (Income): Service cost $ 1,933 $ 2,462 $ 2,770 $ 8 $ 5 $ 19 Interest cost 7,454 16,556 21,574 313 445 452 Amortization 4,960 3,385 4,282 (231) (255) (28) Settlement loss (gain) 99 77,390 (39) — — — Divestitures gain — (4,354) — — — — Other 143 79 (458) — — — Expected return on plan assets (12,773) (19,774) (29,306) — — — Net periodic benefit cost (income) $ 1,816 $ 75,744 $ (1,177) $ 90 $ 195 $ 443 Change in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income: Current year net actuarial (gain) loss $ 10,379 $ 113,995 $ (11,816) $ 1,143 $ (380) $ (723) Current year prior service cost 74 464 3,800 — 15 — Less amounts included in net periodic benefit cost: Amortization of net (gain) loss (4,914) (3,285) (4,330) 231 270 31 Settlement/divestiture/other (gain) loss (177) (83,602) 39 — — — Amortization of prior service cost (46) (100) 48 — (15) (3) Total recognized in Other comprehensive income $ 5,316 $ 27,472 $ (12,259) $ 1,374 $ (110) $ (695) Net periodic benefit cost (income) of $44.4 million and $(1.4) million for the years ended December 31, 2019 and 2018, respectively, are included in Income (loss) from discontinued operations, net of taxes. Net periodic benefit cost included in loss from discontinued operations for the year ended December 31, 2019 includes $43.8 million in settlement loss related to the Air and Gas Handling segment. Each component of Net periodic benefit cost from continuing operations, with the exception of Settlement loss, is included in Selling, general and administrative expense. The following table sets forth the components of net periodic benefit cost and Other comprehensive loss (gain) of the foreign defined benefit pension plans, included in the table above: Foreign Pension Benefits Year Ended December 31, 2020 2019 2018 (In thousands) Components of Net Periodic Benefit Cost: Service cost $ 1,933 $ 2,340 $ 2,634 Interest cost 2,315 9,376 15,183 Amortization 747 334 1,039 Settlement loss (gain) 99 77,390 (39) Divestitures gain — (4,354) — Other 143 79 (458) Expected return on plan assets (2,397) (9,092) (18,310) Net periodic benefit cost $ 2,840 $ 76,073 $ 49 Change in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Loss: Current year net actuarial loss (gain) $ 6,226 $ 122,667 $ (31,854) Current year prior service cost 74 464 3,800 Less amounts included in net periodic benefit cost: Amortization of net loss (701) (234) (1,087) Settlement/divestiture/other (gain) loss (177) (83,602) 39 Amortization of prior service cost (46) (100) 48 Total recognized in Other comprehensive loss $ 5,376 $ 39,195 $ (29,054) The components of net unrecognized pension and other post-retirement benefit cost included in Accumulated other comprehensive loss in the Consolidated Balance Sheets that have not been recognized as a component of net periodic benefit cost are as follows: Pension Benefits Other Post-Retirement December 31, December 31, 2020 2019 2020 2019 (In thousands) Net actuarial loss (gain) $ 105,947 $ 100,659 $ (2,031) $ (3,405) Prior service cost 477 449 — — Total $ 106,424 $ 101,108 $ (2,031) $ (3,405) The components of net unrecognized pension and other post-retirement benefit cost included in Accumulated other comprehensive loss in the Consolidated Balance Sheet that are expected to be recognized as a component of net periodic benefit cost during the year ending December 31, 2021 are as follows: Pension Benefits Other Post- (In thousands) Net actuarial loss (gain) $ 5,929 $ (74) Prior service cost 55 — Total $ 5,984 $ (74) The key economic assumptions used in the measurement of the Company’s pension and other post-retirement benefit obligations are as follows: Pension Benefits Other Post-Retirement December 31, December 31, 2020 2019 2020 2019 Weighted-average discount rate: All plans 1.7 % 2.5 % 2.1 % 3.0 % Foreign plans 1.4 % 1.9 % — % — % Weighted-average rate of increase in compensation levels for active foreign plans 0.6 % 0.8 % — % — % The key economic assumptions used in the computation of net periodic benefit cost are as follows: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 Weighted-average discount rate: All plans 2.5 % 3.0 % 2.6 % 3.0 % 4.0 % 3.4 % Foreign plans 1.9 % 2.7 % 2.4 % — % — % — % Weighted-average expected return on plan assets: All plans 5.7 % 3.1 % 3.8 % — % — % — % Foreign plans 4.1 % 2.4 % 3.2 % — % — % — % Weighted-average rate of increase in compensation levels for active foreign plans 0.8 % 1.8 % 2.1 % — % — % — % In determining discount rates, the Company utilizes the single discount rate equivalent to discounting the expected future cash flows from each plan using the yields at each duration from a published yield curve as of the measurement date. For measurement purposes, a weighted-average annual rate of increase in the per capita cost of covered health care benefits of 6.5% was assumed. The rate was assumed to decrease gradually to 4.5% by 2031 and remain at that level thereafter for benefits covered under the plans. The expected long-term rate of return on plan assets was based on the Company’s investment policy target allocation of the asset portfolio between various asset classes and the expected real returns of each asset class over various periods of time that are consistent with the long-term nature of the underlying obligations of these plans. A one-percentage point change in assumed health care cost trend rates would have the following pre-tax effects: 1% Increase 1% Decrease (In thousands) Effect on total service and interest cost components for the year ended December 31, 2020 $ 17 $ (14) Effect on post-retirement benefit obligation at December 31, 2020 695 (591) The Company maintains defined contribution plans covering certain union and non-union employees. The Company’s expense for the years ended December 31, 2020, 2019 and 2018 was $10.2 million, $6.9 million and $6.3 million, respectively. Total expense included in Income (loss) income from discontinued operations, net of taxes for the years ended December 31, 2019 and 2018 was $4.2 million and $5.9 million, respectively.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level One: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets. Level Two: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level Three: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of financial instruments, including Trade receivables, other receivables and Accounts payable, approximate their fair values due to their short-term maturities. The estimated fair value of the Company’s debt of $2.3 billion as of December 31, 2020 and 2019 was based on current interest rates for similar types of borrowings and is in Level Two of the fair value hierarchy. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. A summary of the Company’s assets and liabilities that are measured at fair value on a recurring basis for each fair value hierarchy level for the periods presented is as follows: December 31, 2020 Level Level Level Total (In thousands) Assets: Cash equivalents $ 7,420 $ — $ — $ 7,420 Foreign currency contracts related to sales - not designated as hedges — 1,897 — 1,897 Foreign currency contracts related to purchases - not designated as hedges — 297 — 297 Deferred compensation plans — 10,881 — 10,881 $ 7,420 $ 13,075 $ — $ 20,495 Liabilities: Foreign currency contracts related to sales - not designated as hedges $ — $ 1,313 $ — $ 1,313 Foreign currency contracts related to purchases - designated as hedges — 468 — 468 Deferred compensation plans — 10,881 — 10,881 $ — $ 12,662 $ — $ 12,662 December 31, 2019 Level Level Level Total (In thousands) Assets: Cash equivalents $ 13,125 $ — $ — $ 13,125 Foreign currency contracts related to sales - not designated as hedges — 74 — 74 Foreign currency contracts related to purchases - not designated as hedges — 408 — 408 Deferred compensation plans — 8,870 — 8,870 $ 13,125 $ 9,352 $ — $ 22,477 Liabilities: Foreign currency contracts related to sales - not designated as hedges $ — $ 328 $ — $ 328 Foreign currency contracts related to purchases - not designated as hedges — 853 — 853 Deferred compensation plans — 8,870 — 8,870 $ — $ 10,051 $ — $ 10,051 There were no transfers in or out of Level One, Two or Three during the years ended December 31, 2020 and 2019. Cash Equivalents The Company’s cash equivalents consist of investments in interest-bearing deposit accounts and money market mutual funds which are valued based on quoted market prices. The fair value of these investments approximate cost due to their short-term maturities and the high credit quality of the issuers of the underlying securities. Derivatives The Company periodically enters into foreign currency derivative contracts. As the Company has manufacturing sites throughout the world and sells its products globally, the Company is exposed to movements in the exchange rates of various currencies. As a result, the Company enters into foreign currency swaps and forward contracts to mitigate this exchange rate risk. Additionally, to mitigate a portion of the foreign exchange risk associated with the translation of the net assets of foreign subsidiaries, the Company has senior unsecured notes denominated in Euro which has been designated as a net investment hedge. See Note 13, “Debt” for details. As the Company’s borrowings under the Credit Facility include variable interest rates, the Company may periodically enter into interest rate swap or collar agreements to mitigate interest rate risk. Commodity derivative contracts can be used to manage costs of raw materials used in the Company’s production processes. There were no changes during the periods presented in the Company’s valuation techniques used to measure asset and liability fair values on a recurring basis. Foreign Currency Contracts Foreign currency contracts are measured using broker quotations or observable market transactions in either listed or over-the-counter markets. The Company primarily uses foreign currency contracts to mitigate the risk associated with customer forward sale agreements denominated in currencies other than the applicable local currency, and to match costs and expected revenues where production facilities have a different currency than the selling currency. As of December 31, 2020 and 2019, the Company had foreign currency contracts with the following notional values: December 31, 2020 2019 (In thousands) Foreign currency contracts sold - not designated as hedges $ 152,504 $ 28,718 Foreign currency contracts purchased - not designated as hedges 97,897 107,090 Total foreign currency derivatives $ 250,401 $ 135,808 The Company recognized the following in its Consolidated Financial Statements related to its derivative instruments: Year Ended 2020 2019 2018 (In thousands) Contracts Designated as Hedges: Unrealized gain (loss) on net investment hedges (1) $ (26,268) $ 6,215 $ 16,745 Contracts Not Designated in a Hedge Relationship: Foreign Currency Contracts - related to customer sales contracts: Unrealized gain 704 (395) 890 Realized gain (loss) 941 (1,565) (1,083) Foreign Currency Contracts - related to supplier purchases contracts: Unrealized gain (loss) 707 (216) (820) Realized gain (loss) (936) 523 (407) (1) The unrealized gain (loss) on net investment hedges is attributable to the change in valuation of Euro denominated debt. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade accounts receivable. Concentrations of credit risk are considered to exist when there are amounts collectible from multiple counterparties with similar characteristics, which could cause their ability to meet contractual obligations to be similarly impacted by economic or other conditions. The Company performs credit evaluations of its customers prior to delivery or commencement of services and normally does not require collateral. Letters of credit are occasionally required when the Company deems necessary. There are no customers which represent more than 10% of the Company’s Accounts receivable, net as of December 31, 2020 and 2019.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Asbestos and Other Product Liability Contingencies Certain subsidiaries are each one of many defendants in a large number of lawsuits that claim personal injury as a result of exposure to asbestos from products manufactured with components that are alleged to have contained asbestos. Such components were acquired from third-party suppliers, and were not manufactured by any of the Company’s subsidiaries nor were the subsidiaries producers or direct suppliers of asbestos. The manufactured products that are alleged to have contained asbestos generally were provided to meet the specifications of the subsidiaries’ customers, including the U.S. Navy. The subsidiaries settle asbestos claims for amounts the Company considers reasonable given the facts and circumstances of each claim. The annual average settlement payment per asbestos claimant has fluctuated during the past several years. The Company expects such fluctuations to continue in the future based upon, among other things, the number and type of claims settled in a particular period and the jurisdictions in which such claims arise. To date, the majority of settled claims have been dismissed for no payment. Pursuant to the purchase agreement from the Fluid Handling business divestiture, the Company retained its asbestos-related contingencies and insurance coverages. However, as the Company does not retain an interest in the ongoing operations of the business subject to the contingencies, asbestos-related activity is classified as part of Income (loss) from discontinued operations, net of taxes in its Consolidated Statements of Operations. Claims activity since December 31 related to asbestos claims is as follows: Year Ended 2020 2019 2018 (Number of claims) Claims unresolved, beginning of period 16,299 16,417 17,737 Claims filed (1) 4,014 4,486 4,078 Claims resolved (2) (5,504) (4,604) (5,398) Claims unresolved, end of period 14,809 16,299 16,417 (In dollars) Average cost of resolved claims (3) $ 12,055 $ 9,455 $ 7,497 (1) Claims filed include all asbestos claims for which notification has been received or a file has been opened. (2) Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants. (3) Excludes claims settled in Mississippi for which the majority of claims have historically been resolved for no payment and insurance recoveries. The Company has projected each subsidiary’s future asbestos-related liability costs with regard to pending and future unasserted claims based upon the Nicholson methodology. The Nicholson methodology is a standard approach used by experts and has been accepted by numerous courts. It is the Company’s policy to record a liability for asbestos-related liability costs for the longest period of time that it can reasonably estimate. The Company believes that it can reasonably estimate the asbestos-related liability for pending and future claims that will be resolved in the next 15 years and has recorded that liability as its best estimate. While it is reasonably possible that the subsidiaries will incur costs after this period, the Company does not believe the reasonably possible loss or a range of reasonably possible losses is estimable at the current time. Accordingly, no accrual has been recorded for any costs which may be paid after the next 15 years. Defense costs associated with asbestos-related liabilities as well as costs incurred related to litigation against the subsidiaries’ insurers are expensed as incurred. Each subsidiary has separate insurance coverage acquired prior to Company ownership of each independent entity. The Company has evaluated the insurance assets for each subsidiary based upon the applicable policy language and allocation methodologies, and law pertaining to the affected subsidiary’s insurance policies. One of the subsidiaries was notified in 2010 by the primary and umbrella carrier who had been fully defending and indemnifying the subsidiary for 20 years that the limits of liability of its primary and umbrella layer policies had been exhausted. The subsidiary has sought coverage from certain excess layer insurers whose coverage obligations were disputed in Delaware state court, and were the subject of various rulings, including a September 12, 2016 ruling on certain appealed issues by the Delaware Supreme Court. This litigation confirmed that asbestos-related costs should be allocated among excess insurers using an “all sums” allocation (which allows an insured to collect all sums paid in connection with a claim from any insurer whose policy is triggered, up to the policy’s applicable limits), that the subsidiary has the right to access coverage available under excess insurance policies purchased by a former owner of the business, and that, the subsidiary has a right to immediately access the excess layer policies. Further, the Delaware Supreme Court ruled in the subsidiary’s favor on a “trigger of coverage” issue, holding that every policy in place during or after the date of a claimant’s first significant exposure to asbestos was “triggered” and potentially could be accessed to cover that claimant’s claim. The Court also largely affirmed but reversed in part some of the prior lower court rulings on defense obligations and whether payment of defense costs erode policy limits or are payable in addition to policy limits. Based upon these rulings, the Company currently estimates that the subsidiary’s future expected recovery percentage is 90.7% of asbestos-related costs, with the subsidiary expected to be responsible for 9.3% of its future asbestos-related costs. Since approximately mid-2011, the Company had funded $173.4 million of the subsidiary’s asbestos-related defense and indemnity costs through December 31, 2020, which it expects to recover from insurers. Based on the above-referenced court rulings, the Company requested that its insurers reimburse all of the $94.9 million that remained outstanding at the time of the ruling, and the Company currently has received substantially all of that amount. The subsidiary also has requested that certain excess insurers provide ongoing coverage for future asbestos-related defense and/or indemnity costs. To the extent any disagreements concerning excess insurers’ payment obligations under the Delaware Supreme Court’s rulings remain, they are expected to be resolved by Delaware court action, which is still pending and has been remanded to the Delaware Superior Court for any further proceedings. In the interim, and while not impacting the results of operations, the Company’s cash funding for future asbestos-related defense and indemnity costs for which it expects reimbursement from insurers could range up to $10 million per quarter. In 2003, another subsidiary filed a lawsuit against a large number of its insurers and its former parent to resolve a variety of disputes concerning insurance for asbestos-related bodily injury claims asserted against it. Court rulings in 2007 and 2009 clarified the insurers allocation methodology as mandated by the New Jersey courts, the allocation calculation related to amounts currently due from insurers, and amounts the Company expects to be reimbursed for asbestos-related costs incurred in future periods. A final judgment at the trial court level was rendered in 2011 and confirmed by the Appellate Division in 2014. In 2015, the New Jersey Supreme Court refused to grant certification of the appeals, effectively ending the matter. The subsidiary expects to be responsible for 22.2% of all future asbestos-related costs. During the year ended December 31, 2018, the Company recorded a $5.9 million increase in asbestos-related liabilities due to the rate of filings and higher settlement values per claim, relating to timing of the mix of claims resolved. The related insurance asset was accordingly increased $4.8 million, resulting in a net pre-tax charge of $1.1 million. During the year ended December 31, 2019, the Company recorded a $28.4 million increase in asbestos-related liabilities due to a revision in forecast assumptions for filing rates and resolution values. The related insurance asset was accordingly increased $15.1 million, resulting in a net pre-tax charge of $13.3 million. During the year ended December 31, 2020, the Company recorded a $11.6 million increase in asbestos-related liabilities due to a revision in forecast assumptions for filing rates and resolution values. The related insurance asset was accordingly increased $3.9 million, resulting in a net pre-tax charge of $7.7 million. For all periods, the net pre-tax charge is included in Income (loss) from discontinued operations, net of taxes in the Consolidated Statements of Operations. The Company’s Consolidated Balance Sheets included the following amounts related to asbestos-related litigation: December 31, 2020 2019 (In thousands) Current asbestos insurance receivable (1) $ — $ 4,474 Long-term asbestos insurance asset (2) 232,712 281,793 Long-term asbestos insurance receivable (2) 31,815 41,629 Accrued asbestos liability (3) 41,626 64,394 Long-term asbestos liability (4) 253,144 286,105 (1) Included in Other current assets in the Consolidated Balance Sheets. (2) Included in Other assets in the Consolidated Balance Sheets. (3) Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay, and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company’s insurers, which is included in Accrued liabilities in the Consolidated Balance Sheets. (4) Included in Other liabilities in the Consolidated Balance Sheets. Management’s analyses are based on currently known facts and a number of assumptions. However, projecting future events, such as new claims to be filed each year, the average cost of resolving each claim, coverage issues among layers of insurers, the method in which losses will be allocated to the various insurance policies, interpretation of the effect on coverage of various policy terms and limits and their interrelationships, the continuing solvency of various insurance companies and the collectability of claims tendered, the amount of remaining insurance available, as well as the numerous uncertainties inherent in asbestos litigation could cause the actual liabilities and insurance recoveries to be higher or lower than those projected or recorded which could materially affect the Company’s financial condition, results of operations or cash flow. General Litigation The Company is also involved in various other pending legal proceedings arising out of the ordinary course of the Company’s business. None of these legal proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings and the litigation and claims described in the preceding paragraphs, management of the Company believes that it will either prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Any costs that management estimates may be paid related to these proceedings or claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these legal proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company. Minimum Lease Obligations The Company’s minimum obligations under non-cancelable operating leases are as follows: December 31, 2020 (In thousands) 2021 $ 42,516 2022 33,809 2023 26,836 2024 18,987 2025 14,073 Thereafter 71,838 Total $ 208,059 The Company’s operating leases extend for varying periods and, in some cases, contain renewal options that would extend the existing terms. During the years ended December 31, 2020, 2019 and 2018, the Company’s net rental expense related to operating leases was $38.0 million, $34.3 million and $26.6 million, respectively. Off-Balance Sheet Arrangements As of December 31, 2020, the Company had $276.9 million of unconditional purchase obligations with suppliers, the majority of which is expected to be paid by December 31, 2021.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Information	Segment Information The Company conducts its continuing operations through the Fabrication Technology and Medical Technology operating segments, which also represent the Company’s reportable segments. • Fabrication Technology - a leading global supplier of consumable products and equipment for use in the cutting, joining and automated welding, as well as gas control equipment, providing a wide range of products with innovative technologies to solve challenges in a wide range of industries. • Medical Technology - a leader in orthopedic solutions, providing devices, software and services spanning the full continuum of patient care, from injury prevention to joint replacement to rehabilitation. Certain amounts not allocated to the two reportable segments and intersegment eliminations are reported under the heading “Corporate and other.” The Company’s management evaluates the operating results of each of its reportable segments based upon Net sales and segment operating income (loss), which represents Operating income (loss) before restructuring and certain other charges. The Company’s segment results were as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net sales: Fabrication Technology $ 1,950,069 $ 2,247,026 $ 2,193,083 Medical Technology 1,120,700 1,080,432 — Total Net sales $ 3,070,769 $ 3,327,458 $ 2,193,083 Segment operating income (loss) (1) : Fabrication Technology $ 246,011 $ 302,601 $ 249,934 Medical Technology 29,079 96,170 — Corporate and other (60,840) (121,412) (69,321) Total segment operating income $ 214,250 $ 277,359 $ 180,613 Depreciation, amortization and other impairment charges: Fabrication Technology $ 76,644 $ 80,072 $ 79,712 Medical Technology 168,227 134,001 — Corporate and other 1,358 1,534 1,495 Total depreciation, amortization and other impairment charges $ 246,229 $ 215,607 $ 81,207 Capital expenditures: Fabrication Technology $ 40,137 $ 44,454 $ 40,512 Medical Technology 74,624 57,326 — Corporate and other 24 59 1,275 Total capital expenditures $ 114,785 $ 101,839 $ 41,787 (1) The following is a reconciliation of Income (loss) before income taxes to segment operating income: Year Ended December 31, 2020 2019 2018 Income from continuing operations before income taxes $ 58,029 $ 50,493 $ 92,364 Loss on short-term investments — — 10,128 Pension settlement loss (gain) — 33,616 (39) Interest expense, net 104,262 119,503 49,083 Restructuring and other related charges (1) 45,027 73,747 29,077 MDR and other costs (2) 6,932 — — Segment operating income $ 214,250 $ 277,359 $ 180,613 (1) Restructuring and other related charges includes $6.6 million and $8.5 million of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and 2019, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. December 31, 2020 2019 (In thousands) Investments in Equity Method Investees: Fabrication Technology $ 32,409 $ 31,134 Medical Technology — — $ 32,409 $ 31,134 Total Assets: Fabrication Technology $ 3,390,747 $ 3,509,023 Medical Technology 3,575,644 3,480,815 Corporate and other 385,158 396,994 Total $ 7,351,549 $ 7,386,832 The detail of the Company’s operations by geography is as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net Sales by Origin (1) : United States $ 1,283,651 $ 1,464,152 $ 540,533 Foreign locations 1,787,118 1,863,306 1,652,550 Total $ 3,070,769 $ 3,327,458 $ 2,193,083 (1) The Company attributes revenues from external customers to individual countries based upon the country in which the sale was originated. December 31, 2020 2019 (In thousands) Property, Plant and Equipment, Net (1) : United States $ 221,549 $ 222,293 Czech Republic 65,188 62,469 India 39,612 41,528 United Kingdom 20,181 20,097 Russia 19,490 23,149 Other Foreign locations 120,940 121,705 Total $ 486,960 $ 491,241 (1) As the Company does not allocate all long-lived assets, specifically intangible assets, to each individual country, evaluation of long-lived assets in total is impracticable.

Selected Quarterly Data - (unau

Selected Quarterly Data - (unaudited)	12 Months Ended
	Dec. 31, 2020
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Data - (unaudited)	Selected Quarterly Data—(unaudited) Provided below is selected unaudited quarterly financial data for the years ended December 31, 2020 and 2019. Quarter Ended April 3, 2020 (1)(3) July 3, 2020 (3) October 2, December 31, 2020 (2)(3)(4) (In thousands, except per share data) Net sales $ 816,356 $ 620,360 $ 805,931 $ 828,122 Gross profit 348,214 241,086 344,120 354,685 Net income (loss) from continuing operations 8,868 (3,142) 16,836 41,520 Loss from discontinued operations, net of taxes (3,360) (4,905) (2,641) (7,405) Net income (loss) attributable to Colfax Corporation 4,481 (8,474) 13,406 33,212 Net income (loss) per share - basic Continuing operations $ 0.06 $ (0.03) $ 0.12 $ 0.30 Discontinued operations $ (0.02) $ (0.04) $ (0.02) $ (0.05) Consolidated operations $ 0.03 $ (0.06) $ 0.10 $ 0.24 Net income (loss) per share - diluted Continuing operations $ 0.06 $ (0.03) $ 0.12 $ 0.29 Discontinued operations $ (0.02) $ (0.04) $ (0.02) $ (0.05) Consolidated operations $ 0.03 $ (0.06) $ 0.10 $ 0.24 (1) The results for the quarter ended April 3, 2020 include the impact of six additional days as compared to the quarter ended March 29, 2019 due to our accounting close schedule and leap year. (2) The results for the quarter ended December 31, 2020 include the impact of five fewer days as compared to the quarter ended December 31, 2019 due to our accounting close schedule. (3) The sum of the net income (loss) per share amounts may not add due to rounding. (4) The results from continuing operations includes the impact from discrete income tax benefits mainly associated with internal entity structural changes and finalization of tax return filing positions. Quarter Ended March 29, June 28, September 27, December 31, (In thousands, except per share data) Net sales $ 683,919 $ 908,647 $ 846,519 $ 888,373 Gross profit 261,013 376,058 368,142 395,843 Net income (loss) from continuing operations (21,530) 2,212 3,770 34,411 Income (loss) from discontinued operations, net of taxes (26,472) (468,817) 9,024 (49,744) Net income (loss) attributable to Colfax Corporation (52,023) (469,234) 10,474 (16,863) Net income (loss) per share - basic Continuing operations $ (0.17) $ 0.01 $ 0.02 $ 0.24 Discontinued operations $ (0.22) $ (3.46) $ 0.06 $ (0.36) Consolidated operations $ (0.39) $ (3.45) $ 0.08 $ (0.12) Net income (loss) per share - diluted Continuing operations $ (0.17) $ 0.01 $ 0.02 $ 0.24 Discontinued operations $ (0.22) $ (3.46) $ 0.06 $ (0.36) Consolidated operations $ (0.39) $ (3.45) $ 0.08 $ (0.12)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 19, 2021, the Company, through its wholly-owned subsidiary, DJO, acquired Trilliant Surgical (“Trilliant”), a national provider of foot and ankle orthopedic implants, for $82.0 million cash consideration. The leading product technologies of Trilliant support the Medical Technology segment’s focused expansion into the adjacent high-growth $1 billion U.S. foot and ankle market. Trilliant has a broad product portfolio that covers the full universe of foot reconstructive and fixation procedures, and includes the novel Arsenal Foot Plating System, designed for greater flexibility and speed of implant placement.

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure	Balance at Charged to Cost and (1) Charged to Other (2) Write-Offs Write-Downs and Foreign Balance at (Dollars in thousands) Year Ended December 31, 2020: Allowance for credit losses (3) $ 36,009 $ 7,574 $ — $ (5,165) $ (752) $ 37,666 Allowance for excess slow-moving and obsolete inventory 36,231 35,836 — (9,346) 119 62,840 Valuation allowance for deferred tax assets 149,037 6,194 48,525 — (415) 203,341 Year Ended December 31, 2019: Allowance for credit losses $ 35,152 $ 14,018 $ — $ (16,255) $ (281) $ 32,634 Allowance for excess slow-moving and obsolete inventory 41,130 10,655 — (15,302) (252) 36,231 Valuation allowance for deferred tax assets 148,023 11,250 9,100 (18,636) (700) 149,037 Year Ended December 31, 2018: Allowance for credit losses $ 31,488 $ 13,258 $ — $ (7,381) $ (2,213) $ 35,152 Allowance for excess slow-moving and obsolete inventory 34,960 20,446 — (12,113) (2,163) 41,130 Valuation allowance for deferred tax assets 155,131 9,743 7,180 (16,706) (7,325) 148,023 (1) Amounts charged to expense are net of recoveries for the respective period. (2) Represents amounts charged to goodwill and reclassifications to deferred tax asset accounts. (3) The Allowance for credit losses as of January 1, 2020 includes the cumulative-effect adjustment of the adoption of ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries and the noncontrolling parties’ ownership share is presented as a noncontrolling interest. All significant intercompany accounts and transactions have been eliminated.
Equity Method Investments	Equity Method InvestmentsInvestments in joint ventures, where the Company has a significant influence but not a controlling interest, are accounted for using the equity method of accounting. Investments accounted for under the equity method are initially recorded at the amount of the Company’s initial investment and adjusted each period for the Company’s share of the investee’s income or loss and dividends paid. All equity investments are reviewed periodically for indications of other-than-temporary impairment, including, but not limited to, significant and sustained decreases in quoted market prices or a series of historic and projected operating losses by investees. If the decline in fair value is considered to be other-than-temporary, an impairment loss is recorded and the investment is written down to a new carrying value. Investments in joint ventures acquired in a business combination are recognized in the opening balance sheet at fair value.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when control of promised goods or services is transferred to the customer. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the goods or services. The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue. Estimates are based on historical or anticipated performance and represent the Company’s best judgment at the time. Any estimates are evaluated on a quarterly basis until the uncertainty is resolved. Additionally, related to sales of its medical device products and services, the Company maintains provisions for estimated contractual allowances for reimbursement amounts from certain third-party payers based on negotiated contracts, historical experience for non-contracted payers, and the impact of new contract terms or modifications of existing arrangements with these customers. We report these allowances as a reduction to net sales. The Company provides a variety of products and services to its customers. Most of the Company’s contracts consist of a single, distinct performance obligation or promise to transfer goods or services to a customer. A majority of revenue recognized by the Company relates to contracts with customers for standard or off-the-shelf products. As control typically transfers to the customer upon shipment of the product in these circumstances, revenue is generally recognized at that point in time. Revenue recognition and billing typically occur simultaneously for contracts recognized at a point in time. Therefore, we do not have material revenues in excess of customer billings or billings to customers in excess of recognized revenues. For service contracts, the Company recognizes revenue ratably over the period of performance as the customer simultaneously receives and consumes the benefits of the services provided. The Company applies the available practical expedient involving the existence of a significant financing component. As the Company generally does not receive payments greater than one year in advance or arrears of revenue recognition, the Company does not consider any arrangements to include financing components. The period of benefit for the Company’s incremental costs of obtaining a contract generally have less than a one-year duration; therefore, the Company applies the practical expedient available and expenses costs to obtain a contract when incurred.
Taxes Collected From Customers and Remitted To Governmental Authorities	Taxes Collected from Customers and Remitted to Governmental Authorities The Company collects various taxes and fees as an agent in connection with the sale of products and remits these amounts to the respective taxing authorities. These taxes and fees have been presented on a net basis in the Consolidated Statements of Operations and are recorded as a component of Accrued liabilities in the Consolidated Balance Sheets until remitted to the respective taxing authority.
Research and Development Expense	Research and Development Expense
Interest Expense, Net	Interest Expense, NetInterest expense, net includes interest income of $3.2 million, $3.2 million and $2.5 million for the years ended December 31, 2020, 2019 and 2018, respectively, primarily associated with interest bearing deposits of certain foreign subsidiaries.
Cash and Cash Equivalents, Restricted Cash	Cash and Cash Equivalents Cash and cash equivalents include all financial instruments purchased with an initial maturity of three months or less. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Consolidated Balance Sheets. Restricted cash is recorded as a component of Other current assets on the Consolidated Balance Sheets.
Trade Receivables	Trade Receivables Trade receivables are presented net of an allowance for credit losses. The Company adopted ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
Inventories	Inventories Inventories, net include the cost of material, labor and overhead and are stated at the lower of cost (determined under various methods including average cost, last-in, first-out and first-in, first-out, but predominantly first-in, first-out) or net realizable value. The value of inventory stated using the last-in, first-out method as of December 31, 2020 and 2019 was $105.1 million and $121.8 million, respectively. The Company periodically reviews its quantities of inventories on hand and compares these amounts to the expected usage of each particular product. The Company records a charge to Cost of sales for any amounts required to reduce the carrying value of inventories to its net realizable value.
Property, Plant and Equipment	Property, Plant and Equipment
Impairment of Goodwill and Indefinite-Lived Intangible Assets	Impairment of Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the costs in excess of the fair value of net assets acquired through acquisitions by the Company. Indefinite-lived intangible assets consist of certain trade names. The Company evaluates the recoverability of Goodwill and indefinite-lived intangible assets annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. The annual impairment test date elected by the Company is the first day of our fourth quarter. Goodwill and indefinite-lived intangible assets are considered to be impaired when the carrying value of a reporting unit or asset exceeds its fair value. The Company currently has two reporting units: Medical Technology and Fabrication Technology. In the evaluation of goodwill for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If the Company determines that it is more likely than not for a reporting unit’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not for a reporting unit’s fair value to be less than its carrying value, a calculation of the reporting entity’s fair value is performed and compared to the carrying value of that entity. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that reporting unit is impaired and an impairment loss is recorded equal to the excess of the reporting unit’s carrying value over its fair value. When a quantitative impairment test is needed, the Company measures fair value of reporting units based on a present value of future discounted cash flows and a market valuation approach. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted average cost of capital, revenue growth rates, long-term rate of growth, profitability of our business, tax rates, and working capital effects. The market valuation approach indicates the fair value of the business based on a comparison against certain market information. Significant estimates in the market approach model include identifying appropriate peer companies, market multiples and assessing earnings before interest, income taxes, depreciation and amortization. A quantitative annual impairment test of Goodwill for the Fabrication Technology reporting unit was performed for the year ended December 31, 2020, while qualitative assessments were performed for the years ended December 31, 2019 and 2018, both of which indicated no impairment existed. A quantitative annual impairment test of Goodwill for the Medical Technology reporting unit was performed for the year ended December 31, 2020, and a qualitative assessment was performed for the year ended December 31, 2019, both of which indicated no impairment existed. In the evaluation of indefinite-lived intangible assets for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying value. If the Company determines that it is more likely than not for the indefinite-lived intangible asset’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not that the indefinite-lived intangible asset’s fair value is less than its carrying value, a calculation is performed and compared to the carrying value of the asset. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying amount of the indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company measures the fair value of its indefinite-lived intangible assets using the “relief from royalty” method. Significant estimates in this approach include projected revenues and royalty and discount rates for each trade name evaluated. A quantitative impairment test was performed for all the indefinite-lived trade name brands in the Fabrication Technology segment for the year ended December 31, 2020, while a combination of quantitative impairment tests and qualitative assessments were performed for the years ended December 31, 2019 and 2018, all of which indicated no impairment existed.
Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets	Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets Intangible assets primarily represent acquired trade names, customer relationships, acquired technology and software license agreements. A portion of the Company’s acquired customer relationships is being amortized on an accelerated basis over periods ranging from seven two The Company assesses its long-lived assets and finite-lived intangible assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected cash flows are less than the carrying amounts, an impairment loss equal to the difference between the carrying amount of the asset and its fair value would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. Assets held for sale are reported at the lower of the carrying amounts or fair value less cost to sell. Management determines fair value using the discounted cash flow method or other accepted valuation techniques. The Company recorded asset impairment losses related to facility closures totaling $3.5 million, $4.2 million and $5.5 million during the years ended December 31, 2020, 2019 and 2018, respectively, as a component of Restructuring and other related charges in the Consolidated Statements of Operations. The aggregate carrying value of these assets subsequent to impairment was $62.5 million, $44.6 million and $39.8 million as of December 31, 2020, 2019 and 2018, respectively.
Derivatives	Derivatives The Company is subject to foreign currency risk associated with the translation of the net assets of foreign subsidiaries to United States (“U.S.”) dollars on a periodic basis. On April 19, 2017. the Company issued senior unsecured notes with an aggregate principal amount of €350 million (as defined and further discussed in Note 13, “Debt”), which has been designated as a net investment hedge in order to mitigate a portion of its foreign currency risk. Derivative instruments are generally recognized on a gross basis in the Consolidated Balance Sheets in either Other current assets, Other assets, Accrued liabilities or Other liabilities depending upon their respective fair values and maturity dates. For all instruments designated as hedges, including net investment hedges and cash flow hedges, the Company formally documents the relationship between the hedging instrument and the hedged item, as well as the risk management objective and the strategy for using the hedging instrument. The Company assesses whether the relationship between the hedging instrument and the hedged item is highly effective at offsetting changes in the fair value both at inception of the hedging relationship and on an ongoing basis. For cash flow hedges and net investment hedges, unrealized gains and losses are recognized as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets to the extent that it is effective at offsetting the change in the fair value of the hedged item and realized gains and losses are recognized in the Consolidated Statements of Operations consistent with the underlying hedged instrument. The Company does not enter into derivative contracts for speculative purposes. See Note 17, “Financial Instruments and Fair Value Measurements” for additional information regarding the Company’s derivative instruments.
Warranty Costs	Warranty Costs Estimated expenses related to product warranties are accrued as the revenue is recognized on products sold to customers and included in Cost of sales in the Consolidated Statements of Operations. Estimates are established using historical information as to the nature, frequency, and average costs of warranty claims. The activity in the Company’s warranty liability, which is included in Accrued liabilities and Other liabilities in the Company’s Consolidated Balance Sheets, consisted of the following: Year Ended December 31, 2020 2019 (In thousands) Warranty liability, beginning of period $ 15,528 $ 12,312 Accrued warranty expense 7,253 6,038 Changes in estimates related to pre-existing warranties 1,849 1,668 Cost of warranty service work performed (9,708) (9,502) Acquisition-related liability 300 5,520 Foreign exchange translation effect 321 (508) Warranty liability, end of period $ 15,543 $ 15,528
Income Taxes	Income Taxes Income taxes for the Company are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the Consolidated Financial Statements and their respective tax basis. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets and liabilities are reported in Other assets and Other liabilities in the Company’s Consolidated Balance Sheets, respectively. The effect on deferred income tax assets and liabilities of a change in tax rates is generally recognized in Income tax expense (benefit) in the period that includes the enactment date. Global Intangible Low-Taxed Income (“GILTI”) is accounted for as a current tax expense in the year the tax is incurred. Valuation allowances are recorded if it is more likely than not that some portion of the deferred income tax assets will not be realized. In evaluating the need for a valuation allowance, the Company considers various factors, including the expected level of future taxable income and available tax planning strategies. Any changes in judgment about the valuation allowance are recorded through Income tax expense (benefit) and are based on changes in facts and circumstances regarding realizability of deferred tax assets. The Company must presume that an income tax position taken in a tax return will be examined by the relevant tax authority and determine whether it is more likely than not that the tax position will be sustained upon examination based upon the technical merits of the position. An income tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The Company establishes a liability for unrecognized income tax benefits for income tax positions for which it is more likely than not that a tax position will not be sustained upon examination by the respective taxing authority to the extent such tax positions reduce the Company’s income tax liability. The Company recognizes interest and penalties related to unrecognized income tax benefits in Income tax expense (benefit) in the Consolidated Statements of Operations.
Foreign Currency Exchange Gains and Losses	Foreign Currency Exchange Gains and Losses The Company’s financial statements are presented in U.S. dollars. The functional currencies of the Company’s operating subsidiaries are generally the local currencies of the countries in which each subsidiary is located. Assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the balance sheet date. The amounts recorded in each year in Foreign currency translation are net of income taxes to the extent the underlying equity balances in the entities are not deemed to be permanently reinvested. Revenues and expenses are translated at average rates of exchange in effect during the year. Transactions in foreign currencies are translated at the exchange rate in effect at the date of each transaction. Differences in exchange rates during the period between the date a transaction denominated in a foreign currency is consummated and the date on which it is either settled or translated for inclusion in the Consolidated Balance Sheets are recognized in Selling, general and administrative expense or Interest expense, net in the Consolidated Statements of Operations for that period.
Debt Issuance Costs and Debt Discount	Debt Issuance Costs and Debt Discount Costs directly related to the placement of debt are capitalized and amortized to Interest expense primarily using the effective interest method over the term of the related obligation. Further, the carrying value of debt is reduced by an original issue discount, which is accreted to Interest expense, net using the effective interest method over the term of the related obligation. As of December 31, 2020, $7.0 million and $15.6 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. As of December 31, 2019, $6.1 million and $17.7 million of deferred issuance costs were included in Other assets and as a reduction of Long-term debt, respectively. See Note 13, “Debt” for additional discussion regarding the Company’s borrowing arrangements.
Use of Estimates	Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates.
New Accounting Pronouncements	Recently Issued Accounting Pronouncements Accounting Guidance Implemented in 2020 Standards Adopted Description Effective Date ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments The ASU eliminates the probable initial recognition threshold under current GAAP and broadens the information an entity must consider when developing its expected credit loss estimates to include forward-looking information. The standard applies to most financial assets held at amortized costs, as well as certain other instruments. Under the current expected credit loss (“CECL”) model, entities must estimate losses over the entire contractual term of the asset from the date of initial recognition. In determining expected losses, consideration must be given to historical loss experience, current conditions, and reasonable and supportable forecasts incorporating forward looking information. The Company adopted Topic 326 on January 1, 2020 using a modified retrospective transition method, which requires a cumulative-effect adjustment to the opening balance sheet of retained earnings to be recognized on the date of adoption without restating prior periods. The cumulative-effect adjustment, net of tax, on January 1, 2020 was $4.8 million. January 1, 2020 ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement The ASU modifies the disclosure requirements for fair value measurements. The adoption of this standard did not result in any changes to the current disclosures, as the requirements modified by the ASU are not applicable or are immaterial for disclosure. January 1, 2020 New Accounting Guidance to be Implemented Standards Pending Adoption Description Anticipated Impact Effective/Adoption Date ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans The ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. This accounting standard update impacts disclosures only. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures. January 1, 2021 ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes The ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of accounting for income taxes. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. January 1, 2021

Summary of Significant Accoun_3

Summary of Significant Accounting Policies Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table summarizes the Company’s Cash and cash equivalents and Restricted cash: December 31, 2020 2019 (In thousands) Cash and cash equivalents $ 97,068 $ 109,632 Restricted cash 4,001 — Total cash and cash equivalents and restricted cash $ 101,069 $ 109,632
Schedule of Product Warranty Liability	The activity in the Company’s warranty liability, which is included in Accrued liabilities and Other liabilities in the Company’s Consolidated Balance Sheets, consisted of the following: Year Ended December 31, 2020 2019 (In thousands) Warranty liability, beginning of period $ 15,528 $ 12,312 Accrued warranty expense 7,253 6,038 Changes in estimates related to pre-existing warranties 1,849 1,668 Cost of warranty service work performed (9,708) (9,502) Acquisition-related liability 300 5,520 Foreign exchange translation effect 321 (508) Warranty liability, end of period $ 15,543 $ 15,528

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2020
Discontinued Operations [Abstract]
Components of income (loss) from discontinued operations	The key components of Income (loss) from discontinued operations, net of taxes related to the Air and Gas Handling business for the years ended December 31, 2020, 2019 and 2018 were as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net sales $ — $ 998,793 $ 1,473,729 Cost of sales — 689,004 1,070,266 Selling, general and administrative expense — 194,589 269,447 Restructuring and other related charges — 13,354 48,609 Goodwill impairment charge — 449,000 — Divestiture-related expense (1) 9,040 48,640 — Operating income (loss) (9,040) (395,794) 85,407 Interest expense (2) — 47,553 (5,031) Pension settlement loss — 43,774 — Gain on disposal — 14,233 — Loss from discontinued operations before income taxes (9,040) (472,888) 90,438 Income tax expense (benefit) (3) (238) 44,062 29,487 Income (loss) from discontinued operations, net of taxes (4) $ (8,802) $ (516,950) $ 60,951 (1) Primarily related to professional, consulting, and legal fees associated with the divestiture including seller due diligence and preparation of regulatory filings, as well as other disposition-related activities. (2) The Company reclassified the portion of its interest expense associated with the mandatory pay down of the Term Loan Facilities using net proceeds from the sale of the business. (3) Income tax expense for the year ended December 31, 2019 is largely due to nondeductible items that do not provide a tax benefit on the loss. (4) Income (loss) from discontinued operations, net of taxes on the Statements of Operations includes the results from retained asbestos-related contingencies attributable to the divested fluid handling business as discussed in the Asbestos Contingencies section below.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The following unaudited proforma financial information presents Colfax’s consolidated financial information assuming the acquisition had taken place on January 1, 2018. These amounts are presented in accordance with U.S. GAAP, consistent with the Company’s accounting policies. Year Ended December 31, 2020 2019 2018 (In thousands) Net sales $ 3,070,769 $ 3,496,624 $ 3,395,018 Net income from continuing operations attributable to Colfax Corporation 68,039 105,491 97,410

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The Company further disaggregates its Fabrication Technology revenue into the following product groups: Year Ended December 31, 2020 2019 2018 (In thousands) Equipment $ 607,504 $ 703,024 $ 623,987 Consumables 1,342,565 1,544,002 1,569,096 Total $ 1,950,069 $ 2,247,026 $ 2,193,083 Year Ended December 31, 2020 2019 (1) (In thousands) Prevention & Rehabilitation $ 781,007 $ 766,429 Reconstructive 339,693 314,003 Total $ 1,120,700 $ 1,080,432 (1) For the year ended December 31, 2019, the Medical Technology segment includes results from the acquisition date of February 22, 2019.
Financing Receivable, Allowance for Credit Loss	A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated Balance Sheets is as follows: Year Ended December 31, 2020 Balance at Charged to Expense, net Write-Offs and Deductions Foreign Balance at (In thousands) Allowance for credit losses $ 36,009 $ 7,574 $ (5,165) $ (752) $ 37,666

Net Income Per Share (Tables)

Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Net income per share from continuing operations was computed as follows: Year Ended December 31, 2020 2019 2018 (In thousands, except share and per share data) Computation of Net income per share from continuing operations - basic: Net income from continuing operations attributable to Colfax Corporation (1) $ 60,936 $ 14,245 $ 121,211 Weighted-average shares of Common stock outstanding – basic 136,766,124 135,716,944 120,288,297 Net income per share from continuing operations – basic $ 0.45 $ 0.10 $ 1.01 Computation of Net income per share from continuing operations - diluted: Net income from continuing operations attributable to Colfax Corporation (1) $ 60,936 $ 14,245 $ 121,211 Weighted-average shares of Common stock outstanding – basic 136,766,124 135,716,944 120,288,297 Net effect of potentially dilutive securities - stock options, restricted stock units and tangible equity units 2,144,304 949,942 506,759 Weighted-average shares of Common stock outstanding – diluted 138,910,428 136,666,886 120,795,056 Net income per share from continuing operations – diluted $ 0.44 $ 0.10 $ 1.00 (1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the income attributable to noncontrolling interest, net of taxes, of $3.1 million, $4.6 million, and $0.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Income from continuing operations before income taxes and Income tax expense (benefit) consisted of the following: Year Ended December 31, 2020 2019 2018 (In thousands) Income from continuing operations before income taxes: Domestic operations $ (156,675) $ (129,182) $ (60,352) Foreign operations 214,704 179,675 152,716 $ 58,029 $ 50,493 $ 92,364 Income tax expense (benefit): Current: Federal $ (39,376) $ 811 $ (15,132) State 1,454 6,712 816 Foreign 56,076 56,477 41,831 $ 18,154 $ 64,000 $ 27,515 Deferred: Domestic operations $ 3,641 $ (24,151) $ (21,908) Foreign operations (27,848) (8,219) (35,115) (24,207) (32,370) (57,023) $ (6,053) $ 31,630 $ (29,508)
Schedule of Effective Income Tax Rate Reconciliation	The Company’s Income tax expense (benefit) from continuing operations differs from the amount that would be computed by applying the U.S. federal statutory rate as follows: Year Ended December 31, 2020 2019 (1) 2018 (1) (In thousands) Taxes calculated at the U.S. federal statutory rate $ 12,186 $ 10,677 $ 19,392 State taxes (2,196) (5,358) (3,543) Effect of tax rates on international operations (18,577) (14,115) (9,323) Change in enacted international tax rates (1,023) (2,843) (2,403) Changes in valuation allowance (24,149) 11,196 (11,577) Changes in tax reserves 1,394 1,119 (1,704) Tax Act - re-measurement of U.S. deferred taxes — — (667) Tax Act - mandatory repatriation taxes (6,766) — (10,804) Research and development tax credits (1,649) (4,029) (7,123) Foreign tax credits (12,197) (15,299) (21,927) Net items not deductible in an international jurisdiction 5,365 10,060 12,077 SubPart F and GILTI 27,797 29,407 12,872 U.S. Deal Costs and other non-deductibles 38 5,556 — Withholding taxes 8,570 4,545 3,446 Non-deductible employee compensation 6,619 714 1,068 Other (1,465) — (9,292) Income tax expense (benefit) $ (6,053) $ 31,630 $ (29,508) (1) Certain prior period amounts have been reclassified to conform with current year presentation.
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred tax assets and liabilities included in continuing operations, in addition to the reconciliation of the beginning and ending amount of gross unrecognized tax benefits, are as follows: December 31, 2020 2019 (In thousands) Deferred tax assets: Post-retirement benefit obligation $ 11,617 $ 11,295 Expenses currently not deductible 147,636 131,921 Net operating loss carryforward 308,965 342,442 Tax credit carryforward 33,674 16,727 Depreciation and amortization 6,433 6,487 Other 42,881 42,407 Valuation allowance (203,341) (149,037) Deferred tax assets, net $ 347,865 $ 402,242 Deferred tax liabilities: Depreciation and amortization $ (403,704) $ (415,888) Inventory (1,559) (3,694) Outside basis differences and other (78,012) (84,706) Total deferred tax liabilities $ (483,275) $ (504,288) Total deferred tax liabilities, net $ (135,410) $ (102,046)
Summary of Income Tax Contingencies	The Company records a liability for unrecognized income tax benefits for the amount of benefit included in its previously filed income tax returns and in its financial results expected to be included in income tax returns to be filed for periods through the date of its Consolidated Financial Statements for income tax positions for which it is more likely than not that a tax position will not be sustained upon examination by the respective taxing authority. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (inclusive of associated interest and penalties): (In thousands) Balance, December 31, 2017 $ 41,018 Addition for tax positions taken in prior periods 2,525 Addition for tax positions taken in the current period 240 Reductions related to settlements with taxing authorities (461) Reductions resulting from a lapse of applicable statute of limitations (4,477) Other, including the impact of foreign currency translation and U.S. tax rate changes (1,224) Balance, December 31, 2018 $ 37,621 Acquisitions and divestitures 18,248 Addition for tax positions taken in prior periods 1,441 Addition for tax positions taken in the current period 2,054 Reductions related to settlements with taxing authorities (118) Reductions resulting from a lapse of applicable statute of limitations (3,643) Other, including the impact of foreign currency translation and U.S. tax rate changes (123) Balance, December 31, 2019 $ 55,480 Addition for tax positions taken in prior periods $ 5,911 Addition for tax positions taken in the current period $ 1,980 Reductions related to settlements with taxing authorities $ — Reductions resulting from a lapse of applicable statute of limitations $ (5,689) Other, including the impact of foreign currency translation and U.S. tax rate changes $ 332 Balance, December 31, 2020 $ 58,014

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table summarizes the activity in Goodwill, by segment during the years ended December 31, 2020 and 2019: Medical Technology Fabrication Total (In thousands) Balance, January 1, 2019 $ — $ 1,497,832 $ 1,497,832 Goodwill attributable to acquisitions (1) 1,674,328 8,406 1,682,734 Impact of foreign currency translation (1,407) 23,358 21,951 Balance, December 31, 2019 1,672,921 1,529,596 3,202,517 Goodwill attributable to acquisitions (1) 72,815 — 72,815 Impact of foreign currency translation 15,574 23,635 39,209 Balance, December 31, 2020 $ 1,761,310 $ 1,553,231 $ 3,314,541 (1) Includes purchase accounting adjustments associated with acquisitions discussed in Note 5, “Acquisitions”.
Schedule Of Intangible Assets	The following table summarizes the Company’s Intangible assets, excluding Goodwill: December 31, 2020 2019 Gross Accumulated Gross Accumulated (In thousands) Indefinite-Lived Intangible Assets Trade names $ 212,048 $ — $ 193,465 $ — Definite-Lived Intangible Assets Acquired customer relationships 952,007 (266,347) 919,574 (182,813) Acquired technology 455,738 (99,748) 440,719 (60,971) Acquired trade names 404,076 (41,960) 389,112 (21,069) Software 129,852 (90,196) 103,274 (71,644) Other intangible assets 24,511 (16,535) 22,809 (13,437) $ 2,178,232 $ (514,786) $ 2,068,953 $ (349,934)
Schedule Of Finite Lived Intangible Assets Amortization Expense	Amortization expense related to intangible assets was included in the Consolidated Statements of Operations as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Selling, general and administrative expense $ 158,427 $ 135,769 $ 43,703
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The Company’s expected annual amortization expense for intangible assets for the next five years: December 31, 2020 (In thousands) 2021 $ 153,923 2022 148,995 2023 143,325 2024 137,707 2025 136,620

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	December 31, Depreciable Life 2020 2019 (In years) (In thousands) Land n/a $ 23,821 $ 25,138 Buildings and improvements 5-40 205,397 196,810 Machinery and equipment 3-15 570,411 528,848 799,629 750,796 Accumulated depreciation (312,669) (259,555) Property, plant and equipment, net $ 486,960 $ 491,241

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories, Net Inventories, net consisted of the following: December 31, 2020 2019 (In thousands) Raw materials $ 110,848 $ 115,587 Work in process 40,517 37,019 Finished goods 476,297 475,933 627,662 628,539 Less: allowance for excess, slow-moving and obsolete inventory (62,840) (56,981) Inventories, net $ 564,822 $ 571,558

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Future Minimum Lease Payments	December 31, 2020 (In thousands) Future lease payments by year: 2021 $ 42,516 2022 33,809 2023 26,836 2024 18,987 2025 14,073 Thereafter 71,838 Total 208,059 Less: present value discount (30,578) Present value of lease liabilities $ 177,481 Weighted-average remaining lease term (in years): Operating leases 8.6 Weighted-average discount rate: Operating leases 3.7 %

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt consisted of the following: December 31, 2020 2019 (In thousands) Term loan $ 781,557 $ 822,945 Euro senior notes 425,045 388,925 TEU amortizing notes 31,251 54,044 2024 and 2026 notes 991,319 989,236 Revolving credit facilities and other 2,071 56,676 Total debt 2,231,243 2,311,826 Less: current portion (27,074) (27,642) Long-term debt $ 2,204,169 $ 2,284,184
Schedule of Maturities of Long-term Debt	The contractual maturities of the Company’s debt as of December 31, 2020 are as follows: (In thousands) 2021 $ 27,074 2022 6,507 2023 — 2024 1,385,000 2025 428,242 Thereafter 400,000 Total contractual maturities 2,246,823 Debt discount (15,580) Total debt $ 2,231,243

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The following table presents the changes in the balances of each component of Accumulated other comprehensive loss including reclassifications out of Accumulated other comprehensive loss for the years ended December 31, 2020, 2019 and 2018. All amounts are net of tax and noncontrolling interest, if any. Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post-Retirement Benefit Cost Foreign Currency Translation Adjustment Unrealized Gain (Loss) On Hedging Activities Changes in Fair Value of Available-for-Sale Securities Total (In thousands) Balance at January 1, 2018 $ (84,338) $ (525,324) $ 30,138 $ 5,152 $ (574,372) Other comprehensive income (loss) before reclassifications: Net actuarial gain 5,609 — — — 5,609 Foreign currency translation adjustment 1,145 (222,158) (424) — (221,437) Loss on long-term intra-entity foreign currency transactions — (5,507) — — (5,507) Gain on net investment hedges — — 16,745 — 16,745 Unrealized loss on cash flow hedges — — (2,153) — (2,153) Other comprehensive income (loss) before reclassifications: 6,754 (227,665) 14,168 — (206,743) Amounts reclassified from Accumulated other comprehensive loss (1) 6,090 — — — 6,090 Net current period Other comprehensive income (loss) 12,844 (227,665) 14,168 — (200,653) Cumulative effect of accounting change — — — (5,152) (5,152) Balance at December 31, 2018 $ (71,494) $ (752,989) $ 44,306 $ — $ (780,177) Other comprehensive income (loss) before reclassifications: Net actuarial loss (27,931) — — — (27,931) Foreign currency translation adjustment (404) (78,468) (65) — (78,937) Divestiture-related AOCI write-off — 400,143 — — 400,143 Gain on long-term intra-entity foreign currency transactions — 29,385 — — 29,385 Gain on net investment hedges — — 6,215 — 6,215 Unrealized loss on cash flow hedges — — 156 — 156 Other comprehensive income (loss) before reclassifications: (28,335) 351,060 6,306 — 329,031 Amounts reclassified from Accumulated other comprehensive loss (1) 2,629 — — — 2,629 Noncontrolling interest share repurchase — (19,960) — (19,960) Net current period Other comprehensive income (loss) (25,706) 331,100 6,306 — 311,700 Cumulative effect of accounting change (9,300) — (6,068) — (15,368) Balance at December 31, 2019 $ (106,500) $ (421,889) $ 44,544 $ — $ (483,845) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (1,849) 57,623 3,378 — 59,152 Gain on long-term intra-entity foreign currency transactions — 3,289 — — 3,289 Loss on net investment hedges — — (26,268) — (26,268) Other comprehensive income (loss) before reclassifications: (1,849) 60,912 (22,890) — 36,173 Amounts reclassified from Accumulated other comprehensive loss (1) (4,434) — — — (4,434) Net current period Other comprehensive income (loss) (6,283) 60,912 (22,890) — 31,739 Balance at December 31, 2020 $ (112,783) $ (360,977) $ 21,654 $ — $ (452,106) (1) Included in the computation of net periodic benefit cost. See Note 16, “Defined Benefit Plans” for additional details.
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The Company’s Consolidated Statements of Operations reflect the following amounts related to stock-based compensation: Year Ended December 31, 2020 2019 2018 (In thousands) Stock-based compensation expense $ 28,911 $ 21,960 $ 25,103 Deferred tax benefit 1,804 1,280 3,418
Tangible Equity Units	The proceeds from the issuance of the TEUs were allocated initially to equity and debt based on the relative fair value of the respective components of each TEU as follows: TEU prepaid stock purchase contracts TEU amortizing notes Total (In millions, except per unit amounts) Fair value per unit $ 84.39 $ 15.61 $ 100.00 Gross proceeds $ 388.2 $ 71.8 $ 460.0 Less: Issuance costs 10.4 1.9 12.3 Net Proceeds $ 377.8 $ 69.9 $ 447.7
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Stock-based compensation expense for stock option awards is based upon the grant-date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense for stock option awards on a straight-line basis over the requisite service period of the entire award. The following table shows the weighted-average assumptions used to calculate the fair value of stock option awards using the Black-Scholes option pricing model, as well as the weighted-average fair value of options granted: Year Ended December 31, 2020 2019 2018 Expected period that options will be outstanding (in years) 4.62 4.56 4.54 Interest rate (based on U.S. Treasury yields at the time of grant) 1.09 % 2.46 % 2.65 % Volatility 37.76 % 34.51 % 31.89 % Dividend yield — — — Weighted-average fair value of options granted $ 11.81 $ 8.80 $ 10.37
Share-based Compensation, Stock Options, Activity	Stock option activity is as follows: Number Weighted- Weighted- Aggregate (1) (In thousands) Outstanding at January 1, 2020 4,675,281 $ 34.93 Granted 618,403 35.89 Exercised (126,576) 27.64 Forfeited and expired (568,041) 45.75 Outstanding at December 31, 2020 4,599,067 33.92 3.53 $ 29,875 Vested or expected to vest at December 31, 2020 4,543,740 33.94 3.53 $ 29,549 Exercisable at December 31, 2020 2,943,374 35.76 2.74 $ 17,315 (1) The aggregate intrinsic value is based upon the difference between the Company’s closing stock price at the date of the Consolidated Balance Sheet and the exercise price of the stock option for in-the-money stock options. The intrinsic value of outstanding stock options fluctuates based upon the trading value of the Company’s Common stock. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was $1.1 million, $2.0 million and $1.4 million, respectively. The fair value of options vested during the years ended December 31, 2020, 2019 and 2018 was $11.9 million, $10.9 million and $8.5 million, respectively.
Schedule of Nonvested Share Activity	The activity in the Company’s PRSUs and RSUs is as follows: PRSUs RSUs Number Weighted- Number Weighted- Nonvested at January 1, 2020 741,375 $ 30.87 595,376 $ 29.25 Granted 142,987 50.91 554,192 34.80 Vested (103,629) 29.90 (226,912) 30.30 Forfeited and expired (49,332) 27.93 (88,693) 29.52 Nonvested at December 31, 2020 731,401 35.12 833,963 32.52

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities in the Consolidated Balance Sheets consisted of the following: December 31, 2020 2019 (In thousands) Accrued compensation and related benefits $ 98,455 $ 100,290 Accrued taxes 57,286 55,258 Accrued asbestos-related liability 41,626 64,394 Warranty liability - current portion 15,543 15,513 Accrued restructuring liability - current portion 7,889 6,961 Accrued third-party commissions 25,480 30,768 Customer advances and billings in excess of costs incurred 36,737 16,009 Lease liability - current portion 39,695 40,021 Accrued interest 27,153 27,333 Other 104,469 113,343 Accrued liabilities $ 454,333 $ 469,890
Schedule of Restructuring Reserve by Type of Cost	The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated Balance Sheets is as follows: Year Ended December 31, 2020 Balance at Beginning of Period Provisions Payments Foreign Currency Translation Balance at End of Period (3) (In thousands) Restructuring and other related charges: Fabrication Technology: Termination benefits (1) $ 1,638 $ 11,381 $ (7,698) $ 15 $ 5,336 Facility closure costs (2) 1,284 8,358 (9,060) 9 591 Subtotal 2,922 19,739 (16,758) 24 5,927 Non-cash charges (2) 1,894 Fabrication Technology total provisions 21,633 Medical Technology: Termination benefits (1) 3,919 3,284 (5,405) 86 1,884 Facility closure costs (2) 257 17,125 (17,085) — 297 Subtotal 4,176 20,409 (22,490) 86 2,181 Non-cash charges (2) 2,985 Medical Technology total provisions 23,394 Total $ 7,098 40,148 $ (39,248) $ 110 $ 8,108 Non-cash charges (2) 4,879 Total Colfax provisions $ 45,027 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment and lease termination expense in connection with the closure of facilities. During the year ended December 31, 2020, the Company recorded a total of $1.9 million and $3.0 million non-cash impairment charges for facilities in the Fabrication Technology and Medical Technology segments, respectively, as part of Corporate approved restructuring activities. Restructuring charges in the Medical Technology segment during the year ended December 31, 2020 include costs related to product and distribution channel transformations, facilities optimization, and integration charges, as well as $6.6 million classified as Cost of sales on the Company’s Consolidated Statements of Operations for the year ended December 31, 2020. (3) As of December 31, 2020, $7.9 million and $0.2 million of the Company’s restructuring liability was included in Accrued liabilities and Other liabilities, respectively. Year Ended December 31, 2019 Balance at Beginning of Period Acquisitions Provisions Payments Foreign Currency Translation Balance at End of Period (3) (In thousands) Restructuring and other related charges: Fabrication Technology: Termination benefits (1) $ 5,494 $ 7,131 $ (10,588) $ (399) $ 1,638 Facility closure costs (2) 662 11,711 (11,136) 47 1,284 6,156 18,842 (21,724) (352) 2,922 Non-cash charges 4,198 23,040 Medical Technology: Termination benefits (1) — 6,096 5,449 (7,626) — 3,919 Facility closure costs (2) — 298 45,258 (45,299) — 257 — 6,394 50,707 (52,925) — 4,176 Total $ 6,156 $ 6,394 69,549 $ (74,649) $ (352) $ 7,098 Non-cash charges (2) 4,198 $ 73,747 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment and lease termination expense in connection with the closure of facilities. During the year ended December 31, 2019, the Company recorded a $4.2 million non-cash impairment charge for facilities in our Fabrication Technology segment as part of Corporate approved restructuring activities. Restructuring charges in the Medical Technology segment also include $8.5 million classified as Cost of sales on the Company’s Consolidated Statements of Operations for the year ended December 31, 2019. (3) As of December 31, 2019, $7.0 million and $0.1 million of the Company’s restructuring liability was included in Accrued liabilities and Other liabilities, respectively.

Defined Benefit Plans Defined_2

Defined Benefit Plans Defined Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Schedule of Changes in Projected Benefit Obligations	The following table summarizes the total changes in the Company’s pension and accrued post-retirement benefits and plan assets and includes a statement of the plans’ funded status: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2020 2019 (In thousands) Change in benefit obligation: Projected benefit obligation, beginning of year $ 361,146 $ 867,345 $ 13,057 $ 13,844 Acquisitions — 2,264 — — Service cost 1,933 2,462 8 5 Interest cost 7,454 16,556 313 445 Plan amendment 95 464 — 15 Actuarial loss (gain) (1) 21,642 183,084 1,139 (382) Foreign exchange effect 9,757 (912) (3) (4) Benefits paid (24,105) (40,131) (1,170) (866) Divestitures — (50,468) — — Settlements (418) (619,756) — — Other 1,791 238 — — Projected benefit obligation, end of year $ 379,295 $ 361,146 $ 13,344 $ 13,057 Accumulated benefit obligation, end of year $ 375,267 $ 356,741 $ 13,344 $ 13,057 Change in plan assets: Fair value of plan assets, beginning of year $ 251,291 $ 850,024 $ — $ — Actual return on plan assets 26,123 88,869 — — Employer contribution 9,830 10,793 1,170 866 Foreign exchange effect 2,806 1,236 — — Benefits paid (24,105) (40,131) (1,170) (866) Divestitures — (39,897) — — Settlements (418) (619,756) — — Other 1,727 153 — — Fair value of plan assets, end of year $ 267,254 $ 251,291 $ — $ — Funded status, end of year $ (112,041) $ (109,855) $ (13,344) $ (13,057) Amounts recognized on the Consolidated Balance Sheet at December 31: Non-current assets $ — $ — $ — $ — Current liabilities (3,800) (3,596) (1,028) (1,177) Non-current liabilities (108,241) (106,259) (12,316) (11,880) Total $ (112,041) $ (109,855) $ (13,344) $ (13,057) (1) The reported actuarial loss in 2020 is primarily due to the decrease in discount rates in most markets. The reported actuarial loss in 2019 is primarily due to the settlements of two pension plans and decrease in discount rates in most markets. The following table summarizes the changes in the Company’s foreign pension benefit obligation, which is determined based upon an employee’s expected date of separation, and plan assets, included in the table above, and includes a statement of the plans’ funded status: Foreign Pension Benefits Year Ended December 31, 2020 2019 (In thousands) Change in benefit obligation: Projected benefit obligation, beginning of year $ 144,739 $ 661,084 Acquisitions — 2,264 Service cost 1,933 2,340 Interest cost 2,315 9,376 Plan amendments 95 464 Actuarial loss (1) 5,778 164,888 Foreign exchange effect 9,757 (912) Benefits paid (8,795) (24,779) Divestitures — (50,468) Settlements (418) (619,756) Other 1,791 238 Projected benefit obligation, end of year $ 157,195 $ 144,739 Accumulated benefit obligation, end of year $ 153,167 $ 140,335 Change in plan assets: Fair value of plan assets, beginning of year $ 67,535 $ 691,758 Acquisitions — — Actual return on plan assets 4,037 51,318 Employer contribution 6,222 7,502 Foreign exchange effect 2,806 1,236 Benefits paid (8,795) (24,779) Divestitures — (39,897) Settlements (418) (619,756) Other 1,727 153 Fair value of plan assets, end of year $ 73,114 $ 67,535 Funded status, end of year $ (84,081) $ (77,204) (1) The reported actuarial loss in 2020 is primarily due to the decrease in discount rates in most markets. The reported actuarial loss in 2019 is primarily due to the settlements of two pension plans and decrease in discount rates in most markets.
Schedule of Expected Benefit Payments	The following benefit payments are expected to be paid during each respective fiscal year: Pension Benefits Other Post-Retirement Benefits All Plans Foreign Plans (In thousands) 2021 $ 25,147 $ 9,276 $ 1,028 2022 24,495 8,925 954 2023 23,858 8,641 884 2024 22,989 8,182 839 2025 22,689 8,315 830 2026 - 2030 105,337 40,832 3,731
Schedule of Allocation of Plan Assets	The following are the actual and target allocation percentages for the Company’s pension plan assets: Actual Asset Allocation 2020 2019 Allocation U.S. Plans: Equity securities: U.S. 44 % 44 % 30%-45% International 16 % 15 % 10% -20% Fixed income 39 % 39 % 30% -50% Other — % — % 0%-20% Cash and cash equivalents 1 % 2 % 0%-5% Foreign Plans: Equity securities 27 % 27 % 0%-40% Fixed income securities 10 % 11 % 0%-15% Cash and cash equivalents — % — % 0%-25% Other 63 % 62 % 55%-90% A summary of the Company’s pension plan assets for each fair value hierarchy level for the periods presented follows (see Note 17, “Financial Instruments and Fair Value Measurements” for further description of the levels within the fair value hierarchy): December 31, 2020 Measured at Net Asset Value (1) Level Level Level (In thousands) U.S. Plans: Cash and cash equivalents $ — $ 1,752 $ — $ — 1,752 Equity securities: U.S. large cap 51,728 — — — 51,728 U.S. small/mid cap 21,175 12,895 — — 34,070 International 30,552 — — — 30,552 Fixed income mutual funds: U.S. government and corporate 74,978 — — — 74,978 Other (2) — 1,060 — — 1,060 Foreign Plans: Cash and cash equivalents — 239 — — 239 Equity securities — 19,513 — — 19,513 Non-U.S. government and corporate bonds — 5,331 1,922 — 7,253 Other (2) — — 46,109 — 46,109 $ 178,433 $ 40,790 $ 48,031 $ — $ 267,254 (1) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term. (2) Represents diversified portfolio funds, reinsurance contracts and money market funds. December 31, 2019 Measured at Net Asset Value (1) Level Level Level (In thousands) U.S. Plans: Cash and cash equivalents $ — $ 2,855 $ — $ — $ 2,855 Equity securities: U.S. large cap 48,582 — — 48,582 U.S. small/mid cap 20,093 12,268 — — 32,361 International 28,573 — — — 28,573 Fixed income mutual funds: U.S. government and corporate 70,334 — — — 70,334 Other (2) — 1,051 — — 1,051 Foreign Plans: Cash and cash equivalents — 215 — — 215 Equity securities — 18,462 — — 18,462 Non-U.S. government and corporate bonds — 5,299 1,911 — 7,210 Other (2) — — 41,648 — 41,648 $ 167,582 $ 40,150 $ 43,559 $ — $ 251,291 (1) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting primarily of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term. (2) Represents diversified portfolio funds, reinsurance contracts and money market funds.
Schedule of Net Benefit Costs	The following table sets forth the components of net periodic benefit cost (income) and Other comprehensive income of the Company’s defined benefit pension plans and other post-retirement employee benefit plans: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 (In thousands) Components of Net Periodic Benefit Cost (Income): Service cost $ 1,933 $ 2,462 $ 2,770 $ 8 $ 5 $ 19 Interest cost 7,454 16,556 21,574 313 445 452 Amortization 4,960 3,385 4,282 (231) (255) (28) Settlement loss (gain) 99 77,390 (39) — — — Divestitures gain — (4,354) — — — — Other 143 79 (458) — — — Expected return on plan assets (12,773) (19,774) (29,306) — — — Net periodic benefit cost (income) $ 1,816 $ 75,744 $ (1,177) $ 90 $ 195 $ 443 Change in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income: Current year net actuarial (gain) loss $ 10,379 $ 113,995 $ (11,816) $ 1,143 $ (380) $ (723) Current year prior service cost 74 464 3,800 — 15 — Less amounts included in net periodic benefit cost: Amortization of net (gain) loss (4,914) (3,285) (4,330) 231 270 31 Settlement/divestiture/other (gain) loss (177) (83,602) 39 — — — Amortization of prior service cost (46) (100) 48 — (15) (3) Total recognized in Other comprehensive income $ 5,316 $ 27,472 $ (12,259) $ 1,374 $ (110) $ (695) Net periodic benefit cost (income) of $44.4 million and $(1.4) million for the years ended December 31, 2019 and 2018, respectively, are included in Income (loss) from discontinued operations, net of taxes. Net periodic benefit cost included in loss from discontinued operations for the year ended December 31, 2019 includes $43.8 million in settlement loss related to the Air and Gas Handling segment. Each component of Net periodic benefit cost from continuing operations, with the exception of Settlement loss, is included in Selling, general and administrative expense. The following table sets forth the components of net periodic benefit cost and Other comprehensive loss (gain) of the foreign defined benefit pension plans, included in the table above: Foreign Pension Benefits Year Ended December 31, 2020 2019 2018 (In thousands) Components of Net Periodic Benefit Cost: Service cost $ 1,933 $ 2,340 $ 2,634 Interest cost 2,315 9,376 15,183 Amortization 747 334 1,039 Settlement loss (gain) 99 77,390 (39) Divestitures gain — (4,354) — Other 143 79 (458) Expected return on plan assets (2,397) (9,092) (18,310) Net periodic benefit cost $ 2,840 $ 76,073 $ 49 Change in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Loss: Current year net actuarial loss (gain) $ 6,226 $ 122,667 $ (31,854) Current year prior service cost 74 464 3,800 Less amounts included in net periodic benefit cost: Amortization of net loss (701) (234) (1,087) Settlement/divestiture/other (gain) loss (177) (83,602) 39 Amortization of prior service cost (46) (100) 48 Total recognized in Other comprehensive loss $ 5,376 $ 39,195 $ (29,054)
Schedule of Net Periodic Benefit Cost Not yet Recognized	The components of net unrecognized pension and other post-retirement benefit cost included in Accumulated other comprehensive loss in the Consolidated Balance Sheets that have not been recognized as a component of net periodic benefit cost are as follows: Pension Benefits Other Post-Retirement December 31, December 31, 2020 2019 2020 2019 (In thousands) Net actuarial loss (gain) $ 105,947 $ 100,659 $ (2,031) $ (3,405) Prior service cost 477 449 — — Total $ 106,424 $ 101,108 $ (2,031) $ (3,405) The components of net unrecognized pension and other post-retirement benefit cost included in Accumulated other comprehensive loss in the Consolidated Balance Sheet that are expected to be recognized as a component of net periodic benefit cost during the year ending December 31, 2021 are as follows: Pension Benefits Other Post- (In thousands) Net actuarial loss (gain) $ 5,929 $ (74) Prior service cost 55 — Total $ 5,984 $ (74)
Schedule of Assumptions Used	The key economic assumptions used in the measurement of the Company’s pension and other post-retirement benefit obligations are as follows: Pension Benefits Other Post-Retirement December 31, December 31, 2020 2019 2020 2019 Weighted-average discount rate: All plans 1.7 % 2.5 % 2.1 % 3.0 % Foreign plans 1.4 % 1.9 % — % — % Weighted-average rate of increase in compensation levels for active foreign plans 0.6 % 0.8 % — % — % The key economic assumptions used in the computation of net periodic benefit cost are as follows: Pension Benefits Other Post-Retirement Benefits Year Ended December 31, Year Ended December 31, 2020 2019 2018 2020 2019 2018 Weighted-average discount rate: All plans 2.5 % 3.0 % 2.6 % 3.0 % 4.0 % 3.4 % Foreign plans 1.9 % 2.7 % 2.4 % — % — % — % Weighted-average expected return on plan assets: All plans 5.7 % 3.1 % 3.8 % — % — % — % Foreign plans 4.1 % 2.4 % 3.2 % — % — % — % Weighted-average rate of increase in compensation levels for active foreign plans 0.8 % 1.8 % 2.1 % — % — % — %
Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates	A one-percentage point change in assumed health care cost trend rates would have the following pre-tax effects: 1% Increase 1% Decrease (In thousands) Effect on total service and interest cost components for the year ended December 31, 2020 $ 17 $ (14) Effect on post-retirement benefit obligation at December 31, 2020 695 (591)

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	A summary of the Company’s assets and liabilities that are measured at fair value on a recurring basis for each fair value hierarchy level for the periods presented is as follows: December 31, 2020 Level Level Level Total (In thousands) Assets: Cash equivalents $ 7,420 $ — $ — $ 7,420 Foreign currency contracts related to sales - not designated as hedges — 1,897 — 1,897 Foreign currency contracts related to purchases - not designated as hedges — 297 — 297 Deferred compensation plans — 10,881 — 10,881 $ 7,420 $ 13,075 $ — $ 20,495 Liabilities: Foreign currency contracts related to sales - not designated as hedges $ — $ 1,313 $ — $ 1,313 Foreign currency contracts related to purchases - designated as hedges — 468 — 468 Deferred compensation plans — 10,881 — 10,881 $ — $ 12,662 $ — $ 12,662 December 31, 2019 Level Level Level Total (In thousands) Assets: Cash equivalents $ 13,125 $ — $ — $ 13,125 Foreign currency contracts related to sales - not designated as hedges — 74 — 74 Foreign currency contracts related to purchases - not designated as hedges — 408 — 408 Deferred compensation plans — 8,870 — 8,870 $ 13,125 $ 9,352 $ — $ 22,477 Liabilities: Foreign currency contracts related to sales - not designated as hedges $ — $ 328 $ — $ 328 Foreign currency contracts related to purchases - not designated as hedges — 853 — 853 Deferred compensation plans — 8,870 — 8,870 $ — $ 10,051 $ — $ 10,051 There were no transfers in or out of Level One, Two or Three during the years ended December 31, 2020 and 2019.
Schedule of Foreign Exchange Contracts, Notional Values	As of December 31, 2020 and 2019, the Company had foreign currency contracts with the following notional values: December 31, 2020 2019 (In thousands) Foreign currency contracts sold - not designated as hedges $ 152,504 $ 28,718 Foreign currency contracts purchased - not designated as hedges 97,897 107,090 Total foreign currency derivatives $ 250,401 $ 135,808
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The Company recognized the following in its Consolidated Financial Statements related to its derivative instruments: Year Ended 2020 2019 2018 (In thousands) Contracts Designated as Hedges: Unrealized gain (loss) on net investment hedges (1) $ (26,268) $ 6,215 $ 16,745 Contracts Not Designated in a Hedge Relationship: Foreign Currency Contracts - related to customer sales contracts: Unrealized gain 704 (395) 890 Realized gain (loss) 941 (1,565) (1,083) Foreign Currency Contracts - related to supplier purchases contracts: Unrealized gain (loss) 707 (216) (820) Realized gain (loss) (936) 523 (407) (1) The unrealized gain (loss) on net investment hedges is attributable to the change in valuation of Euro denominated debt.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Loss Contingencies By Claims Quantities	Claims activity since December 31 related to asbestos claims is as follows: Year Ended 2020 2019 2018 (Number of claims) Claims unresolved, beginning of period 16,299 16,417 17,737 Claims filed (1) 4,014 4,486 4,078 Claims resolved (2) (5,504) (4,604) (5,398) Claims unresolved, end of period 14,809 16,299 16,417 (In dollars) Average cost of resolved claims (3) $ 12,055 $ 9,455 $ 7,497 (1) Claims filed include all asbestos claims for which notification has been received or a file has been opened. (2) Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants. (3) Excludes claims settled in Mississippi for which the majority of claims have historically been resolved for no payment and insurance recoveries.
Schedule Of Asbestos Related Litigation	The Company’s Consolidated Balance Sheets included the following amounts related to asbestos-related litigation: December 31, 2020 2019 (In thousands) Current asbestos insurance receivable (1) $ — $ 4,474 Long-term asbestos insurance asset (2) 232,712 281,793 Long-term asbestos insurance receivable (2) 31,815 41,629 Accrued asbestos liability (3) 41,626 64,394 Long-term asbestos liability (4) 253,144 286,105 (1) Included in Other current assets in the Consolidated Balance Sheets. (2) Included in Other assets in the Consolidated Balance Sheets. (3) Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay, and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company’s insurers, which is included in Accrued liabilities in the Consolidated Balance Sheets. (4) Included in Other liabilities in the Consolidated Balance Sheets.
Lessee, Operating Lease, Disclosure	The Company’s minimum obligations under non-cancelable operating leases are as follows: December 31, 2020 (In thousands) 2021 $ 42,516 2022 33,809 2023 26,836 2024 18,987 2025 14,073 Thereafter 71,838 Total $ 208,059

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The Company’s segment results were as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net sales: Fabrication Technology $ 1,950,069 $ 2,247,026 $ 2,193,083 Medical Technology 1,120,700 1,080,432 — Total Net sales $ 3,070,769 $ 3,327,458 $ 2,193,083 Segment operating income (loss) (1) : Fabrication Technology $ 246,011 $ 302,601 $ 249,934 Medical Technology 29,079 96,170 — Corporate and other (60,840) (121,412) (69,321) Total segment operating income $ 214,250 $ 277,359 $ 180,613 Depreciation, amortization and other impairment charges: Fabrication Technology $ 76,644 $ 80,072 $ 79,712 Medical Technology 168,227 134,001 — Corporate and other 1,358 1,534 1,495 Total depreciation, amortization and other impairment charges $ 246,229 $ 215,607 $ 81,207 Capital expenditures: Fabrication Technology $ 40,137 $ 44,454 $ 40,512 Medical Technology 74,624 57,326 — Corporate and other 24 59 1,275 Total capital expenditures $ 114,785 $ 101,839 $ 41,787 (1) The following is a reconciliation of Income (loss) before income taxes to segment operating income: Year Ended December 31, 2020 2019 2018 Income from continuing operations before income taxes $ 58,029 $ 50,493 $ 92,364 Loss on short-term investments — — 10,128 Pension settlement loss (gain) — 33,616 (39) Interest expense, net 104,262 119,503 49,083 Restructuring and other related charges (1) 45,027 73,747 29,077 MDR and other costs (2) 6,932 — — Segment operating income $ 214,250 $ 277,359 $ 180,613 (1) Restructuring and other related charges includes $6.6 million and $8.5 million of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and 2019, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. December 31, 2020 2019 (In thousands) Investments in Equity Method Investees: Fabrication Technology $ 32,409 $ 31,134 Medical Technology — — $ 32,409 $ 31,134 Total Assets: Fabrication Technology $ 3,390,747 $ 3,509,023 Medical Technology 3,575,644 3,480,815 Corporate and other 385,158 396,994 Total $ 7,351,549 $ 7,386,832
Revenue from External Customers by Products and Services	The detail of the Company’s operations by geography is as follows: Year Ended December 31, 2020 2019 2018 (In thousands) Net Sales by Origin (1) : United States $ 1,283,651 $ 1,464,152 $ 540,533 Foreign locations 1,787,118 1,863,306 1,652,550 Total $ 3,070,769 $ 3,327,458 $ 2,193,083 (1) The Company attributes revenues from external customers to individual countries based upon the country in which the sale was originated.
Long-Lived Assets, by Geographical Areas	December 31, 2020 2019 (In thousands) Property, Plant and Equipment, Net (1) : United States $ 221,549 $ 222,293 Czech Republic 65,188 62,469 India 39,612 41,528 United Kingdom 20,181 20,097 Russia 19,490 23,149 Other Foreign locations 120,940 121,705 Total $ 486,960 $ 491,241 (1) As the Company does not allocate all long-lived assets, specifically intangible assets, to each individual country, evaluation of long-lived assets in total is impracticable.

Selected Quarterly Data - (un_2

Selected Quarterly Data - (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Selected Quarterly Financial Information [Abstract]
Schedule of Quarterly Financial Information	Provided below is selected unaudited quarterly financial data for the years ended December 31, 2020 and 2019. Quarter Ended April 3, 2020 (1)(3) July 3, 2020 (3) October 2, December 31, 2020 (2)(3)(4) (In thousands, except per share data) Net sales $ 816,356 $ 620,360 $ 805,931 $ 828,122 Gross profit 348,214 241,086 344,120 354,685 Net income (loss) from continuing operations 8,868 (3,142) 16,836 41,520 Loss from discontinued operations, net of taxes (3,360) (4,905) (2,641) (7,405) Net income (loss) attributable to Colfax Corporation 4,481 (8,474) 13,406 33,212 Net income (loss) per share - basic Continuing operations $ 0.06 $ (0.03) $ 0.12 $ 0.30 Discontinued operations $ (0.02) $ (0.04) $ (0.02) $ (0.05) Consolidated operations $ 0.03 $ (0.06) $ 0.10 $ 0.24 Net income (loss) per share - diluted Continuing operations $ 0.06 $ (0.03) $ 0.12 $ 0.29 Discontinued operations $ (0.02) $ (0.04) $ (0.02) $ (0.05) Consolidated operations $ 0.03 $ (0.06) $ 0.10 $ 0.24 (1) The results for the quarter ended April 3, 2020 include the impact of six additional days as compared to the quarter ended March 29, 2019 due to our accounting close schedule and leap year. (2) The results for the quarter ended December 31, 2020 include the impact of five fewer days as compared to the quarter ended December 31, 2019 due to our accounting close schedule. (3) The sum of the net income (loss) per share amounts may not add due to rounding. (4) The results from continuing operations includes the impact from discrete income tax benefits mainly associated with internal entity structural changes and finalization of tax return filing positions. Quarter Ended March 29, June 28, September 27, December 31, (In thousands, except per share data) Net sales $ 683,919 $ 908,647 $ 846,519 $ 888,373 Gross profit 261,013 376,058 368,142 395,843 Net income (loss) from continuing operations (21,530) 2,212 3,770 34,411 Income (loss) from discontinued operations, net of taxes (26,472) (468,817) 9,024 (49,744) Net income (loss) attributable to Colfax Corporation (52,023) (469,234) 10,474 (16,863) Net income (loss) per share - basic Continuing operations $ (0.17) $ 0.01 $ 0.02 $ 0.24 Discontinued operations $ (0.22) $ (3.46) $ 0.06 $ (0.36) Consolidated operations $ (0.39) $ (3.45) $ 0.08 $ (0.12) Net income (loss) per share - diluted Continuing operations $ (0.17) $ 0.01 $ 0.02 $ 0.24 Discontinued operations $ (0.22) $ (3.46) $ 0.06 $ (0.36) Consolidated operations $ (0.39) $ (3.45) $ 0.08 $ (0.12)

Organization and Nature of Op_2

Organization and Nature of Operations (Details)	12 Months Ended
	Dec. 31, 2020segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies Accounting Policies (Details Textual) € in Millions	12 Months Ended
	Dec. 31, 2020USD ($)acquisition	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Apr. 19, 2017USD ($)	Apr. 19, 2017EUR (€)
LIFO inventory amount	$ 105,100,000	$ 121,800,000
Number of reporting units | acquisition	2
Asset Impairments Related to Facility Closures
Non-cash impairment provisions	$ 3,500,000	4,200,000	$ 5,500,000
Carrying amount after impairment	62,500,000	44,600,000	39,800,000
Interest expense
Interest income, other	3,200,000	3,200,000	2,500,000
Foreign currency transaction (loss) gain	2,800,000	500,000	(1,400,000)
Selling, general and administrative expense
Research and development costs	68,600,000	61,800,000	34,200,000
Foreign currency transaction (loss) gain	(2,400,000)	(700,000)	$ (7,800,000)
Other Assets
Deferred issuance costs	7,000,000	6,100,000
Long-term Debt
Deferred issuance costs	$ 15,600,000	$ 17,700,000
Acquired customer relationships | Minimum
Intangible asset, useful life	7 years
Acquired customer relationships | Maximum
Intangible asset, useful life	30 years
Finite Lived Intangible Assets, Excluding Customer Relationships | Minimum
Intangible asset, useful life	2 years
Finite Lived Intangible Assets, Excluding Customer Relationships | Maximum
Intangible asset, useful life	20 years
Senior Notes
Principal amount | €					€ 350
Deferred issuance costs				$ 6,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies Accounting Policies - Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 97,068	$ 109,632
Restricted Cash	4,001	0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$ 101,069	$ 109,632	$ 245,019	$ 262,019

Summary of Significant Accoun_6

Summary of Significant Accounting Policies Accounting Policies Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Warranty liability, beginning of period	$ 15,528	$ 12,312
Accrued warranty expense	7,253	6,038
Changes in estimates related to pre-existing warranties	1,849	1,668
Cost of warranty service work performed	(9,708)	(9,502)
Acquisitions	300	5,520
Foreign exchange translation effect	321	(508)
Warranty liability, end of period	$ 15,543	$ 15,528

Recently Issued Accounting Pr_2

Recently Issued Accounting Pronouncements Details Textual (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cumulative effect of accounting change	$ (4,818)	$ 0	$ 0

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accumulated other comprehensive loss	$ (452,106)	$ (483,845)
Gain on disposal	0	14,233	$ (4,337)
Net loss related to asbestos contingencies and 2017 divestiture	9,500	19,000	28,400
Air and Gas Handling Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration for sale		1,800,000
Cash consideration for sale		1,670,000
Discontinued operation, loss on discontinued operations		(481,000)
Goodwill impairment charge	0	449,000	0
Valuation allowance		32,000
Accumulated other comprehensive loss		350,000
Gain on disposal	0	14,233	0
Divestiture-related expense	9,040	48,640	0
Income attributable to noncontrolling interest		5,900	13,600
Cash used in operating activities, discontinued operations	9,400	18,100	(127,800)
Cash used in investing activities, discontinued operations		(27,500)	43,600
Fluid Handling
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities, discontinued operations	$ (2,200)	$ (3,200)	$ (5,600)

Discontinued Operations - Compo

Discontinued Operations - Components of Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Oct. 02, 2020	Jul. 03, 2020	Apr. 03, 2020	Dec. 31, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on disposal									$ 0	$ 14,233	$ (4,337)
Income (loss) from discontinued operations, net of taxes	$ (7,405)	$ (2,641)	$ (4,905)	$ (3,360)	$ (49,744)	$ 9,024	$ (468,817)	$ (26,472)	(18,311)	(536,009)	32,601
Air and Gas Handling Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales									0	998,793	1,473,729
Cost of sales									0	689,004	1,070,266
Selling, general and administrative expense									0	194,589	269,447
Restructuring and other related charges									0	13,354	48,609
Goodwill impairment charge									0	449,000	0
Divestiture-related expense									9,040	48,640	0
Operating income (loss)									(9,040)	(395,794)	85,407
Interest expense									0	47,553	(5,031)
Pension settlement loss									0	43,774	0
Gain on disposal									0	14,233	0
Loss from discontinued operations before income taxes									(9,040)	(472,888)	90,438
Income taxes									(238)	44,062	29,487
Income (loss) from discontinued operations, net of taxes									$ (8,802)	$ (516,950)	$ 60,951

Acquisitions (Details Textual)

Acquisitions (Details Textual) $ in Millions	Feb. 22, 2019USD ($)	Dec. 31, 2020USD ($)acquisition	Apr. 03, 2020USD ($)	Dec. 31, 2020USD ($)acquisition	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)acquisition
Business Acquisition [Line Items]
Net sales associated with acquisitions				$ 7.1	$ 1,080.4	$ 78.9
Revenue reported by acquired entity for last annual period					57.3
Number of businesses acquired | acquisition		4		5
Percentage of consolidated revenues				2.00%
Medical Technology
Business Acquisition [Line Items]
Number of businesses acquired | acquisition				5
Total consideration		$ 39.6		$ 67.5
Goodwill acquired				21.4
Goodwill acquired, deductible for income tax purposes		$ 15.9		15.9
Net working capital, percentage of consideration paid		10.00%
Intangible assets acquired, percentage of consideration paid		69.00%
Medical Technology | Accrued Liabilities
Business Acquisition [Line Items]
Valuation allowance on deferred taxes			$ 51.4
Fabrication Technology
Business Acquisition [Line Items]
Number of businesses acquired | acquisition						2
Total consideration						$ 245.1
DJO Acquisition | Medical Technology
Business Acquisition [Line Items]
Total consideration	$ 3,150
DJO Global Inc. | Medical Technology | Selling, general and administrative expense
Business Acquisition [Line Items]
Professional fees				$ 2.8	$ 60.8

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information (Details) - DJO Acquisition - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Net sales	$ 3,070,769	$ 3,496,624	$ 3,395,018
Net income from continuing operations attributable to Colfax Corporation	$ 68,039	$ 105,491	$ 97,410

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Oct. 02, 2020	Jul. 03, 2020	Apr. 03, 2020	Dec. 31, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 828,122	$ 805,931	$ 620,360	$ 816,356	$ 888,373	$ 846,519	$ 908,647	$ 683,919	$ 3,070,769	$ 3,327,458	$ 2,193,083
Fabrication Technology
Disaggregation of Revenue [Line Items]
Net sales									1,950,069	2,247,026	2,193,083
Fabrication Technology | Equipment
Disaggregation of Revenue [Line Items]
Net sales									607,504	703,024	623,987
Fabrication Technology | Consumables
Disaggregation of Revenue [Line Items]
Net sales									1,342,565	1,544,002	1,569,096
Medical Technology
Disaggregation of Revenue [Line Items]
Net sales									1,120,700	1,080,432	$ 0
Medical Technology | Prevention & Rehabilitation
Disaggregation of Revenue [Line Items]
Net sales									781,007	766,429
Medical Technology | Reconstructive
Disaggregation of Revenue [Line Items]
Net sales									$ 339,693	$ 314,003

Revenue - Details Textual (Deta

Revenue - Details Textual (Details) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Contract liabilities	$ 36.6	$ 14.8	$ 13

Revenue - Allowance for Credit

Revenue - Allowance for Credit Losses (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Balance at Beginning of Period	$ 36,009
Charged to Expense, net	7,574
Write-Offs and Deductions	(5,165)
Foreign Currency Translation	(752)
Balance at End of Period	$ 37,666

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Oct. 02, 2020	Jul. 03, 2020	Apr. 03, 2020	Dec. 31, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net income (loss) attributable to Colfax Corporation	$ 33,212	$ 13,406	$ (8,474)	$ 4,481	$ (16,863)	$ 10,474	$ (469,234)	$ (52,023)
Weighted-average shares of common stock outstanding - basic (in shares)									136,766,124	135,716,944	120,288,297
Net income per share from continuing operations - basic (in usd per share)	$ 0.30	$ 0.12	$ (0.03)	$ 0.06	$ 0.24	$ 0.02	$ 0.01	$ (0.17)	$ 0.45	$ 0.10	$ 1.01
Net income from continuing operations attributable to Colfax corporations									$ 60,936	$ 14,245	$ 121,211
Net effect of potentially dilutive securities - stock options, restricted stock units and tangible equity units (in shares)									2,144,304	949,942	506,759
Weighted - average shares of common stock outstanding - diluted (in shares)									138,910,428	136,666,886	120,795,056
Net income per share from continuing operations - diluted (in usd per share)	$ 0.29	$ 0.12	$ (0.03)	$ 0.06	$ 0.24	$ 0.02	$ 0.01	$ (0.17)	$ 0.44	$ 0.10	$ 1
Income attributable to noncontrolling interest									$ 3,100	$ 4,600	$ 700

Net Income Per Share (Details T

Net Income Per Share (Details Textual) - shares shares in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share
Shares related to issuance of tangible equity units - diluted (in shares)	0.9
Stock-based compensation awards, anti-dilutive (in shares)	4.2	4.3	3.4
Tangible Equity Unit
Antidilutive Securities Excluded from Computation of Earnings Per Share
Shares related to issuance of tangible equity units - basic (in shares)	18.4	18.4

Income Taxes Domestic and Forei

Income Taxes Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income from continuing operations before income taxes:
Domestic operations	$ (156,675)	$ (129,182)	$ (60,352)
Foreign operations	214,704	179,675	152,716
Income before income taxes	58,029	50,493	92,364
Current:
Federal	(39,376)	811	(15,132)
State	1,454	6,712	816
Foreign	56,076	56,477	41,831
Current income tax	18,154	64,000	27,515
Deferred:
Domestic operations	3,641	(24,151)	(21,908)
Foreign operations	(27,848)	(8,219)	(35,115)
Deferred income tax	(24,207)	(32,370)	(57,023)
Income tax expense (benefit)	$ (6,053)	$ 31,630	$ (29,508)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Examination [Line Items]
Tax Act - mandatory repatriation taxes	$ (6,766)	$ 0	$ (10,804)
Tax Act - re-measurement of U.S. deferred taxes	0	0	(667)
Deferred tax assets, valuation allowance	203,341	149,037
Foreign tax credit carryforwards	22,700
Research and development tax credit	14,000
Undistributed earnings of foreign subsidiaries	184,000
Deferred tax liability, undistributed earnings of foreign subsidiaries	1,900
Deferred tax liability, increase (decrease)	(2,000)
Unrecognized tax benefits	58,014	55,480	37,621	$ 41,018
Unrecognized tax benefits, income tax penalties and interest accrued	6,900	5,700
Unrecognized tax benefits, income tax penalties and interest expense	700	$ 1,000	$ 1,100
Unrecognized tax benefits, estimated reduction of income tax expense	4,800
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset
Income Tax Examination [Line Items]
Valuation allowance, charged to cost and expense	(6,200)
Valuation allowance, charged to cost and expense from acquisition	48,500
Valuation allowance, foreign currency translation	(400)
Domestic Tax Authority
Income Tax Examination [Line Items]
Net operating loss carryforward, subject to expiration	611,300
Net operating loss carryforwards, not subject to expiration	72,600
Foreign Tax Authority
Income Tax Examination [Line Items]
Operating loss carryforwards	$ 581,300

Income Taxes Reconciliation (De

Income Taxes Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Taxes calculated at the U.S. federal statutory rate	$ 12,186	$ 10,677	$ 19,392
State taxes	(2,196)	(5,358)	(3,543)
Effect of tax rates on international operations	(18,577)	(14,115)	(9,323)
Change in enacted international tax rates	(1,023)	(2,843)	(2,403)
Changes in valuation allowance	(24,149)	11,196	(11,577)
Changes in tax reserves	1,394	1,119	(1,704)
Tax Act - re-measurement of U.S. deferred taxes	0	0	(667)
Tax Act - mandatory repatriation taxes	(6,766)	0	(10,804)
Research and development tax credits	(1,649)	(4,029)	(7,123)
Foreign tax credits	(12,197)	(15,299)	(21,927)
Net items not deductible in an international jurisdiction	5,365	10,060	12,077
SubPart F and GILTI	27,797	29,407	12,872
U.S. Deal Costs and other non-deductibles	38	5,556	0
Withholding taxes	8,570	4,545	3,446
Non-deductible employee compensation	6,619	714	1,068
Other	(1,465)	0	(9,292)
Income tax expense (benefit)	$ (6,053)	$ 31,630	$ (29,508)

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Post-retirement benefit obligation	$ 11,617	$ 11,295
Expenses currently not deductible	147,636	131,921
Net operating loss carryforward	308,965	342,442
Tax credit carryforward	33,674	16,727
Depreciation and amortization	6,433	6,487
Other	42,881	42,407
Valuation allowance	(203,341)	(149,037)
Deferred tax assets, net	347,865	402,242
Depreciation and amortization	(403,704)	(415,888)
Inventory	(1,559)	(3,694)
Outside basis differences and other	(78,012)	(84,706)
Total deferred tax liabilities	(483,275)	(504,288)
Total deferred tax liabilities, net	$ (135,410)	$ (102,046)

Income Taxes Gross Unrecognized

Income Taxes Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Beginning Balance	$ 55,480	$ 37,621	$ 41,018
Acquisitions and divestitures		18,248
Addition for tax positions taken in prior periods	5,911	1,441	2,525
Addition for tax positions taken in the current period	1,980	2,054	240
Reductions related to settlements with taxing authorities	0	(118)	(461)
Reductions resulting from a lapse of applicable statute of limitations	(5,689)	(3,643)	(4,477)
Other, including the impact of foreign currency translation and U.S. tax rate changes	332	(123)	(1,224)
Ending Balance	$ 58,014	$ 55,480	$ 37,621

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Balance beginning of period		$ 3,202,517	$ 1,497,832
Goodwill attributable to acquisitions	[1]	72,815	1,682,734
Impact of foreign currency translation		39,209	21,951
Balance end of period		3,314,541	3,202,517
Medical Technology
Goodwill [Line Items]
Balance beginning of period		1,672,921	0
Goodwill attributable to acquisitions		72,815	1,674,328
Impact of foreign currency translation		15,574	(1,407)
Balance end of period		1,761,310	1,672,921
Fabrication Technology
Goodwill [Line Items]
Balance beginning of period		1,529,596	1,497,832
Goodwill attributable to acquisitions	[1]	0	8,406
Impact of foreign currency translation		23,635	23,358
Balance end of period		$ 1,553,231	$ 1,529,596
[1]	Includes purchase accounting adjustments associated with acquisitions discussed in Note 5, “Acquisitions”.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Intangible Assets Schedule [Line Items]
Accumulated Amortization	$ (514,786)	$ (349,934)
Gross Carrying Amount	2,178,232	2,068,953
Acquired customer relationships
Intangible Assets Schedule [Line Items]
Accumulated Amortization	(266,347)	(182,813)
Gross Carrying Amount	952,007	919,574
Acquired technology
Intangible Assets Schedule [Line Items]
Accumulated Amortization	(99,748)	(60,971)
Gross Carrying Amount	455,738	440,719
Acquired trade names
Intangible Assets Schedule [Line Items]
Accumulated Amortization	(41,960)	(21,069)
Gross Carrying Amount	404,076	389,112
Software
Intangible Assets Schedule [Line Items]
Accumulated Amortization	(90,196)	(71,644)
Gross Carrying Amount	129,852	103,274
Other intangible assets
Intangible Assets Schedule [Line Items]
Accumulated Amortization	(16,535)	(13,437)
Gross Carrying Amount	24,511	22,809
Trade names
Intangible Assets Schedule [Line Items]
Indefinite-Lived Intangible Assets	$ 212,048	$ 193,465

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 158,427	$ 135,769	$ 43,703

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Details Textual) $ in Thousands	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 153,923
2022	148,995
2023	143,325
2024	137,707
2025	$ 136,620

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 799,629	$ 750,796
Accumulated depreciation	(312,669)	(259,555)
Property, plant and equipment, net	486,960	491,241
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	23,821	25,138
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 205,397	196,810
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Depreciable Life	5 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Depreciable Life	40 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 570,411	$ 528,848
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Depreciable Life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Depreciable Life	15 years

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Tangible Asset Impairment Charges	$ 2.1	$ 0.5	$ 3.1
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Depreciation	$ 85.5	$ 76.1	$ 34.2

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 110,848	$ 115,587
Work in process	40,517	37,019
Finished goods	476,297	475,933
Inventory, gross	627,662	628,539
Less: allowance for excess, slow-moving and obsolete inventory	(62,840)	(56,981)
Inventories, net	$ 564,822	$ 571,558

Leases (Details)

Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Leases [Abstract]
Operating lease expense	$ 45,000
Future lease payments by year
2021	42,516
2022	33,809
2023	26,836
2024	18,987
2025	14,073
Thereafter	71,838
Total	208,059
Less: present value discount	(30,578)
Present value of lease liabilities	$ 177,481
Weighted-average remaining lease term (in years):
Operating leases	8 years 7 months 6 days
Weighted-average discount rate:
Operating leases	3.70%

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total debt	$ 2,231,243	$ 2,311,826
Less: current portion	(27,074)	(27,642)
Long-term debt	2,204,169	2,284,184
Term loan
Debt Instrument [Line Items]
Total debt	781,557	822,945
Euro senior notes
Debt Instrument [Line Items]
Total debt	425,045	388,925
TEU amortizing notes
Debt Instrument [Line Items]
Total debt	31,251	54,044
2024 and 2026 notes
Debt Instrument [Line Items]
Total debt	991,319	989,236
Revolving credit facilities and other
Debt Instrument [Line Items]
Total debt	$ 2,071	$ 56,676

Debt (Details Textual)

Debt (Details Textual) $ / shares in Units, € in Millions	May 01, 2020USD ($)	Feb. 05, 2019USD ($)salesChannel	Jan. 11, 2019USD ($)$ / sharesshares	Apr. 19, 2017EUR (€)	Oct. 02, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Apr. 19, 2017USD ($)	Apr. 19, 2017EUR (€)
Debt Instrument [Line Items]
Repayments of long-term debt					$ 40,000,000	$ 40,000,000	$ 1,387,500,000	$ 131,250,000
Pricing percentage fee	0.50%
Weighted-average interest rate						1.90%
Remaining borrowing capacity						$ 975,000,000
Repayments of debt | €				€ 283.5
Gross proceeds			$ 460,000,000			$ 460,000,000
Tangible equity units issued, number (in shares) | shares			4,000,000
Interest rate of tangible equity notes			5.75%			6.50%
Tangible equity units issued, par value (in usd per share) | $ / shares			$ 100
Tangible equity units issued, number, additional issuable (in shares) | shares			600,000
Tangible equity units issued, cash proceeds			$ 447,700,000
Proceeds from prepaid stock purchase contracts			377,800,000			$ 0	$ 377,814,000	$ 0
Proceeds from sale of tangible equity units senior amortizing notes			$ 69,900,000
Number of debt tranches | salesChannel		2
Maximum capacity						340,500,000
Letters of credit outstanding						76,400,000
Debt discount						$ 22,600,000
Amended Credit Facility
Debt Instrument [Line Items]
Unrestricted cash and cash equivalents from debt component	$ 125,000,000
Step down maximum total leverage ratio	4.50					6.50											6.50	5.75
Interest coverate ratio																	2.75	3
Gross leverage ratio	5
Amended Credit Facility | Forecast
Debt Instrument [Line Items]
Step down maximum total leverage ratio									3.50	4	4	4.25	4.25	4.50	5.25	6.50
Interest coverate ratio														3	2.75	2.75
Revolving credit facilities and other
Debt Instrument [Line Items]
Deferred financing fees						$ 10,400,000
Term A1 Loan
Debt Instrument [Line Items]
Principal amount						825,000,000
DJO Global Inc Financing Facilities | New Revolving Credit Facility
Debt Instrument [Line Items]
Swing-line loan sub facility						50,000,000
DJO Global Inc Financing Facilities | New Revolving Credit Facility | Revolving credit facilities and other
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 975,000,000
Senior Notes
Debt Instrument [Line Items]
Principal amount | €																				€ 350
Deferred financing fees																			$ 6,000,000
Euro bond coupon rate						3.25%
2024 Notes
Debt Instrument [Line Items]
Proceeds from notes payable		$ 600,000,000
Stated interest rate		6.00%
2026 Notes
Debt Instrument [Line Items]
Proceeds from notes payable		$ 400,000,000
Stated interest rate		6.375%
Bilateral agreements
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 195,000,000
Eurocurrency
Debt Instrument [Line Items]
Pricing percentage fee	2.50%
Base Rate
Debt Instrument [Line Items]
Pricing percentage fee	1.50%

Debt (Schedule of Debt Maturiti

Debt (Schedule of Debt Maturities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
2021	$ 27,074
2022	6,507
2023	0
2024	1,385,000
2025	428,242
Thereafter	400,000
Total contractual maturities	2,246,823
Debt discount	(15,580)
Total debt	$ 2,231,243	$ 2,311,826

Equity (Details)

Equity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ (483,845)
Net actuarial gain (loss)		$ 27,931		$ 5,609
Foreign currency translation adjustment	59,152	(78,937)		(221,437)
Divestiture-related AOCI write-off		400,143
Gain on long-term intra-entity foreign currency transactions	3,289	29,385		(5,507)
Gain (loss) on net investment hedges	(26,268)	6,215		16,745
Unrealized (loss) gain on cash flow hedges		156		(2,153)
Other comprehensive income (loss) before reclassifications:	36,173	329,031		(206,743)
Amounts reclassified from Accumulated other comprehensive loss	(4,434)	2,629	[1]	6,090	[1]
Noncontrolling interest share repurchase		(19,960)
Net current period Other comprehensive income (loss)	31,739	311,700		(200,653)
Cumulative effect of accounting change		(4,818)		0		$ 0
Ending balance	(452,106)	(483,845)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(483,845)	(780,177)		(574,372)
Cumulative effect of accounting change				(15,368)		(5,152)
Ending balance	(452,106)	(483,845)		(780,177)
Net Unrecognized Pension And Other Post-Retirement Benefit Cost
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(106,500)	(71,494)		(84,338)
Net actuarial gain (loss)		(27,931)		5,609
Foreign currency translation adjustment	(1,849)	(404)		1,145
Other comprehensive income (loss) before reclassifications:	(1,849)	(28,335)		6,754
Amounts reclassified from Accumulated other comprehensive loss	(4,434)	2,629	[1]	6,090	[1]
Net current period Other comprehensive income (loss)	(6,283)	(25,706)		12,844
Cumulative effect of accounting change				(9,300)
Ending balance	(112,783)	(106,500)		(71,494)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(421,889)	(752,989)		(525,324)
Foreign currency translation adjustment	57,623	(78,468)		(222,158)
Gain on long-term intra-entity foreign currency transactions	3,289	29,385		(5,507)
Other comprehensive income (loss) before reclassifications:	60,912	351,060		(227,665)
Noncontrolling interest share repurchase		(19,960)
Net current period Other comprehensive income (loss)	60,912	331,100		(227,665)
Ending balance	(360,977)	(421,889)		(752,989)
Unrealized Gain (Loss) On Hedging Activities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	44,544	44,306		30,138
Foreign currency translation adjustment	3,378	(65)		(424)
Unrealized (loss) gain on cash flow hedges		156		(2,153)
Other comprehensive income (loss) before reclassifications:	(22,890)	6,306		14,168
Net current period Other comprehensive income (loss)	(22,890)	6,306		14,168
Cumulative effect of accounting change				(6,068)
Ending balance	21,654	44,544		44,306
Changes in Fair Value of Available-for-Sale Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	0	0		5,152
Net current period Other comprehensive income (loss)				0
Cumulative effect of accounting change						$ (5,152)
Ending balance	$ 0	$ 0		$ 0
[1]	Included in the computation of net periodic benefit cost. See Note 16, “Defined Benefit Plans” for additional details.

Equity - Narrative (Details)

Equity - Narrative (Details)	Jan. 11, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)$ / sharesshares	Jul. 19, 2018USD ($)	Jun. 06, 2018USD ($)	Feb. 12, 2018USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount		$ 100,000,000			$ 100,000,000	$ 100,000,000	$ 100,000,000
Stock repurchased during period (in shares) | shares				6,449,425
Stock repurchased during period, value		0	$ 0	$ 200,000,000
Other comprehensive income, portion attributable to noncontrolling interest increase (decrease)		2,600,000	107,600,000	22,800,000
Unrecognized stock-based compensation expense		$ 32,400,000
Unrecognized compensation cost, period for recognition		10 months 24 days
Intrinsic value of awards		$ 11,500,000	11,200,000	10,200,000
Fair value of vested shares		9,700,000	$ 10,900,000	$ 10,000,000
Gross proceeds	$ 460,000,000	$ 460,000,000
Tangible equity units issued, number (in shares) | shares	4,000,000
Interest rate of tangible equity notes	5.75%	6.50%
Tangible equity units issued, par value (in usd per share) | $ / shares	$ 100
Tangible equity units issued, number, additional issuable (in shares) | shares	600,000
Tangible equity units issued, cash proceeds	$ 447,700,000
Fair value of prepaid stock purchase contract	377,800,000
Fair value of TEU amortizing notes	69,900,000
TEU issued, noncurrent	47,300,000	$ 6,500,000
TEU issued, current	$ 22,600,000	$ 25,000,000
Threshold appreciation price (in usd per share) | $ / shares		$ 25
TEU reference price (in shares) | $ / shares		20.81
TEU initial principal amount | $ / shares		15.6099
TEU quarterly cash installment (in usd per share) | $ / shares		$ 1.4375
TEU quarterly cash installment, percentage		5.75%
Partial payment on TEU		$ 26,500,000
Stock purchase contracts outstanding (in shares) | shares		4,600,000
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued per purchase contract (in shares)		4
TEU threshold for conversion | shares		18,400,000
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued per purchase contract (in shares)		4.8054
TEU threshold for conversion | shares		22,100,000
PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Profit performance metric, percentage of awards		50.00%
Performance vesting period		3 years
Granted (in usd per share) | $ / shares		$ 50.91	$ 24.77	$ 33.92
Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term		10 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance vesting period		3 years
Granted (in usd per share) | $ / shares		$ 34.80	$ 27.58	$ 32.92

Equity Stock-based compensation

Equity Stock-based compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Stock-based compensation expense	$ 28,911	$ 21,960	$ 25,103
Deferred tax benefit	$ 1,804	$ 1,280	$ 3,418

Equity Option Valuation Assumpt

Equity Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Expected period that options will be outstanding (in years)	4 years 7 months 13 days	4 years 6 months 21 days	4 years 6 months 14 days
Interest rate (based on U.S. Treasury yields at the time of grant)	1.09%	2.46%	2.65%
Volatility	37.76%	34.51%	31.89%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of options granted	$ 11.81	$ 8.80	$ 10.37

Equity Option Award Activity (D

Equity Option Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, beginning balance (in shares)		4,675,281
Granted (in shares)		618,403
Exercised (in shares)		(126,576)
Forfeited and expired (in shares)		(568,041)
Options outstanding, ending balance (in shares)		4,599,067	4,675,281
Vested or expected to vest (in shares)		4,543,740
Exercisable (in shares)		2,943,374
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-average exercise price, outstanding, beginning balance (in usd per share)		$ 34.93
Weighted-average exercise price, granted (in shares)		35.89
Weighted-average exercise price, exercised (in shares)		27.64
Weighted-average exercise price, forfeited and expired (in shares)		45.75
Weighted-average exercise price, outstanding, ending balance (in usd per share)		33.92	$ 34.93
Weighted-average exercise price, vested or expected to vest (in shares)		33.94
Weighted-average exercise price, exercisable (in shares)		$ 35.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted- Average Remaining Contractual Term (In years)		3 years 6 months 10 days
Vested or expected to vest at December 31, 2020		3 years 6 months 10 days
Exercisable at December 31, 2020		2 years 8 months 26 days
Aggregate intrinsic value, outstanding	[1]	$ 29,875
Vested or expected to vest at December 31, 2020	[1]	29,549
Exercisable at December 31, 2020	[1]	17,315
Intrinsic value of awards		1,100	$ 2,000	$ 1,400
Fair value of options vested in period		$ 11,900	$ 10,900	$ 8,500
[1]	The aggregate intrinsic value is based upon the difference between the Company’s closing stock price at the date of the Consolidated Balance Sheet and the exercise price of the stock option for in-the-money stock options. The intrinsic value of outstanding stock options fluctuates based upon the trading value of the Company’s Common stock.The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 was $1.1 million, $2.0 million and $1.4 million, respectively. The fair value of options vested during the years ended December 31, 2020, 2019 and 2018 was $11.9 million, $10.9 million and $8.5 million, respectively.

Equity PRSU and RSU Activity (D

Equity PRSU and RSU Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
PRSUs
Number of Units
Number of units, nonvested, beginning balance (in shares)	741,375
Granted (in shares)	142,987
Vested (in shares)	(103,629)
Forfeited and expired (in shares)	49,332
Number of units, nonvested, ending balance (in shares)	731,401	741,375
Weighted- Average Grant-Date Fair Value
Weighted-average grant date fair value, nonvested, beginning balance (in usd per share)	$ 30.87
Granted (in usd per share)	50.91	$ 24.77	$ 33.92
Vested (in usd per share)	29.90
Forfeited and expired (in usd per share)	27.93
Weighted-average grant date fair value, nonvested, ending balance (in usd per share)	$ 35.12	$ 30.87
RSUs
Number of Units
Number of units, nonvested, beginning balance (in shares)	595,376
Granted (in shares)	554,192
Vested (in shares)	(226,912)
Forfeited and expired (in shares)	88,693
Number of units, nonvested, ending balance (in shares)	833,963	595,376
Weighted- Average Grant-Date Fair Value
Weighted-average grant date fair value, nonvested, beginning balance (in usd per share)	$ 29.25
Granted (in usd per share)	34.80	$ 27.58	$ 32.92
Vested (in usd per share)	30.30
Forfeited and expired (in usd per share)	29.52
Weighted-average grant date fair value, nonvested, ending balance (in usd per share)	$ 32.52	$ 29.25

Equity Equity (Tangible Equity

Equity Equity (Tangible Equity Units) (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 11, 2019	Dec. 31, 2020
Class of Stock [Line Items]
Tangible equity units issued, par value (in usd per share)	$ 100
Gross proceeds	$ 460	$ 460
Less: Issuance costs		12.3
Net Proceeds		447.7
TEU prepaid stock purchase contracts
Class of Stock [Line Items]
Tangible equity units issued, par value (in usd per share)	$ 84.39
Gross proceeds		388.2
Less: Issuance costs		10.4
Net Proceeds		377.8
TEU amortizing notes
Class of Stock [Line Items]
Tangible equity units issued, par value (in usd per share)	$ 15.61
Gross proceeds		71.8
Less: Issuance costs		1.9
Net Proceeds		$ 69.9

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Accrued compensation and related benefits	$ 98,455	$ 100,290
Accrued taxes	57,286	55,258
Accrued asbestos-related liability	41,626	64,394
Warranty liability - current portion	15,543	15,513
Accrued restructuring liability - current portion	7,889	6,961
Accrued third-party commissions	25,480	30,768
Customer advances and billings in excess of costs incurred	36,737	16,009
Lease liability - current portion	39,695	40,021
Accrued interest	27,153	27,333
Other	104,469	113,343
Accrued liabilities	$ 454,333	$ 469,890
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:AccruedLiabilitiesCurrent	us-gaap:AccruedLiabilitiesCurrent

Accrued Liabilities Restructuri

Accrued Liabilities Restructuring (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		$ 7,098	[1]	$ 6,156
Acquisitions				6,394
Provisions		40,148		69,549
Payments		(39,248)		(74,649)
Foreign Currency Translation		110		(352)
Balance at end of period		8,108		7,098	[1]	$ 6,156
Non cash charges		4,879		4,198	[2]
Provisions		45,027		73,747
Accrued restructuring liability - current portion		7,889		6,961
Impairment of property, plant and equipment		0		0		7,086
Restructuring and other related charges		45,027		73,747		29,077
Cost of Sales
Restructuring Reserve [Roll Forward]
Restructuring and other related charges		6,600		8,500
Fabrication Technology
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		2,922	[1]	6,156
Provisions		19,739		18,842
Payments		(16,758)		(21,724)
Foreign Currency Translation		24		(352)
Balance at end of period		5,927		2,922	[1]	6,156
Non cash charges		1,894		4,198
Provisions		21,633		23,040
Impairment of property, plant and equipment				4,200
Fabrication Technology | Termination Benefits
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	[3]	1,638	[1]	5,494
Provisions		11,381		7,131	[3]
Payments		(7,698)		(10,588)	[3]
Foreign Currency Translation		15		(399)	[3]
Balance at end of period		5,336		1,638	[1],[3]	5,494	[3]
Fabrication Technology | Facility Closure Costs
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	[2]	1,284	[1]	662
Provisions		8,358		11,711	[2]
Payments		(9,060)		(11,136)	[2]
Foreign Currency Translation		9		47	[2]
Balance at end of period		591		1,284	[1],[2]	662	[2]
Medical Technology
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		4,176		0
Acquisitions				6,394
Provisions		20,409		50,707
Payments		(22,490)		(52,925)
Foreign Currency Translation		86		0
Balance at end of period		2,181		4,176		0
Non cash charges		2,985
Provisions		23,394
Medical Technology | Termination Benefits
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		3,919		0
Acquisitions				6,096
Provisions		3,284		5,449
Payments		(5,405)		(7,626)
Foreign Currency Translation		86		0
Balance at end of period		1,884		3,919		0
Medical Technology | Facility Closure Costs
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		257		0
Acquisitions				298
Provisions		17,125		45,258
Payments		(17,085)		(45,299)
Foreign Currency Translation		0		0
Balance at end of period		297		257		$ 0
Accrued Liabilities
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		7,000
Balance at end of period				7,000
Accrued restructuring liability - current portion		7,900
Other Noncurrent Liabilities
Restructuring Reserve [Roll Forward]
Accrued restructuring liability - noncurrent portion		200
Other Liabilities
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period		$ 100
Balance at end of period				$ 100
[1]	As of December 31, 2019, $7.0 million and $0.1 million of the Company’s restructuring liability was included in Accrued liabilities and Other liabilities, respectively.
[2]	Includes the cost of relocating associates, relocating equipment and lease termination expense in connection with the closure of facilities. During the year ended December 31, 2020, the Company recorded a total of $1.9 million and $3.0 million non-cash impairment charges for facilities in the Fabrication Technology and Medical Technology segments, respectively, as part of Corporate approved restructuring activities. Restructuring charges in the Medical Technology segment during the year ended December 31, 2020 include costs related to product and distribution channel transformations, facilities optimization, and integration charges, as well as $6.6 million classified as Cost of sales on the Company’s Consolidated Statements of Operations for the year ended December 31, 2020.
[3]	Includes severance and other termination benefits, including outplacement services.

Defined Benefit Plans Details T

Defined Benefit Plans Details Textual (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2031
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss)		$ 77,400
Accumulated benefit obligation	$ 367,400	345,100
Fair value of plan assets	259,100	238,900
Projected benefit obligation	376,000	359,500
Fair value of plan assets	263,900	249,600
Expected employer contributions	$ 6,900
Weighted-average annual rate of increase	6.50%
Defined contribution plan, cost	$ 10,200	6,900	$ 6,300
Forecast
Defined Benefit Plan Disclosure [Line Items]
Health care cost trend rate				4.50%
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost (income)	1,816	75,744	(1,177)
Discontinued Operations
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost (income)		44,400	(1,400)
Defined contribution plan, cost		4,200	5,900
Air and Gas Handling Business
Defined Benefit Plan Disclosure [Line Items]
Settlement gain (loss), discontinued operations		43,800
Pension settlement loss	$ 0	$ 43,774	$ 0

Defined Benefit Plans Defined_3

Defined Benefit Plans Defined Benefit Plans Obligation and Asset Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	$ 251,291
Fair value of plan assets, end of year	267,254	$ 251,291
Pension Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Change in benefit obligation:	361,146	867,345
Acquisitions	0	2,264
Service cost	1,933	2,462	$ 2,770
Interest cost	7,454	16,556	21,574
Plan amendments	95	464
Actuarial loss (gain)	21,642	183,084
Foreign exchange effect	9,757	(912)
Benefits paid	(24,105)	(40,131)
Divestitures	0	(50,468)
Settlements	(418)	(619,756)
Other	1,791	238
Projected benefit obligation, end of year	379,295	361,146	867,345
Accumulated benefit obligation, end of year	375,267	356,741
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	251,291	850,024
Actual return on plan assets	26,123	88,869
Employer contribution	9,830	10,793
Foreign exchange effect	2,806	1,236
Benefits paid	(24,105)	(40,131)
Divestitures	0	(39,897)
Settlements	(418)	(619,756)
Other	1,727	153
Fair value of plan assets, end of year	267,254	251,291	850,024
Funded status, end of year	(112,041)	(109,855)
Non-current assets	0	0
Current liabilities	(3,800)	(3,596)
Non-current liabilities	(108,241)	(106,259)
Total	(112,041)	(109,855)
Pension Benefits | Foreign Plan
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Change in benefit obligation:	144,739		661,084
Acquisitions	0	2,264
Service cost	1,933	2,340	2,634
Interest cost	2,315	9,376	15,183
Plan amendments	95	464
Actuarial loss (gain)	5,778	164,888
Foreign exchange effect	9,757	(912)
Benefits paid	(8,795)	(24,779)
Divestitures	0	(50,468)
Settlements	(418)	(619,756)
Other	1,791	238
Projected benefit obligation, end of year	157,195	144,739
Accumulated benefit obligation, end of year	153,167	140,335
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	67,535		691,758
Acquisitions	0	0
Actual return on plan assets	4,037	51,318
Employer contribution	6,222	7,502
Foreign exchange effect	2,806	1,236
Benefits paid	(8,795)	(24,779)
Divestitures	0	(39,897)
Settlements	(418)	(619,756)
Other	1,727	153
Fair value of plan assets, end of year	73,114	67,535
Funded status, end of year	(84,081)	(77,204)
Other Post-Retirement Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Change in benefit obligation:	13,057	13,844
Acquisitions	0	0
Service cost	8	5	19
Interest cost	313	445	452
Plan amendments	0	15
Actuarial loss (gain)	1,139	(382)
Foreign exchange effect	(3)	(4)
Benefits paid	(1,170)	(866)
Divestitures	0	0
Settlements	0	0
Other	0	0
Projected benefit obligation, end of year	13,344	13,057	13,844
Accumulated benefit obligation, end of year	13,344	13,057
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning of year	0	0
Actual return on plan assets	0	0
Employer contribution	1,170	866
Foreign exchange effect	0	0
Benefits paid	(1,170)	(866)
Divestitures	0	0
Settlements	0	0
Other	0	0
Fair value of plan assets, end of year	0	0	$ 0
Funded status, end of year	(13,344)	(13,057)
Non-current assets	0	0
Current liabilities	(1,028)	(1,177)
Non-current liabilities	(12,316)	(11,880)
Total	$ (13,344)	$ (13,057)

Defined Benefit Plans Defined_4

Defined Benefit Plans Defined Benefit Expected Benefit Payments (Details) $ in Thousands	Dec. 31, 2020USD ($)
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
2021	$ 25,147
2022	24,495
2023	23,858
2024	22,989
2025	22,689
2026-2030	105,337
Pension Benefits | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
2021	9,276
2022	8,925
2023	8,641
2024	8,182
2025	8,315
2026-2030	40,832
Other Post-Retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
2021	1,028
2022	954
2023	884
2024	839
2025	830
2026-2030	$ 3,731

Defined Benefit Plans Plan Asse

Defined Benefit Plans Plan Asset Allocation (Details)	Dec. 31, 2020	Dec. 31, 2019
U.S. | United States
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	44.00%	44.00%
U.S. | United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	30.00%
U.S. | United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	45.00%
International | United States
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	16.00%	15.00%
International | United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	10.00%
International | United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	20.00%
Fixed income | United States
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	39.00%	39.00%
Fixed income | United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	30.00%
Fixed income | United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	50.00%
Fixed income | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	10.00%	11.00%
Fixed income | Foreign Plan | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	0.00%
Fixed income | Foreign Plan | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	15.00%
Other | United States
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	0.00%	0.00%
Other | United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	0.00%
Other | United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	20.00%
Other | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	63.00%	62.00%
Other | Foreign Plan | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	55.00%
Other | Foreign Plan | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	90.00%
Cash and cash equivalents | United States
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	1.00%	2.00%
Cash and cash equivalents | United States | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	0.00%
Cash and cash equivalents | United States | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	5.00%
Cash and cash equivalents | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	0.00%	0.00%
Cash and cash equivalents | Foreign Plan | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	0.00%
Cash and cash equivalents | Foreign Plan | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	25.00%
Equity securities | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Actual asset allocation	27.00%	27.00%
Equity securities | Foreign Plan | Minimum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	0.00%
Equity securities | Foreign Plan | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target allocation	40.00%

Defined Benefit Plans Plan As_2

Defined Benefit Plans Plan Asset Allocation, Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2020		Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 267,254		$ 251,291
Measured at net asset value
Defined Benefit Plan Disclosure [Line Items]
Plan assets	178,433	[1]	167,582	[2]
Level One
Defined Benefit Plan Disclosure [Line Items]
Plan assets	40,790		40,150
Level Two
Defined Benefit Plan Disclosure [Line Items]
Plan assets	48,031		43,559
Level Three
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	1,752		2,855
United States | U.S. large cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	51,728		48,582
United States | U.S. small/mid cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	34,070		32,361
United States | International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	30,552		28,573
United States | U.S. government and corporate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	74,978		70,334
United States | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	1,060	[3]	1,051	[4]
United States | Measured at net asset value | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[1]	0	[2]
United States | Measured at net asset value | U.S. large cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	51,728	[1]	48,582	[2]
United States | Measured at net asset value | U.S. small/mid cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	21,175	[1]	20,093	[2]
United States | Measured at net asset value | International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	30,552	[1]	28,573	[2]
United States | Measured at net asset value | U.S. government and corporate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	74,978	[1]	70,334	[2]
United States | Measured at net asset value | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[1],[3]	0	[2],[4]
United States | Level One | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	1,752		2,855
United States | Level One | U.S. large cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0
United States | Level One | U.S. small/mid cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	12,895		12,268
United States | Level One | International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level One | U.S. government and corporate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level One | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	1,060	[3]	1,051	[4]
United States | Level Two | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Two | U.S. large cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Two | U.S. small/mid cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Two | International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Two | U.S. government and corporate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Two | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[3]	0	[4]
United States | Level Three | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Three | U.S. large cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Three | U.S. small/mid cap
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Three | International
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Three | U.S. government and corporate
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
United States | Level Three | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[3]	0	[4]
Foreign Plan | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	239		215
Foreign Plan | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	46,109	[3]	41,648	[4]
Foreign Plan | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets	19,513		18,462
Foreign Plan | Non-U.S. government and corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	7,253		7,210
Foreign Plan | Measured at net asset value | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[1]	0	[2]
Foreign Plan | Measured at net asset value | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[1],[3]	0	[2],[4]
Foreign Plan | Measured at net asset value | Non-U.S. government and corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[1]	0	[2]
Foreign Plan | Level One | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	239		215
Foreign Plan | Level One | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets	19,513		18,462
Foreign Plan | Level One | Non-U.S. government and corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	5,331		5,299
Foreign Plan | Level Two | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
Foreign Plan | Level Two | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	46,109	[3]	41,648	[4]
Foreign Plan | Level Two | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0
Foreign Plan | Level Two | Non-U.S. government and corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	1,922		1,911
Foreign Plan | Level Three | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
Foreign Plan | Level Three | Other
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0	[3]	0	[4]
Foreign Plan | Level Three | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan assets	0		0
Foreign Plan | Level Three | Non-U.S. government and corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 0		$ 0
[1]	Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term.
[2]	Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting primarily of common/collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund, that are traded in an active market, less its liabilities. These investments are able to be redeemed in the near-term.
[3]	Represents diversified portfolio funds, reinsurance contracts and money market funds.
[4]	Represents diversified portfolio funds, reinsurance contracts and money market funds.

Defined Benefit Plans Net Perio

Defined Benefit Plans Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Settlement loss (gain)	$ 0	$ 33,616	$ (39)
Current year net actuarial (gain) loss	(8,169)	(27,931)	10,116
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	1,933	2,462	2,770
Interest cost	7,454	16,556	21,574
Amortization	4,960	3,385	4,282
Settlement loss (gain)	99	77,390	(39)
Divestitures gain	0	(4,354)	0
Other	143	79	(458)
Expected return on plan assets	(12,773)	(19,774)	(29,306)
Net periodic benefit cost (income)	1,816	75,744	(1,177)
Current year net actuarial (gain) loss	(10,379)	(113,995)	11,816
Current year prior service cost	74	464	3,800
Amortization of net (gain) loss	(4,914)	(3,285)	(4,330)
Settlement/divestiture/other (gain) loss	(177)	(83,602)	39
Amortization of prior service cost	(46)	(100)	48
Total recognized in Other comprehensive income	(5,316)	(27,472)	12,259
Pension Benefits | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	1,933	2,340	2,634
Interest cost	2,315	9,376	15,183
Amortization	747	334	1,039
Settlement loss (gain)	99	77,390	(39)
Divestitures gain	0	(4,354)	0
Other	143	79	(458)
Expected return on plan assets	(2,397)	(9,092)	(18,310)
Net periodic benefit cost (income)	2,840	76,073	49
Current year net actuarial (gain) loss	(6,226)	(122,667)	31,854
Current year prior service cost	74	464	3,800
Amortization of net (gain) loss	(701)	(234)	(1,087)
Settlement/divestiture/other (gain) loss	(177)	(83,602)	39
Amortization of prior service cost	(46)	(100)	48
Total recognized in Other comprehensive income	(5,376)	(39,195)	29,054
Other Post-Retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	8	5	19
Interest cost	313	445	452
Amortization	(231)	(255)	(28)
Settlement loss (gain)	0	0	0
Divestitures gain	0	0	0
Other	0	0	0
Expected return on plan assets	0	0	0
Net periodic benefit cost (income)	90	195	443
Current year net actuarial (gain) loss	(1,143)	380	723
Current year prior service cost	0	15	0
Amortization of net (gain) loss	231	270	31
Settlement/divestiture/other (gain) loss	0	0	0
Amortization of prior service cost	0	(15)	(3)
Total recognized in Other comprehensive income	$ (1,374)	$ 110	$ 695

Defined Benefit Plans Defined_5

Defined Benefit Plans Defined Benefit Plan, Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss (gain)	$ 105,947	$ 100,659
Prior service cost	477	449
Total	106,424	101,108
Net actuarial loss (gain)	5,929
Prior service cost	55
Total	5,984
Other Post-Retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss (gain)	(2,031)	(3,405)
Prior service cost	0	0
Total	(2,031)	$ (3,405)
Net actuarial loss (gain)	(74)
Prior service cost	0
Total	$ (74)

Defined Benefit Plans Key Econo

Defined Benefit Plans Key Economic Assumptions (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted-average discount rate, benefit obligation	1.70%	2.50%
Weighted-average discount rate, net periodic benefit cost	2.50%	3.00%	2.60%
Weighted-average expected return on plan assets, net periodic benefit cost	5.70%	3.10%	3.80%
Other Post-Retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted-average discount rate, benefit obligation	2.10%	3.00%
Weighted-average discount rate, net periodic benefit cost	3.00%	4.00%	3.40%
Foreign Plan | Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted-average discount rate, benefit obligation	1.40%	1.90%
Weighted-average rate of increase in compensation levels for active foreign plans, benefit obligation	0.60%	0.80%
Weighted-average discount rate, net periodic benefit cost	1.90%	2.70%	2.40%
Weighted-average expected return on plan assets, net periodic benefit cost	4.10%	2.40%	3.20%
Weighted-average rate of increase in compensation levels for active foreign plans, net periodic benefit cost	0.80%	1.80%	2.10%
Foreign Plan | Other Post-Retirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Weighted-average discount rate, benefit obligation		0.00%

Defined Benefit Plans Health Ca

Defined Benefit Plans Health Care Assumption Effect (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Retirement Benefits [Abstract]
Effect on total service and interest cost components for the year ended December 31, 2020	$ 17
Effect on total service and interest cost components for the year ended December 31, 2020	(14)
Effect on post-retirement benefit obligation at December 31, 2020	695
Effect on post-retirement benefit obligation at December 31, 2020	$ (591)

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Details Textual) $ in Billions	Dec. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Long-term debt, fair value	$ 2.3

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	$ 7,420	$ 13,125
Deferred compensation plans	10,881	8,870
Assets, fair value disclosure	20,495	22,477
Liabilities, Fair Value Disclosure [Abstract]
Deferred compensation plans	10,881	8,870
Liabilities, fair value disclosure	12,662	10,051
Level One
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	7,420	13,125
Foreign currency contract, asset		0
Deferred compensation plans	0	0
Assets, fair value disclosure	7,420	13,125
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		0
Deferred compensation plans	0	0
Liabilities, fair value disclosure	0	0
Level One | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	0
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	0
Level One | Designated as Hedging Instrument
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	0
Level Two
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	0	0
Deferred compensation plans	10,881	8,870
Assets, fair value disclosure	13,075	9,352
Liabilities, Fair Value Disclosure [Abstract]
Deferred compensation plans	10,881	8,870
Liabilities, fair value disclosure	12,662	10,051
Level Three
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	0	0
Foreign currency contract, asset		0
Deferred compensation plans	0	0
Assets, fair value disclosure	0	0
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		0
Deferred compensation plans	0	0
Liabilities, fair value disclosure	0	0
Level Three | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	0
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	0
Level Three | Designated as Hedging Instrument
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	0
Customer Sales Contracts
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset		74
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		328
Customer Sales Contracts | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	1,897
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	1,313
Customer Sales Contracts | Designated as Hedging Instrument
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	468
Customer Sales Contracts | Level Two
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset		74
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		328
Customer Sales Contracts | Level Two | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	1,897
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	1,313
Customer Sales Contracts | Level Two | Designated as Hedging Instrument
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability	468
Supplier Purchase Contracts
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset		408
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		853
Supplier Purchase Contracts | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	297
Supplier Purchase Contracts | Level Two
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset		408
Liabilities, Fair Value Disclosure [Abstract]
Foreign currency contract, liability		$ 853
Supplier Purchase Contracts | Level Two | Not Designated as Hedging Instrument
Assets, Fair Value Disclosure [Abstract]
Foreign currency contract, asset	$ 297

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements Nontional Values (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Notional Amount	$ 250,401	$ 135,808
Not Designated as Hedging Instrument | Customer Sales Contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Notional Amount	152,504	28,718
Not Designated as Hedging Instrument | Supplier Purchase Contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset, Notional Amount	$ 97,897	$ 107,090

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements Gain (Loss) on Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) on net investment hedges	$ (26,268)	$ 6,215	$ 16,745
Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) on net investment hedges	(26,268)	6,215	16,745	[1]
Customer Sales Contracts | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain (loss)	704	(395)	890
Realized gain (loss)	941	(1,565)	(1,083)
Supplier Purchase Contracts | Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain (loss)	707	(216)	(820)
Realized gain (loss)	$ (936)	$ 523	$ (407)
[1]	The unrealized gain (loss) on net investment hedges is attributable to the change in valuation of Euro denominated debt.

Commitments and Contingencies C

Commitments and Contingencies Claims Rollforward (Details)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Loss Contingency Accrual [Roll Forward]
Claims unresolved, beginning of period	16,299	16,417	17,737
Claims filed	4,014	4,486	4,078
Claims resolved	(5,504)	(4,604)	(5,398)
Claims unresolved, end of period	14,809	16,299	16,417
Average cost of resolved claims	$ 12,055	$ 9,455	$ 7,497

Commitments and Contingencies_2

Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2010
Other Commitments [Line Items]
Future claims period	15 years
Pre-tax charge	$ 7.7	$ 13.3	$ 1.1
Increase (decrease) in asbestos-related liabilities	11.6	28.4	5.9
Asbestos insurance asset increase	3.9	15.1	4.8
Operating lease, expense	38	$ 34.3	$ 26.6
Unconditional purchase obligation	$ 276.9
Subsidiary 1
Other Commitments [Line Items]
Indemnification period				20 years
Future expected recovery percentage	90.70%
Future expected asbestos cost percentage	9.30%
Asbestos related defense and indemnity costs	$ 173.4
Funding requirement amount	10
Requested Insurer Reimburse
Other Commitments [Line Items]
Asbestos related defense and indemnity costs	$ 94.9
Subsidiary 2
Other Commitments [Line Items]
Future expected asbestos cost percentage	22.20%

Commitments and Contingencies A

Commitments and Contingencies Asbestos Litigation (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Current asbestos insurance receivable	[1]	$ 0	$ 4,474
Long-term asbestos insurance asset		232,712	281,793
Long-term asbestos insurance receivable		31,815	41,629
Accrued asbestos liability		41,626	64,394
Long-term asbestos liability		$ 253,144	$ 286,105
[1]	Included in Other current assets in the Consolidated Balance Sheets.

Commitments and Contingencies O

Commitments and Contingencies Operating Lease (Details 2) $ in Thousands	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 42,516
2022	33,809
2023	26,836
2024	18,987
2025	14,073
Thereafter	71,838
Total	$ 208,059

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020USD ($)	Oct. 02, 2020USD ($)	Jul. 03, 2020USD ($)	Apr. 03, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 27, 2019USD ($)	Jun. 28, 2019USD ($)	Mar. 29, 2019USD ($)	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment									2
Net sales:	$ 828,122	$ 805,931	$ 620,360	$ 816,356	$ 888,373	$ 846,519	$ 908,647	$ 683,919	$ 3,070,769	$ 3,327,458	$ 2,193,083
Segment operating income (loss)									214,250	277,359	180,613	[1]
Depreciation, amortization and other impairment charges:									246,229	215,607	81,207
Capital expenditures:									114,785	101,839	41,787
Income (loss) from continuing operations before income taxes									(58,029)	(50,493)	(92,364)
Loss on short-term investments									0	0	10,128
Pension settlement loss (gain)									0	33,616	(39)
Interest expense, net									104,262	119,503	49,083
Restructuring and other related charges									45,027	73,747	29,077
MDR and other costs									6,932	0	0
Investments in Equity Method Investees:	32,409				31,134				32,409	31,134
Total Assets:	7,351,549				7,386,832				7,351,549	7,386,832
Cost of Sales
Segment Reporting Information [Line Items]
Restructuring and other related charges									6,600	8,500
Fabrication Technology
Segment Reporting Information [Line Items]
Net sales:									1,950,069	2,247,026	2,193,083
Segment operating income (loss)									246,011	302,601	249,934
Depreciation, amortization and other impairment charges:									76,644	80,072	79,712
Capital expenditures:									40,137	44,454	40,512
Investments in Equity Method Investees:	32,409				31,134				32,409	31,134
Total Assets:	3,390,747				3,509,023				3,390,747	3,509,023
Medical Technology
Segment Reporting Information [Line Items]
Net sales:									1,120,700	1,080,432	0
Segment operating income (loss)									29,079	96,170	0
Depreciation, amortization and other impairment charges:									168,227	134,001	0
Capital expenditures:									74,624	57,326	0
Investments in Equity Method Investees:	0				0				0	0
Total Assets:	3,575,644				3,480,815				3,575,644	3,480,815
Corporate and other
Segment Reporting Information [Line Items]
Segment operating income (loss)									(60,840)	(121,412)	(69,321)
Depreciation, amortization and other impairment charges:									1,358	1,534	1,495
Capital expenditures:									24	59	$ 1,275
Total Assets:	385,158				396,994				385,158	396,994
All Segments
Segment Reporting Information [Line Items]
Total Assets:	$ 7,351,549				$ 7,386,832				$ 7,351,549	$ 7,386,832
[1]	The following is a reconciliation of Income (loss) before income taxes to segment operating income:

Segment Information Net Sales a

Segment Information Net Sales and PPE by Geography (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2020	Oct. 02, 2020	Jul. 03, 2020	Apr. 03, 2020	Dec. 31, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales		$ 828,122	$ 805,931	$ 620,360	$ 816,356	$ 888,373	$ 846,519	$ 908,647	$ 683,919	$ 3,070,769	$ 3,327,458	$ 2,193,083
Property, plant and equipment, net		486,960				491,241				486,960	491,241
United States
Segment Reporting Information [Line Items]
Net sales	[1]									1,283,651	1,464,152	540,533
Property, plant and equipment, net	[2]	221,549				222,293				221,549	222,293
Foreign locations
Segment Reporting Information [Line Items]
Net sales	[1]									1,787,118	1,863,306	$ 1,652,550
Property, plant and equipment, net	[2]	120,940				121,705				120,940	121,705
Czech Republic
Segment Reporting Information [Line Items]
Property, plant and equipment, net	[2]	65,188				62,469				65,188	62,469
India
Segment Reporting Information [Line Items]
Property, plant and equipment, net	[2]	39,612				41,528				39,612	41,528
United Kingdom
Segment Reporting Information [Line Items]
Property, plant and equipment, net		20,181				20,097				20,181	20,097
Russia
Segment Reporting Information [Line Items]
Property, plant and equipment, net	[2]	$ 19,490				$ 23,149				$ 19,490	$ 23,149
[1]	The Company attributes revenues from external customers to individual countries based upon the country in which the sale was originated.
[2]	As the Company does not allocate all long-lived assets, specifically intangible assets, to each individual country, evaluation of long-lived assets in total is impracticable.

Selected Quarterly Data - (un_3

Selected Quarterly Data - (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Oct. 02, 2020	Jul. 03, 2020	Apr. 03, 2020	Dec. 31, 2019	Sep. 27, 2019	Jun. 28, 2019	Mar. 29, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Selected Quarterly Financial Information [Abstract]
Net sales	$ 828,122	$ 805,931	$ 620,360	$ 816,356	$ 888,373	$ 846,519	$ 908,647	$ 683,919	$ 3,070,769	$ 3,327,458	$ 2,193,083
Gross profit	354,685	344,120	241,086	348,214	395,843	368,142	376,058	261,013	1,288,105	1,401,056	729,376
Net income (loss) from continuing operations	41,520	16,836	(3,142)	8,868	34,411	3,770	2,212	(21,530)
Income (loss) from discontinued operations, net of taxes	(7,405)	(2,641)	(4,905)	(3,360)	(49,744)	9,024	(468,817)	(26,472)	$ (18,311)	$ (536,009)	$ 32,601
Net income (loss) attributable to Colfax Corporation	$ 33,212	$ 13,406	$ (8,474)	$ 4,481	$ (16,863)	$ 10,474	$ (469,234)	$ (52,023)
Net income (loss) per share - basic
Net income per share from continuing operations - basic (in usd per share)	$ 0.30	$ 0.12	$ (0.03)	$ 0.06	$ 0.24	$ 0.02	$ 0.01	$ (0.17)	$ 0.45	$ 0.10	$ 1.01
Net income (loss) per share from discontinued operations - basic	(0.05)	(0.02)	(0.04)	(0.02)	(0.36)	0.06	(3.46)	(0.22)	(0.13)	(3.99)	0.16
Net income (loss) per share from consolidated operations - basic	0.24	0.10	(0.06)	0.03	(0.12)	0.08	(3.45)	(0.39)	0.31	(3.89)	1.17
Net income (loss) per share - diluted
Net income per share from continuing operations - diluted (in usd per share)	0.29	0.12	(0.03)	0.06	0.24	0.02	0.01	(0.17)	0.44	0.10	1
Net income (loss) per share from discontinued operations - diluted	(0.05)	(0.02)	(0.04)	(0.02)	(0.36)	0.06	(3.46)	(0.22)	(0.13)	(3.99)	0.16
Net income (loss) per share from consolidated operations - diluted	$ 0.24	$ 0.10	$ (0.06)	$ 0.03	$ (0.12)	$ 0.08	$ (3.45)	$ (0.39)	$ 0.31	$ (3.89)	$ 1.16

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	Jan. 19, 2021USD ($)
Subsequent Event
Subsequent Event [Line Items]
Cash consideration	$ 82,000

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-09, Allowance, Credit Loss
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 32,634	$ 35,152	$ 31,488
Charged to cost and expense	7,574	14,018	13,258
Charged to other accounts	0	0	0
Write-Offs Write-Downs and Deductions	(5,165)	(16,255)	(7,381)
Foreign Currency Translation	(752)	(281)	(2,213)
Balance at End of Period	37,666	32,634	35,152
SEC Schedule, 12-09, Allowance, Credit Loss | Cumulative Effect, Period of Adoption, Adjustment
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	36,009
Balance at End of Period		36,009
SEC Schedule, 12-09, Reserve, Inventory
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	36,231	41,130	34,960
Charged to cost and expense	35,836	10,655	20,446
Charged to other accounts	0	0	0
Write-Offs Write-Downs and Deductions	(9,346)	(15,302)	(12,113)
Foreign Currency Translation	119	(252)	(2,163)
Balance at End of Period	62,840	36,231	41,130
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	149,037	148,023	155,131
Charged to cost and expense	6,194	11,250	9,743
Charged to other accounts	48,525	9,100	7,180
Write-Offs Write-Downs and Deductions	0	(18,636)	(16,706)
Foreign Currency Translation	(415)	(700)	(7,325)
Balance at End of Period	$ 203,341	$ 149,037	$ 148,023